1
|
Staplin N, Haynes R, Judge PK, Wanner C, Green JB, Emberson J, Preiss D, Mayne KJ, Ng SYA, Sammons E, Zhu D, Hill M, Stevens W, Wallendszus K, Brenner S, Cheung AK, Liu ZH, Li J, Hooi LS, Liu WJ, Kadowaki T, Nangaku M, Levin A, Cherney D, Maggioni AP, Pontremoli R, Deo R, Goto S, Rossello X, Tuttle KR, Steubl D, Petrini M, Seidi S, Landray MJ, Baigent C, Herrington WG, Abat S, Abd Rahman R, Abdul Cader R, Abdul Hafidz MI, Abdul Wahab MZ, Abdullah NK, Abdul-Samad T, Abe M, Abraham N, Acheampong S, Achiri P, Acosta JA, Adeleke A, Adell V, Adewuyi-Dalton R, Adnan N, Africano A, Agharazii M, Aguilar F, Aguilera A, Ahmad M, Ahmad MK, Ahmad NA, Ahmad NH, Ahmad NI, Ahmad Miswan N, Ahmad Rosdi H, Ahmed I, Ahmed S, Ahmed S, Aiello J, Aitken A, AitSadi R, Aker S, Akimoto S, Akinfolarin A, Akram S, Alberici F, Albert C, Aldrich L, Alegata M, Alexander L, Alfaress S, Alhadj Ali M, Ali A, Ali A, Alicic R, Aliu A, Almaraz R, Almasarwah R, Almeida J, Aloisi A, Al-Rabadi L, Alscher D, Alvarez P, Al-Zeer B, Amat M, Ambrose C, Ammar H, An Y, Andriaccio L, Ansu K, Apostolidi A, Arai N, Araki H, Araki S, Arbi A, Arechiga O, Armstrong S, Arnold T, Aronoff S, Arriaga W, Arroyo J, Arteaga D, Asahara S, Asai A, Asai N, Asano S, Asawa M, Asmee MF, Aucella F, Augustin M, Avery A, Awad A, Awang IY, Awazawa M, Axler A, Ayub W, Azhari Z, Baccaro R, Badin C, Bagwell B, Bahlmann-Kroll E, Bahtar AZ, Baigent C, Bains D, Bajaj H, Baker R, Baldini E, Banas B, Banerjee D, Banno S, Bansal S, Barberi S, Barnes S, Barnini C, Barot C, Barrett K, Barrios R, Bartolomei Mecatti B, Barton I, Barton J, Basily W, Bavanandan S, Baxter A, Becker L, Beddhu S, Beige J, Beigh S, Bell S, Benck U, Beneat A, Bennett A, Bennett D, Benyon S, Berdeprado J, Bergler T, Bergner A, Berry M, Bevilacqua M, Bhairoo J, Bhandari S, Bhandary N, Bhatt A, Bhattarai M, Bhavsar M, Bian W, Bianchini F, Bianco S, Bilous R, Bilton J, Bilucaglia D, Bird C, Birudaraju D, Biscoveanu M, Blake C, Bleakley N, Bocchicchia K, Bodine S, Bodington R, Boedecker S, Bolduc M, Bolton S, Bond C, Boreky F, Boren K, Bouchi R, Bough L, Bovan D, Bowler C, Bowman L, Brar N, Braun C, Breach A, Breitenfeldt M, Brenner S, Brettschneider B, Brewer A, Brewer G, Brindle V, Brioni E, Brown C, Brown H, Brown L, Brown R, Brown S, Browne D, Bruce K, Brueckmann M, Brunskill N, Bryant M, Brzoska M, Bu Y, Buckman C, Budoff M, Bullen M, Burke A, Burnette S, Burston C, Busch M, Bushnell J, Butler S, Büttner C, Byrne C, Caamano A, Cadorna J, Cafiero C, Cagle M, Cai J, Calabrese K, Calvi C, Camilleri B, Camp S, Campbell D, Campbell R, Cao H, Capelli I, Caple M, Caplin B, Cardone A, Carle J, Carnall V, Caroppo M, Carr S, Carraro G, Carson M, Casares P, Castillo C, Castro C, Caudill B, Cejka V, Ceseri M, Cham L, Chamberlain A, Chambers J, Chan CBT, Chan JYM, Chan YC, Chang E, Chang E, Chant T, Chavagnon T, Chellamuthu P, Chen F, Chen J, Chen P, Chen TM, Chen Y, Chen Y, Cheng C, Cheng H, Cheng MC, Cherney D, Cheung AK, Ching CH, Chitalia N, Choksi R, Chukwu C, Chung K, Cianciolo G, Cipressa L, Clark S, Clarke H, Clarke R, Clarke S, Cleveland B, Cole E, Coles H, Condurache L, Connor A, Convery K, Cooper A, Cooper N, Cooper Z, Cooperman L, Cosgrove L, Coutts P, Cowley A, Craik R, Cui G, Cummins T, Dahl N, Dai H, Dajani L, D'Amelio A, Damian E, Damianik K, Danel L, Daniels C, Daniels T, Darbeau S, Darius H, Dasgupta T, Davies J, Davies L, Davis A, Davis J, Davis L, Dayanandan R, Dayi S, Dayrell R, De Nicola L, Debnath S, Deeb W, Degenhardt S, DeGoursey K, Delaney M, Deo R, DeRaad R, Derebail V, Dev D, Devaux M, Dhall P, Dhillon G, Dienes J, Dobre M, Doctolero E, Dodds V, Domingo D, Donaldson D, Donaldson P, Donhauser C, Donley V, Dorestin S, Dorey S, Doulton T, Draganova D, Draxlbauer K, Driver F, Du H, Dube F, Duck T, Dugal T, Dugas J, Dukka H, Dumann H, Durham W, Dursch M, Dykas R, Easow R, Eckrich E, Eden G, Edmerson E, Edwards H, Ee LW, Eguchi J, Ehrl Y, Eichstadt K, Eid W, Eilerman B, Ejima Y, Eldon H, Ellam T, Elliott L, Ellison R, Emberson J, Epp R, Er A, Espino-Obrero M, Estcourt S, Estienne L, Evans G, Evans J, Evans S, Fabbri G, Fajardo-Moser M, Falcone C, Fani F, Faria-Shayler P, Farnia F, Farrugia D, Fechter M, Fellowes D, Feng F, Fernandez J, Ferraro P, Field A, Fikry S, Finch J, Finn H, Fioretto P, Fish R, Fleischer A, Fleming-Brown D, Fletcher L, Flora R, Foellinger C, Foligno N, Forest S, Forghani Z, Forsyth K, Fottrell-Gould D, Fox P, Frankel A, Fraser D, Frazier R, Frederick K, Freking N, French H, Froment A, Fuchs B, Fuessl L, Fujii H, Fujimoto A, Fujita A, Fujita K, Fujita Y, Fukagawa M, Fukao Y, Fukasawa A, Fuller T, Funayama T, Fung E, Furukawa M, Furukawa Y, Furusho M, Gabel S, Gaidu J, Gaiser S, Gallo K, Galloway C, Gambaro G, Gan CC, Gangemi C, Gao M, Garcia K, Garcia M, Garofalo C, Garrity M, Garza A, Gasko S, Gavrila M, Gebeyehu B, Geddes A, Gentile G, George A, George J, Gesualdo L, Ghalli F, Ghanem A, Ghate T, Ghavampour S, Ghazi A, Gherman A, Giebeln-Hudnell U, Gill B, Gillham S, Girakossyan I, Girndt M, Giuffrida A, Glenwright M, Glider T, Gloria R, Glowski D, Goh BL, Goh CB, Gohda T, Goldenberg R, Goldfaden R, Goldsmith C, Golson B, Gonce V, Gong Q, Goodenough B, Goodwin N, Goonasekera M, Gordon A, Gordon J, Gore A, Goto H, Goto S, Goto S, Gowen D, Grace A, Graham J, Grandaliano G, Gray M, Green JB, Greene T, Greenwood G, Grewal B, Grifa R, Griffin D, Griffin S, Grimmer P, Grobovaite E, Grotjahn S, Guerini A, Guest C, Gunda S, Guo B, Guo Q, Haack S, Haase M, Haaser K, Habuki K, Hadley A, Hagan S, Hagge S, Haller H, Ham S, Hamal S, Hamamoto Y, Hamano N, Hamm M, Hanburry A, Haneda M, Hanf C, Hanif W, Hansen J, Hanson L, Hantel S, Haraguchi T, Harding E, Harding T, Hardy C, Hartner C, Harun Z, Harvill L, Hasan A, Hase H, Hasegawa F, Hasegawa T, Hashimoto A, Hashimoto C, Hashimoto M, Hashimoto S, Haskett S, Hauske SJ, Hawfield A, Hayami T, Hayashi M, Hayashi S, Haynes R, Hazara A, Healy C, Hecktman J, Heine G, Henderson H, Henschel R, Hepditch A, Herfurth K, Hernandez G, Hernandez Pena A, Hernandez-Cassis C, Herrington WG, Herzog C, Hewins S, Hewitt D, Hichkad L, Higashi S, Higuchi C, Hill C, Hill L, Hill M, Himeno T, Hing A, Hirakawa Y, Hirata K, Hirota Y, Hisatake T, Hitchcock S, Hodakowski A, Hodge W, Hogan R, Hohenstatt U, Hohenstein B, Hooi L, Hope S, Hopley M, Horikawa S, Hosein D, Hosooka T, Hou L, Hou W, Howie L, Howson A, Hozak M, Htet Z, Hu X, Hu Y, Huang J, Huda N, Hudig L, Hudson A, Hugo C, Hull R, Hume L, Hundei W, Hunt N, Hunter A, Hurley S, Hurst A, Hutchinson C, Hyo T, Ibrahim FH, Ibrahim S, Ihana N, Ikeda T, Imai A, Imamine R, Inamori A, Inazawa H, Ingell J, Inomata K, Inukai Y, Ioka M, Irtiza-Ali A, Isakova T, Isari W, Iselt M, Ishiguro A, Ishihara K, Ishikawa T, Ishimoto T, Ishizuka K, Ismail R, Itano S, Ito H, Ito K, Ito M, Ito Y, Iwagaitsu S, Iwaita Y, Iwakura T, Iwamoto M, Iwasa M, Iwasaki H, Iwasaki S, Izumi K, Izumi K, Izumi T, Jaafar SM, Jackson C, Jackson Y, Jafari G, Jahangiriesmaili M, Jain N, Jansson K, Jasim H, Jeffers L, Jenkins A, Jesky M, Jesus-Silva J, Jeyarajah D, Jiang Y, Jiao X, Jimenez G, Jin B, Jin Q, Jochims J, Johns B, Johnson C, Johnson T, Jolly S, Jones L, Jones L, Jones S, Jones T, Jones V, Joseph M, Joshi S, Judge P, Junejo N, Junus S, Kachele M, Kadowaki T, Kadoya H, Kaga H, Kai H, Kajio H, Kaluza-Schilling W, Kamaruzaman L, Kamarzarian A, Kamimura Y, Kamiya H, Kamundi C, Kan T, Kanaguchi Y, Kanazawa A, Kanda E, Kanegae S, Kaneko K, Kaneko K, Kang HY, Kano T, Karim M, Karounos D, Karsan W, Kasagi R, Kashihara N, Katagiri H, Katanosaka A, Katayama A, Katayama M, Katiman E, Kato K, Kato M, Kato N, Kato S, Kato T, Kato Y, Katsuda Y, Katsuno T, Kaufeld J, Kavak Y, Kawai I, Kawai M, Kawai M, Kawase A, Kawashima S, Kazory A, Kearney J, Keith B, Kellett J, Kelley S, Kershaw M, Ketteler M, Khai Q, Khairullah Q, Khandwala H, Khoo KKL, Khwaja A, Kidokoro K, Kielstein J, Kihara M, Kimber C, Kimura S, Kinashi H, Kingston H, Kinomura M, Kinsella-Perks E, Kitagawa M, Kitajima M, Kitamura S, Kiyosue A, Kiyota M, Klauser F, Klausmann G, Kmietschak W, Knapp K, Knight C, Knoppe A, Knott C, Kobayashi M, Kobayashi R, Kobayashi T, Koch M, Kodama S, Kodani N, Kogure E, Koizumi M, Kojima H, Kojo T, Kolhe N, Komaba H, Komiya T, Komori H, Kon SP, Kondo M, Kondo M, Kong W, Konishi M, Kono K, Koshino M, Kosugi T, Kothapalli B, Kozlowski T, Kraemer B, Kraemer-Guth A, Krappe J, Kraus D, Kriatselis C, Krieger C, Krish P, Kruger B, Ku Md Razi KR, Kuan Y, Kubota S, Kuhn S, Kumar P, Kume S, Kummer I, Kumuji R, Küpper A, Kuramae T, Kurian L, Kuribayashi C, Kurien R, Kuroda E, Kurose T, Kutschat A, Kuwabara N, Kuwata H, La Manna G, Lacey M, Lafferty K, LaFleur P, Lai V, Laity E, Lambert A, Landray MJ, Langlois M, Latif F, Latore E, Laundy E, Laurienti D, Lawson A, Lay M, Leal I, Leal I, Lee AK, Lee J, Lee KQ, Lee R, Lee SA, Lee YY, Lee-Barkey Y, Leonard N, Leoncini G, Leong CM, Lerario S, Leslie A, Levin A, Lewington A, Li J, Li N, Li X, Li Y, Liberti L, Liberti ME, Liew A, Liew YF, Lilavivat U, Lim SK, Lim YS, Limon E, Lin H, Lioudaki E, Liu H, Liu J, Liu L, Liu Q, Liu WJ, Liu X, Liu Z, Loader D, Lochhead H, Loh CL, Lorimer A, Loudermilk L, Loutan J, Low CK, Low CL, Low YM, Lozon Z, Lu Y, Lucci D, Ludwig U, Luker N, Lund D, Lustig R, Lyle S, Macdonald C, MacDougall I, Machicado R, MacLean D, Macleod P, Madera A, Madore F, Maeda K, Maegawa H, Maeno S, Mafham M, Magee J, Maggioni AP, Mah DY, Mahabadi V, Maiguma M, Makita Y, Makos G, Manco L, Mangiacapra R, Manley J, Mann P, Mano S, Marcotte G, Maris J, Mark P, Markau S, Markovic M, Marshall C, Martin M, Martinez C, Martinez S, Martins G, Maruyama K, Maruyama S, Marx K, Maselli A, Masengu A, Maskill A, Masumoto S, Masutani K, Matsumoto M, Matsunaga T, Matsuoka N, Matsushita M, Matthews M, Matthias S, Matvienko E, Maurer M, Maxwell P, Mayne KJ, Mazlan N, Mazlan SA, Mbuyisa A, McCafferty K, McCarroll F, McCarthy T, McClary-Wright C, McCray K, McDermott P, McDonald C, McDougall R, McHaffie E, McIntosh K, McKinley T, McLaughlin S, McLean N, McNeil L, Measor A, Meek J, Mehta A, Mehta R, Melandri M, Mené P, Meng T, Menne J, Merritt K, Merscher S, Meshykhi C, Messa P, Messinger L, Miftari N, Miller R, Miller Y, Miller-Hodges E, Minatoguchi M, Miners M, Minutolo R, Mita T, Miura Y, Miyaji M, Miyamoto S, Miyatsuka T, Miyazaki M, Miyazawa I, Mizumachi R, Mizuno M, Moffat S, Mohamad Nor FS, Mohamad Zaini SN, Mohamed Affandi FA, Mohandas C, Mohd R, Mohd Fauzi NA, Mohd Sharif NH, Mohd Yusoff Y, Moist L, Moncada A, Montasser M, Moon A, Moran C, Morgan N, Moriarty J, Morig G, Morinaga H, Morino K, Morisaki T, Morishita Y, Morlok S, Morris A, Morris F, Mostafa S, Mostefai Y, Motegi M, Motherwell N, Motta D, Mottl A, Moys R, Mozaffari S, Muir J, Mulhern J, Mulligan S, Munakata Y, Murakami C, Murakoshi M, Murawska A, Murphy K, Murphy L, Murray S, Murtagh H, Musa MA, Mushahar L, Mustafa R, Mustafar R, Muto M, Nadar E, Nagano R, Nagasawa T, Nagashima E, Nagasu H, Nagelberg S, Nair H, Nakagawa Y, Nakahara M, Nakamura J, Nakamura R, Nakamura T, Nakaoka M, Nakashima E, Nakata J, Nakata M, Nakatani S, Nakatsuka A, Nakayama Y, Nakhoul G, Nangaku M, Naverrete G, Navivala A, Nazeer I, Negrea L, Nethaji C, Newman E, Ng SYA, Ng TJ, Ngu LLS, Nimbkar T, Nishi H, Nishi M, Nishi S, Nishida Y, Nishiyama A, Niu J, Niu P, Nobili G, Nohara N, Nojima I, Nolan J, Nosseir H, Nozawa M, Nunn M, Nunokawa S, Oda M, Oe M, Oe Y, Ogane K, Ogawa W, Ogihara T, Oguchi G, Ohsugi M, Oishi K, Okada Y, Okajyo J, Okamoto S, Okamura K, Olufuwa O, Oluyombo R, Omata A, Omori Y, Ong LM, Ong YC, Onyema J, Oomatia A, Oommen A, Oremus R, Orimo Y, Ortalda V, Osaki Y, Osawa Y, Osmond Foster J, O'Sullivan A, Otani T, Othman N, Otomo S, O'Toole J, Owen L, Ozawa T, Padiyar A, Page N, Pajak S, Paliege A, Pandey A, Pandey R, Pariani H, Park J, Parrigon M, Passauer J, Patecki M, Patel M, Patel R, Patel T, Patel Z, Paul R, Paul R, Paulsen L, Pavone L, Peixoto A, Peji J, Peng BC, Peng K, Pennino L, Pereira E, Perez E, Pergola P, Pesce F, Pessolano G, Petchey W, Petr EJ, Pfab T, Phelan P, Phillips R, Phillips T, Phipps M, Piccinni G, Pickett T, Pickworth S, Piemontese M, Pinto D, Piper J, Plummer-Morgan J, Poehler D, Polese L, Poma V, Pontremoli R, Postal A, Pötz C, Power A, Pradhan N, Pradhan R, Preiss D, Preiss E, Preston K, Prib N, Price L, Provenzano C, Pugay C, Pulido R, Putz F, Qiao Y, Quartagno R, Quashie-Akponeware M, Rabara R, Rabasa-Lhoret R, Radhakrishnan D, Radley M, Raff R, Raguwaran S, Rahbari-Oskoui F, Rahman M, Rahmat K, Ramadoss S, Ramanaidu S, Ramasamy S, Ramli R, Ramli S, Ramsey T, Rankin A, Rashidi A, Raymond L, Razali WAFA, Read K, Reiner H, Reisler A, Reith C, Renner J, Rettenmaier B, Richmond L, Rijos D, Rivera R, Rivers V, Robinson H, Rocco M, Rodriguez-Bachiller I, Rodriquez R, Roesch C, Roesch J, Rogers J, Rohnstock M, Rolfsmeier S, Roman M, Romo A, Rosati A, Rosenberg S, Ross T, Rossello X, Roura M, Roussel M, Rovner S, Roy S, Rucker S, Rump L, Ruocco M, Ruse S, Russo F, Russo M, Ryder M, Sabarai A, Saccà C, Sachson R, Sadler E, Safiee NS, Sahani M, Saillant A, Saini J, Saito C, Saito S, Sakaguchi K, Sakai M, Salim H, Salviani C, Sammons E, Sampson A, Samson F, Sandercock P, Sanguila S, Santorelli G, Santoro D, Sarabu N, Saram T, Sardell R, Sasajima H, Sasaki T, Satko S, Sato A, Sato D, Sato H, Sato H, Sato J, Sato T, Sato Y, Satoh M, Sawada K, Schanz M, Scheidemantel F, Schemmelmann M, Schettler E, Schettler V, Schlieper GR, Schmidt C, Schmidt G, Schmidt U, Schmidt-Gurtler H, Schmude M, Schneider A, Schneider I, Schneider-Danwitz C, Schomig M, Schramm T, Schreiber A, Schricker S, Schroppel B, Schulte-Kemna L, Schulz E, Schumacher B, Schuster A, Schwab A, Scolari F, Scott A, Seeger W, Seeger W, Segal M, Seifert L, Seifert M, Sekiya M, Sellars R, Seman MR, Shah S, Shah S, Shainberg L, Shanmuganathan M, Shao F, Sharma K, Sharpe C, Sheikh-Ali M, Sheldon J, Shenton C, Shepherd A, Shepperd M, Sheridan R, Sheriff Z, Shibata Y, Shigehara T, Shikata K, Shimamura K, Shimano H, Shimizu Y, Shimoda H, Shin K, Shivashankar G, Shojima N, Silva R, Sim CSB, Simmons K, Sinha S, Sitter T, Sivanandam S, Skipper M, Sloan K, Sloan L, Smith R, Smyth J, Sobande T, Sobata M, Somalanka S, Song X, Sonntag F, Sood B, Sor SY, Soufer J, Sparks H, Spatoliatore G, Spinola T, Squyres S, Srivastava A, Stanfield J, Staplin N, Staylor K, Steele A, Steen O, Steffl D, Stegbauer J, Stellbrink C, Stellbrink E, Stevens W, Stevenson A, Stewart-Ray V, Stickley J, Stoffler D, Stratmann B, Streitenberger S, Strutz F, Stubbs J, Stumpf J, Suazo N, Suchinda P, Suckling R, Sudin A, Sugamori K, Sugawara H, Sugawara K, Sugimoto D, Sugiyama H, Sugiyama H, Sugiyama T, Sullivan M, Sumi M, Suresh N, Sutton D, Suzuki H, Suzuki R, Suzuki Y, Suzuki Y, Suzuki Y, Swanson E, Swift P, Syed S, Szerlip H, Taal M, Taddeo M, Tailor C, Tajima K, Takagi M, Takahashi K, Takahashi K, Takahashi M, Takahashi T, Takahira E, Takai T, Takaoka M, Takeoka J, Takesada A, Takezawa M, Talbot M, Taliercio J, Talsania T, Tamori Y, Tamura R, Tamura Y, Tan CHH, Tan EZZ, Tanabe A, Tanabe K, Tanaka A, Tanaka A, Tanaka N, Tang S, Tang Z, Tanigaki K, Tarlac M, Tatsuzawa A, Tay JF, Tay LL, Taylor J, Taylor K, Taylor K, Te A, Tenbusch L, Teng KS, Terakawa A, Terry J, Tham ZD, Tholl S, Thomas G, Thong KM, Tietjen D, Timadjer A, Tindall H, Tipper S, Tobin K, Toda N, Tokuyama A, Tolibas M, Tomita A, Tomita T, Tomlinson J, Tonks L, Topf J, Topping S, Torp A, Torres A, Totaro F, Toth P, Toyonaga Y, Tripodi F, Trivedi K, Tropman E, Tschope D, Tse J, Tsuji K, Tsunekawa S, Tsunoda R, Tucky B, Tufail S, Tuffaha A, Turan E, Turner H, Turner J, Turner M, Tuttle KR, Tye YL, Tyler A, Tyler J, Uchi H, Uchida H, Uchida T, Uchida T, Udagawa T, Ueda S, Ueda Y, Ueki K, Ugni S, Ugwu E, Umeno R, Unekawa C, Uozumi K, Urquia K, Valleteau A, Valletta C, van Erp R, Vanhoy C, Varad V, Varma R, Varughese A, Vasquez P, Vasseur A, Veelken R, Velagapudi C, Verdel K, Vettoretti S, Vezzoli G, Vielhauer V, Viera R, Vilar E, Villaruel S, Vinall L, Vinathan J, Visnjic M, Voigt E, von-Eynatten M, Vourvou M, Wada J, Wada J, Wada T, Wada Y, Wakayama K, Wakita Y, Wallendszus K, Walters T, Wan Mohamad WH, Wang L, Wang W, Wang X, Wang X, Wang Y, Wanner C, Wanninayake S, Watada H, Watanabe K, Watanabe K, Watanabe M, Waterfall H, Watkins D, Watson S, Weaving L, Weber B, Webley Y, Webster A, Webster M, Weetman M, Wei W, Weihprecht H, Weiland L, Weinmann-Menke J, Weinreich T, Wendt R, Weng Y, Whalen M, Whalley G, Wheatley R, Wheeler A, Wheeler J, Whelton P, White K, Whitmore B, Whittaker S, Wiebel J, Wiley J, Wilkinson L, Willett M, Williams A, Williams E, Williams K, Williams T, Wilson A, Wilson P, Wincott L, Wines E, Winkelmann B, Winkler M, Winter-Goodwin B, Witczak J, Wittes J, Wittmann M, Wolf G, Wolf L, Wolfling R, Wong C, Wong E, Wong HS, Wong LW, Wong YH, Wonnacott A, Wood A, Wood L, Woodhouse H, Wooding N, Woodman A, Wren K, Wu J, Wu P, Xia S, Xiao H, Xiao X, Xie Y, Xu C, Xu Y, Xue H, Yahaya H, Yalamanchili H, Yamada A, Yamada N, Yamagata K, Yamaguchi M, Yamaji Y, Yamamoto A, Yamamoto S, Yamamoto S, Yamamoto T, Yamanaka A, Yamano T, Yamanouchi Y, Yamasaki N, Yamasaki Y, Yamasaki Y, Yamashita C, Yamauchi T, Yan Q, Yanagisawa E, Yang F, Yang L, Yano S, Yao S, Yao Y, Yarlagadda S, Yasuda Y, Yiu V, Yokoyama T, Yoshida S, Yoshidome E, Yoshikawa H, Young A, Young T, Yousif V, Yu H, Yu Y, Yuasa K, Yusof N, Zalunardo N, Zander B, Zani R, Zappulo F, Zayed M, Zemann B, Zettergren P, Zhang H, Zhang L, Zhang L, Zhang N, Zhang X, Zhao J, Zhao L, Zhao S, Zhao Z, Zhong H, Zhou N, Zhou S, Zhu D, Zhu L, Zhu S, Zietz M, Zippo M, Zirino F, Zulkipli FH. Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial. Lancet Diabetes Endocrinol 2024; 12:39-50. [PMID: 38061371 PMCID: PMC7615591 DOI: 10.1016/s2213-8587(23)00321-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/05/2023] [Revised: 10/24/2023] [Accepted: 10/25/2023] [Indexed: 12/23/2023]
Abstract
BACKGROUND Sodium-glucose co-transporter-2 (SGLT2) inhibitors reduce progression of chronic kidney disease and the risk of cardiovascular morbidity and mortality in a wide range of patients. However, their effects on kidney disease progression in some patients with chronic kidney disease are unclear because few clinical kidney outcomes occurred among such patients in the completed trials. In particular, some guidelines stratify their level of recommendation about who should be treated with SGLT2 inhibitors based on diabetes status and albuminuria. We aimed to assess the effects of empagliflozin on progression of chronic kidney disease both overall and among specific types of participants in the EMPA-KIDNEY trial. METHODS EMPA-KIDNEY, a randomised, controlled, phase 3 trial, was conducted at 241 centres in eight countries (Canada, China, Germany, Italy, Japan, Malaysia, the UK, and the USA), and included individuals aged 18 years or older with an estimated glomerular filtration rate (eGFR) of 20 to less than 45 mL/min per 1·73 m2, or with an eGFR of 45 to less than 90 mL/min per 1·73 m2 with a urinary albumin-to-creatinine ratio (uACR) of 200 mg/g or higher. We explored the effects of 10 mg oral empagliflozin once daily versus placebo on the annualised rate of change in estimated glomerular filtration rate (eGFR slope), a tertiary outcome. We studied the acute slope (from randomisation to 2 months) and chronic slope (from 2 months onwards) separately, using shared parameter models to estimate the latter. Analyses were done in all randomly assigned participants by intention to treat. EMPA-KIDNEY is registered at ClinicalTrials.gov, NCT03594110. FINDINGS Between May 15, 2019, and April 16, 2021, 6609 participants were randomly assigned and then followed up for a median of 2·0 years (IQR 1·5-2·4). Prespecified subgroups of eGFR included 2282 (34·5%) participants with an eGFR of less than 30 mL/min per 1·73 m2, 2928 (44·3%) with an eGFR of 30 to less than 45 mL/min per 1·73 m2, and 1399 (21·2%) with an eGFR 45 mL/min per 1·73 m2 or higher. Prespecified subgroups of uACR included 1328 (20·1%) with a uACR of less than 30 mg/g, 1864 (28·2%) with a uACR of 30 to 300 mg/g, and 3417 (51·7%) with a uACR of more than 300 mg/g. Overall, allocation to empagliflozin caused an acute 2·12 mL/min per 1·73 m2 (95% CI 1·83-2·41) reduction in eGFR, equivalent to a 6% (5-6) dip in the first 2 months. After this, it halved the chronic slope from -2·75 to -1·37 mL/min per 1·73 m2 per year (relative difference 50%, 95% CI 42-58). The absolute and relative benefits of empagliflozin on the magnitude of the chronic slope varied significantly depending on diabetes status and baseline levels of eGFR and uACR. In particular, the absolute difference in chronic slopes was lower in patients with lower baseline uACR, but because this group progressed more slowly than those with higher uACR, this translated to a larger relative difference in chronic slopes in this group (86% [36-136] reduction in the chronic slope among those with baseline uACR <30 mg/g compared with a 29% [19-38] reduction for those with baseline uACR ≥2000 mg/g; ptrend<0·0001). INTERPRETATION Empagliflozin slowed the rate of progression of chronic kidney disease among all types of participant in the EMPA-KIDNEY trial, including those with little albuminuria. Albuminuria alone should not be used to determine whether to treat with an SGLT2 inhibitor. FUNDING Boehringer Ingelheim and Eli Lilly.
Collapse
|
2
|
Judge PK, Staplin N, Mayne KJ, Wanner C, Green JB, Hauske SJ, Emberson JR, Preiss D, Ng SYA, Roddick AJ, Sammons E, Zhu D, Hill M, Stevens W, Wallendszus K, Brenner S, Cheung AK, Liu ZH, Li J, Hooi LS, Liu WJ, Kadowaki T, Nangaku M, Levin A, Cherney D, Maggioni AP, Pontremoli R, Deo R, Goto S, Rossello X, Tuttle KR, Steubl D, Massey D, Landray MJ, Baigent C, Haynes R, Herrington WG, Abat S, Abd Rahman R, Abdul Cader R, Abdul Hafidz MI, Abdul Wahab MZ, Abdullah NK, Abdul-Samad T, Abe M, Abraham N, Acheampong S, Achiri P, Acosta JA, Adeleke A, Adell V, Adewuyi-Dalton R, Adnan N, Africano A, Agharazii M, Aguilar F, Aguilera A, Ahmad M, Ahmad MK, Ahmad NA, Ahmad NH, Ahmad NI, Ahmad Miswan N, Ahmad Rosdi H, Ahmed I, Ahmed S, Ahmed S, Aiello J, Aitken A, AitSadi R, Aker S, Akimoto S, Akinfolarin A, Akram S, Alberici F, Albert C, Aldrich L, Alegata M, Alexander L, Alfaress S, Alhadj Ali M, Ali A, Ali A, Alicic R, Aliu A, Almaraz R, Almasarwah R, Almeida J, Aloisi A, Al-Rabadi L, Alscher D, Alvarez P, Al-Zeer B, Amat M, Ambrose C, Ammar H, An Y, Andriaccio L, Ansu K, Apostolidi A, Arai N, Araki H, Araki S, Arbi A, Arechiga O, Armstrong S, Arnold T, Aronoff S, Arriaga W, Arroyo J, Arteaga D, Asahara S, Asai A, Asai N, Asano S, Asawa M, Asmee MF, Aucella F, Augustin M, Avery A, Awad A, Awang IY, Awazawa M, Axler A, Ayub W, Azhari Z, Baccaro R, Badin C, Bagwell B, Bahlmann-Kroll E, Bahtar AZ, Baigent C, Bains D, Bajaj H, Baker R, Baldini E, Banas B, Banerjee D, Banno S, Bansal S, Barberi S, Barnes S, Barnini C, Barot C, Barrett K, Barrios R, Bartolomei Mecatti B, Barton I, Barton J, Basily W, Bavanandan S, Baxter A, Becker L, Beddhu S, Beige J, Beigh S, Bell S, Benck U, Beneat A, Bennett A, Bennett D, Benyon S, Berdeprado J, Bergler T, Bergner A, Berry M, Bevilacqua M, Bhairoo J, Bhandari S, Bhandary N, Bhatt A, Bhattarai M, Bhavsar M, Bian W, Bianchini F, Bianco S, Bilous R, Bilton J, Bilucaglia D, Bird C, Birudaraju D, Biscoveanu M, Blake C, Bleakley N, Bocchicchia K, Bodine S, Bodington R, Boedecker S, Bolduc M, Bolton S, Bond C, Boreky F, Boren K, Bouchi R, Bough L, Bovan D, Bowler C, Bowman L, Brar N, Braun C, Breach A, Breitenfeldt M, Brenner S, Brettschneider B, Brewer A, Brewer G, Brindle V, Brioni E, Brown C, Brown H, Brown L, Brown R, Brown S, Browne D, Bruce K, Brueckmann M, Brunskill N, Bryant M, Brzoska M, Bu Y, Buckman C, Budoff M, Bullen M, Burke A, Burnette S, Burston C, Busch M, Bushnell J, Butler S, Büttner C, Byrne C, Caamano A, Cadorna J, Cafiero C, Cagle M, Cai J, Calabrese K, Calvi C, Camilleri B, Camp S, Campbell D, Campbell R, Cao H, Capelli I, Caple M, Caplin B, Cardone A, Carle J, Carnall V, Caroppo M, Carr S, Carraro G, Carson M, Casares P, Castillo C, Castro C, Caudill B, Cejka V, Ceseri M, Cham L, Chamberlain A, Chambers J, Chan CBT, Chan JYM, Chan YC, Chang E, Chang E, Chant T, Chavagnon T, Chellamuthu P, Chen F, Chen J, Chen P, Chen TM, Chen Y, Chen Y, Cheng C, Cheng H, Cheng MC, Cherney D, Cheung AK, Ching CH, Chitalia N, Choksi R, Chukwu C, Chung K, Cianciolo G, Cipressa L, Clark S, Clarke H, Clarke R, Clarke S, Cleveland B, Cole E, Coles H, Condurache L, Connor A, Convery K, Cooper A, Cooper N, Cooper Z, Cooperman L, Cosgrove L, Coutts P, Cowley A, Craik R, Cui G, Cummins T, Dahl N, Dai H, Dajani L, D'Amelio A, Damian E, Damianik K, Danel L, Daniels C, Daniels T, Darbeau S, Darius H, Dasgupta T, Davies J, Davies L, Davis A, Davis J, Davis L, Dayanandan R, Dayi S, Dayrell R, De Nicola L, Debnath S, Deeb W, Degenhardt S, DeGoursey K, Delaney M, Deo R, DeRaad R, Derebail V, Dev D, Devaux M, Dhall P, Dhillon G, Dienes J, Dobre M, Doctolero E, Dodds V, Domingo D, Donaldson D, Donaldson P, Donhauser C, Donley V, Dorestin S, Dorey S, Doulton T, Draganova D, Draxlbauer K, Driver F, Du H, Dube F, Duck T, Dugal T, Dugas J, Dukka H, Dumann H, Durham W, Dursch M, Dykas R, Easow R, Eckrich E, Eden G, Edmerson E, Edwards H, Ee LW, Eguchi J, Ehrl Y, Eichstadt K, Eid W, Eilerman B, Ejima Y, Eldon H, Ellam T, Elliott L, Ellison R, Emberson J, Epp R, Er A, Espino-Obrero M, Estcourt S, Estienne L, Evans G, Evans J, Evans S, Fabbri G, Fajardo-Moser M, Falcone C, Fani F, Faria-Shayler P, Farnia F, Farrugia D, Fechter M, Fellowes D, Feng F, Fernandez J, Ferraro P, Field A, Fikry S, Finch J, Finn H, Fioretto P, Fish R, Fleischer A, Fleming-Brown D, Fletcher L, Flora R, Foellinger C, Foligno N, Forest S, Forghani Z, Forsyth K, Fottrell-Gould D, Fox P, Frankel A, Fraser D, Frazier R, Frederick K, Freking N, French H, Froment A, Fuchs B, Fuessl L, Fujii H, Fujimoto A, Fujita A, Fujita K, Fujita Y, Fukagawa M, Fukao Y, Fukasawa A, Fuller T, Funayama T, Fung E, Furukawa M, Furukawa Y, Furusho M, Gabel S, Gaidu J, Gaiser S, Gallo K, Galloway C, Gambaro G, Gan CC, Gangemi C, Gao M, Garcia K, Garcia M, Garofalo C, Garrity M, Garza A, Gasko S, Gavrila M, Gebeyehu B, Geddes A, Gentile G, George A, George J, Gesualdo L, Ghalli F, Ghanem A, Ghate T, Ghavampour S, Ghazi A, Gherman A, Giebeln-Hudnell U, Gill B, Gillham S, Girakossyan I, Girndt M, Giuffrida A, Glenwright M, Glider T, Gloria R, Glowski D, Goh BL, Goh CB, Gohda T, Goldenberg R, Goldfaden R, Goldsmith C, Golson B, Gonce V, Gong Q, Goodenough B, Goodwin N, Goonasekera M, Gordon A, Gordon J, Gore A, Goto H, Goto S, Goto S, Gowen D, Grace A, Graham J, Grandaliano G, Gray M, Green JB, Greene T, Greenwood G, Grewal B, Grifa R, Griffin D, Griffin S, Grimmer P, Grobovaite E, Grotjahn S, Guerini A, Guest C, Gunda S, Guo B, Guo Q, Haack S, Haase M, Haaser K, Habuki K, Hadley A, Hagan S, Hagge S, Haller H, Ham S, Hamal S, Hamamoto Y, Hamano N, Hamm M, Hanburry A, Haneda M, Hanf C, Hanif W, Hansen J, Hanson L, Hantel S, Haraguchi T, Harding E, Harding T, Hardy C, Hartner C, Harun Z, Harvill L, Hasan A, Hase H, Hasegawa F, Hasegawa T, Hashimoto A, Hashimoto C, Hashimoto M, Hashimoto S, Haskett S, Hauske SJ, Hawfield A, Hayami T, Hayashi M, Hayashi S, Haynes R, Hazara A, Healy C, Hecktman J, Heine G, Henderson H, Henschel R, Hepditch A, Herfurth K, Hernandez G, Hernandez Pena A, Hernandez-Cassis C, Herrington WG, Herzog C, Hewins S, Hewitt D, Hichkad L, Higashi S, Higuchi C, Hill C, Hill L, Hill M, Himeno T, Hing A, Hirakawa Y, Hirata K, Hirota Y, Hisatake T, Hitchcock S, Hodakowski A, Hodge W, Hogan R, Hohenstatt U, Hohenstein B, Hooi L, Hope S, Hopley M, Horikawa S, Hosein D, Hosooka T, Hou L, Hou W, Howie L, Howson A, Hozak M, Htet Z, Hu X, Hu Y, Huang J, Huda N, Hudig L, Hudson A, Hugo C, Hull R, Hume L, Hundei W, Hunt N, Hunter A, Hurley S, Hurst A, Hutchinson C, Hyo T, Ibrahim FH, Ibrahim S, Ihana N, Ikeda T, Imai A, Imamine R, Inamori A, Inazawa H, Ingell J, Inomata K, Inukai Y, Ioka M, Irtiza-Ali A, Isakova T, Isari W, Iselt M, Ishiguro A, Ishihara K, Ishikawa T, Ishimoto T, Ishizuka K, Ismail R, Itano S, Ito H, Ito K, Ito M, Ito Y, Iwagaitsu S, Iwaita Y, Iwakura T, Iwamoto M, Iwasa M, Iwasaki H, Iwasaki S, Izumi K, Izumi K, Izumi T, Jaafar SM, Jackson C, Jackson Y, Jafari G, Jahangiriesmaili M, Jain N, Jansson K, Jasim H, Jeffers L, Jenkins A, Jesky M, Jesus-Silva J, Jeyarajah D, Jiang Y, Jiao X, Jimenez G, Jin B, Jin Q, Jochims J, Johns B, Johnson C, Johnson T, Jolly S, Jones L, Jones L, Jones S, Jones T, Jones V, Joseph M, Joshi S, Judge P, Junejo N, Junus S, Kachele M, Kadowaki T, Kadoya H, Kaga H, Kai H, Kajio H, Kaluza-Schilling W, Kamaruzaman L, Kamarzarian A, Kamimura Y, Kamiya H, Kamundi C, Kan T, Kanaguchi Y, Kanazawa A, Kanda E, Kanegae S, Kaneko K, Kaneko K, Kang HY, Kano T, Karim M, Karounos D, Karsan W, Kasagi R, Kashihara N, Katagiri H, Katanosaka A, Katayama A, Katayama M, Katiman E, Kato K, Kato M, Kato N, Kato S, Kato T, Kato Y, Katsuda Y, Katsuno T, Kaufeld J, Kavak Y, Kawai I, Kawai M, Kawai M, Kawase A, Kawashima S, Kazory A, Kearney J, Keith B, Kellett J, Kelley S, Kershaw M, Ketteler M, Khai Q, Khairullah Q, Khandwala H, Khoo KKL, Khwaja A, Kidokoro K, Kielstein J, Kihara M, Kimber C, Kimura S, Kinashi H, Kingston H, Kinomura M, Kinsella-Perks E, Kitagawa M, Kitajima M, Kitamura S, Kiyosue A, Kiyota M, Klauser F, Klausmann G, Kmietschak W, Knapp K, Knight C, Knoppe A, Knott C, Kobayashi M, Kobayashi R, Kobayashi T, Koch M, Kodama S, Kodani N, Kogure E, Koizumi M, Kojima H, Kojo T, Kolhe N, Komaba H, Komiya T, Komori H, Kon SP, Kondo M, Kondo M, Kong W, Konishi M, Kono K, Koshino M, Kosugi T, Kothapalli B, Kozlowski T, Kraemer B, Kraemer-Guth A, Krappe J, Kraus D, Kriatselis C, Krieger C, Krish P, Kruger B, Ku Md Razi KR, Kuan Y, Kubota S, Kuhn S, Kumar P, Kume S, Kummer I, Kumuji R, Küpper A, Kuramae T, Kurian L, Kuribayashi C, Kurien R, Kuroda E, Kurose T, Kutschat A, Kuwabara N, Kuwata H, La Manna G, Lacey M, Lafferty K, LaFleur P, Lai V, Laity E, Lambert A, Landray MJ, Langlois M, Latif F, Latore E, Laundy E, Laurienti D, Lawson A, Lay M, Leal I, Leal I, Lee AK, Lee J, Lee KQ, Lee R, Lee SA, Lee YY, Lee-Barkey Y, Leonard N, Leoncini G, Leong CM, Lerario S, Leslie A, Levin A, Lewington A, Li J, Li N, Li X, Li Y, Liberti L, Liberti ME, Liew A, Liew YF, Lilavivat U, Lim SK, Lim YS, Limon E, Lin H, Lioudaki E, Liu H, Liu J, Liu L, Liu Q, Liu WJ, Liu X, Liu Z, Loader D, Lochhead H, Loh CL, Lorimer A, Loudermilk L, Loutan J, Low CK, Low CL, Low YM, Lozon Z, Lu Y, Lucci D, Ludwig U, Luker N, Lund D, Lustig R, Lyle S, Macdonald C, MacDougall I, Machicado R, MacLean D, Macleod P, Madera A, Madore F, Maeda K, Maegawa H, Maeno S, Mafham M, Magee J, Maggioni AP, Mah DY, Mahabadi V, Maiguma M, Makita Y, Makos G, Manco L, Mangiacapra R, Manley J, Mann P, Mano S, Marcotte G, Maris J, Mark P, Markau S, Markovic M, Marshall C, Martin M, Martinez C, Martinez S, Martins G, Maruyama K, Maruyama S, Marx K, Maselli A, Masengu A, Maskill A, Masumoto S, Masutani K, Matsumoto M, Matsunaga T, Matsuoka N, Matsushita M, Matthews M, Matthias S, Matvienko E, Maurer M, Maxwell P, Mayne KJ, Mazlan N, Mazlan SA, Mbuyisa A, McCafferty K, McCarroll F, McCarthy T, McClary-Wright C, McCray K, McDermott P, McDonald C, McDougall R, McHaffie E, McIntosh K, McKinley T, McLaughlin S, McLean N, McNeil L, Measor A, Meek J, Mehta A, Mehta R, Melandri M, Mené P, Meng T, Menne J, Merritt K, Merscher S, Meshykhi C, Messa P, Messinger L, Miftari N, Miller R, Miller Y, Miller-Hodges E, Minatoguchi M, Miners M, Minutolo R, Mita T, Miura Y, Miyaji M, Miyamoto S, Miyatsuka T, Miyazaki M, Miyazawa I, Mizumachi R, Mizuno M, Moffat S, Mohamad Nor FS, Mohamad Zaini SN, Mohamed Affandi FA, Mohandas C, Mohd R, Mohd Fauzi NA, Mohd Sharif NH, Mohd Yusoff Y, Moist L, Moncada A, Montasser M, Moon A, Moran C, Morgan N, Moriarty J, Morig G, Morinaga H, Morino K, Morisaki T, Morishita Y, Morlok S, Morris A, Morris F, Mostafa S, Mostefai Y, Motegi M, Motherwell N, Motta D, Mottl A, Moys R, Mozaffari S, Muir J, Mulhern J, Mulligan S, Munakata Y, Murakami C, Murakoshi M, Murawska A, Murphy K, Murphy L, Murray S, Murtagh H, Musa MA, Mushahar L, Mustafa R, Mustafar R, Muto M, Nadar E, Nagano R, Nagasawa T, Nagashima E, Nagasu H, Nagelberg S, Nair H, Nakagawa Y, Nakahara M, Nakamura J, Nakamura R, Nakamura T, Nakaoka M, Nakashima E, Nakata J, Nakata M, Nakatani S, Nakatsuka A, Nakayama Y, Nakhoul G, Nangaku M, Naverrete G, Navivala A, Nazeer I, Negrea L, Nethaji C, Newman E, Ng SYA, Ng TJ, Ngu LLS, Nimbkar T, Nishi H, Nishi M, Nishi S, Nishida Y, Nishiyama A, Niu J, Niu P, Nobili G, Nohara N, Nojima I, Nolan J, Nosseir H, Nozawa M, Nunn M, Nunokawa S, Oda M, Oe M, Oe Y, Ogane K, Ogawa W, Ogihara T, Oguchi G, Ohsugi M, Oishi K, Okada Y, Okajyo J, Okamoto S, Okamura K, Olufuwa O, Oluyombo R, Omata A, Omori Y, Ong LM, Ong YC, Onyema J, Oomatia A, Oommen A, Oremus R, Orimo Y, Ortalda V, Osaki Y, Osawa Y, Osmond Foster J, O'Sullivan A, Otani T, Othman N, Otomo S, O'Toole J, Owen L, Ozawa T, Padiyar A, Page N, Pajak S, Paliege A, Pandey A, Pandey R, Pariani H, Park J, Parrigon M, Passauer J, Patecki M, Patel M, Patel R, Patel T, Patel Z, Paul R, Paul R, Paulsen L, Pavone L, Peixoto A, Peji J, Peng BC, Peng K, Pennino L, Pereira E, Perez E, Pergola P, Pesce F, Pessolano G, Petchey W, Petr EJ, Pfab T, Phelan P, Phillips R, Phillips T, Phipps M, Piccinni G, Pickett T, Pickworth S, Piemontese M, Pinto D, Piper J, Plummer-Morgan J, Poehler D, Polese L, Poma V, Pontremoli R, Postal A, Pötz C, Power A, Pradhan N, Pradhan R, Preiss D, Preiss E, Preston K, Prib N, Price L, Provenzano C, Pugay C, Pulido R, Putz F, Qiao Y, Quartagno R, Quashie-Akponeware M, Rabara R, Rabasa-Lhoret R, Radhakrishnan D, Radley M, Raff R, Raguwaran S, Rahbari-Oskoui F, Rahman M, Rahmat K, Ramadoss S, Ramanaidu S, Ramasamy S, Ramli R, Ramli S, Ramsey T, Rankin A, Rashidi A, Raymond L, Razali WAFA, Read K, Reiner H, Reisler A, Reith C, Renner J, Rettenmaier B, Richmond L, Rijos D, Rivera R, Rivers V, Robinson H, Rocco M, Rodriguez-Bachiller I, Rodriquez R, Roesch C, Roesch J, Rogers J, Rohnstock M, Rolfsmeier S, Roman M, Romo A, Rosati A, Rosenberg S, Ross T, Rossello X, Roura M, Roussel M, Rovner S, Roy S, Rucker S, Rump L, Ruocco M, Ruse S, Russo F, Russo M, Ryder M, Sabarai A, Saccà C, Sachson R, Sadler E, Safiee NS, Sahani M, Saillant A, Saini J, Saito C, Saito S, Sakaguchi K, Sakai M, Salim H, Salviani C, Sammons E, Sampson A, Samson F, Sandercock P, Sanguila S, Santorelli G, Santoro D, Sarabu N, Saram T, Sardell R, Sasajima H, Sasaki T, Satko S, Sato A, Sato D, Sato H, Sato H, Sato J, Sato T, Sato Y, Satoh M, Sawada K, Schanz M, Scheidemantel F, Schemmelmann M, Schettler E, Schettler V, Schlieper GR, Schmidt C, Schmidt G, Schmidt U, Schmidt-Gurtler H, Schmude M, Schneider A, Schneider I, Schneider-Danwitz C, Schomig M, Schramm T, Schreiber A, Schricker S, Schroppel B, Schulte-Kemna L, Schulz E, Schumacher B, Schuster A, Schwab A, Scolari F, Scott A, Seeger W, Seeger W, Segal M, Seifert L, Seifert M, Sekiya M, Sellars R, Seman MR, Shah S, Shah S, Shainberg L, Shanmuganathan M, Shao F, Sharma K, Sharpe C, Sheikh-Ali M, Sheldon J, Shenton C, Shepherd A, Shepperd M, Sheridan R, Sheriff Z, Shibata Y, Shigehara T, Shikata K, Shimamura K, Shimano H, Shimizu Y, Shimoda H, Shin K, Shivashankar G, Shojima N, Silva R, Sim CSB, Simmons K, Sinha S, Sitter T, Sivanandam S, Skipper M, Sloan K, Sloan L, Smith R, Smyth J, Sobande T, Sobata M, Somalanka S, Song X, Sonntag F, Sood B, Sor SY, Soufer J, Sparks H, Spatoliatore G, Spinola T, Squyres S, Srivastava A, Stanfield J, Staplin N, Staylor K, Steele A, Steen O, Steffl D, Stegbauer J, Stellbrink C, Stellbrink E, Stevens W, Stevenson A, Stewart-Ray V, Stickley J, Stoffler D, Stratmann B, Streitenberger S, Strutz F, Stubbs J, Stumpf J, Suazo N, Suchinda P, Suckling R, Sudin A, Sugamori K, Sugawara H, Sugawara K, Sugimoto D, Sugiyama H, Sugiyama H, Sugiyama T, Sullivan M, Sumi M, Suresh N, Sutton D, Suzuki H, Suzuki R, Suzuki Y, Suzuki Y, Suzuki Y, Swanson E, Swift P, Syed S, Szerlip H, Taal M, Taddeo M, Tailor C, Tajima K, Takagi M, Takahashi K, Takahashi K, Takahashi M, Takahashi T, Takahira E, Takai T, Takaoka M, Takeoka J, Takesada A, Takezawa M, Talbot M, Taliercio J, Talsania T, Tamori Y, Tamura R, Tamura Y, Tan CHH, Tan EZZ, Tanabe A, Tanabe K, Tanaka A, Tanaka A, Tanaka N, Tang S, Tang Z, Tanigaki K, Tarlac M, Tatsuzawa A, Tay JF, Tay LL, Taylor J, Taylor K, Taylor K, Te A, Tenbusch L, Teng KS, Terakawa A, Terry J, Tham ZD, Tholl S, Thomas G, Thong KM, Tietjen D, Timadjer A, Tindall H, Tipper S, Tobin K, Toda N, Tokuyama A, Tolibas M, Tomita A, Tomita T, Tomlinson J, Tonks L, Topf J, Topping S, Torp A, Torres A, Totaro F, Toth P, Toyonaga Y, Tripodi F, Trivedi K, Tropman E, Tschope D, Tse J, Tsuji K, Tsunekawa S, Tsunoda R, Tucky B, Tufail S, Tuffaha A, Turan E, Turner H, Turner J, Turner M, Tuttle KR, Tye YL, Tyler A, Tyler J, Uchi H, Uchida H, Uchida T, Uchida T, Udagawa T, Ueda S, Ueda Y, Ueki K, Ugni S, Ugwu E, Umeno R, Unekawa C, Uozumi K, Urquia K, Valleteau A, Valletta C, van Erp R, Vanhoy C, Varad V, Varma R, Varughese A, Vasquez P, Vasseur A, Veelken R, Velagapudi C, Verdel K, Vettoretti S, Vezzoli G, Vielhauer V, Viera R, Vilar E, Villaruel S, Vinall L, Vinathan J, Visnjic M, Voigt E, von-Eynatten M, Vourvou M, Wada J, Wada J, Wada T, Wada Y, Wakayama K, Wakita Y, Wallendszus K, Walters T, Wan Mohamad WH, Wang L, Wang W, Wang X, Wang X, Wang Y, Wanner C, Wanninayake S, Watada H, Watanabe K, Watanabe K, Watanabe M, Waterfall H, Watkins D, Watson S, Weaving L, Weber B, Webley Y, Webster A, Webster M, Weetman M, Wei W, Weihprecht H, Weiland L, Weinmann-Menke J, Weinreich T, Wendt R, Weng Y, Whalen M, Whalley G, Wheatley R, Wheeler A, Wheeler J, Whelton P, White K, Whitmore B, Whittaker S, Wiebel J, Wiley J, Wilkinson L, Willett M, Williams A, Williams E, Williams K, Williams T, Wilson A, Wilson P, Wincott L, Wines E, Winkelmann B, Winkler M, Winter-Goodwin B, Witczak J, Wittes J, Wittmann M, Wolf G, Wolf L, Wolfling R, Wong C, Wong E, Wong HS, Wong LW, Wong YH, Wonnacott A, Wood A, Wood L, Woodhouse H, Wooding N, Woodman A, Wren K, Wu J, Wu P, Xia S, Xiao H, Xiao X, Xie Y, Xu C, Xu Y, Xue H, Yahaya H, Yalamanchili H, Yamada A, Yamada N, Yamagata K, Yamaguchi M, Yamaji Y, Yamamoto A, Yamamoto S, Yamamoto S, Yamamoto T, Yamanaka A, Yamano T, Yamanouchi Y, Yamasaki N, Yamasaki Y, Yamasaki Y, Yamashita C, Yamauchi T, Yan Q, Yanagisawa E, Yang F, Yang L, Yano S, Yao S, Yao Y, Yarlagadda S, Yasuda Y, Yiu V, Yokoyama T, Yoshida S, Yoshidome E, Yoshikawa H, Young A, Young T, Yousif V, Yu H, Yu Y, Yuasa K, Yusof N, Zalunardo N, Zander B, Zani R, Zappulo F, Zayed M, Zemann B, Zettergren P, Zhang H, Zhang L, Zhang L, Zhang N, Zhang X, Zhao J, Zhao L, Zhao S, Zhao Z, Zhong H, Zhou N, Zhou S, Zhu D, Zhu L, Zhu S, Zietz M, Zippo M, Zirino F, Zulkipli FH. Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial. Lancet Diabetes Endocrinol 2024; 12:51-60. [PMID: 38061372 DOI: 10.1016/s2213-8587(23)00322-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/05/2023] [Revised: 10/24/2023] [Accepted: 10/25/2023] [Indexed: 12/23/2023]
Abstract
BACKGROUND The EMPA-KIDNEY trial showed that empagliflozin reduced the risk of the primary composite outcome of kidney disease progression or cardiovascular death in patients with chronic kidney disease mainly through slowing progression. We aimed to assess how effects of empagliflozin might differ by primary kidney disease across its broad population. METHODS EMPA-KIDNEY, a randomised, controlled, phase 3 trial, was conducted at 241 centres in eight countries (Canada, China, Germany, Italy, Japan, Malaysia, the UK, and the USA). Patients were eligible if their estimated glomerular filtration rate (eGFR) was 20 to less than 45 mL/min per 1·73 m2, or 45 to less than 90 mL/min per 1·73 m2 with a urinary albumin-to-creatinine ratio (uACR) of 200 mg/g or higher at screening. They were randomly assigned (1:1) to 10 mg oral empagliflozin once daily or matching placebo. Effects on kidney disease progression (defined as a sustained ≥40% eGFR decline from randomisation, end-stage kidney disease, a sustained eGFR below 10 mL/min per 1·73 m2, or death from kidney failure) were assessed using prespecified Cox models, and eGFR slope analyses used shared parameter models. Subgroup comparisons were performed by including relevant interaction terms in models. EMPA-KIDNEY is registered with ClinicalTrials.gov, NCT03594110. FINDINGS Between May 15, 2019, and April 16, 2021, 6609 participants were randomly assigned and followed up for a median of 2·0 years (IQR 1·5-2·4). Prespecified subgroupings by primary kidney disease included 2057 (31·1%) participants with diabetic kidney disease, 1669 (25·3%) with glomerular disease, 1445 (21·9%) with hypertensive or renovascular disease, and 1438 (21·8%) with other or unknown causes. Kidney disease progression occurred in 384 (11·6%) of 3304 patients in the empagliflozin group and 504 (15·2%) of 3305 patients in the placebo group (hazard ratio 0·71 [95% CI 0·62-0·81]), with no evidence that the relative effect size varied significantly by primary kidney disease (pheterogeneity=0·62). The between-group difference in chronic eGFR slopes (ie, from 2 months to final follow-up) was 1·37 mL/min per 1·73 m2 per year (95% CI 1·16-1·59), representing a 50% (42-58) reduction in the rate of chronic eGFR decline. This relative effect of empagliflozin on chronic eGFR slope was similar in analyses by different primary kidney diseases, including in explorations by type of glomerular disease and diabetes (p values for heterogeneity all >0·1). INTERPRETATION In a broad range of patients with chronic kidney disease at risk of progression, including a wide range of non-diabetic causes of chronic kidney disease, empagliflozin reduced risk of kidney disease progression. Relative effect sizes were broadly similar irrespective of the cause of primary kidney disease, suggesting that SGLT2 inhibitors should be part of a standard of care to minimise risk of kidney failure in chronic kidney disease. FUNDING Boehringer Ingelheim, Eli Lilly, and UK Medical Research Council.
Collapse
|
3
|
Li Y, Yamamoto S, Oshiro Y, Inamura N, Nemoto T, Horii K, Takeuchi JS, Mizoue T, Konishi M, Ozeki M, Sugiyama H, Sugiura W, Ohmagari N. Comparison of risk factors for SARS-CoV-2 infection among healthcare workers during Omicron and Delta dominance periods in Japan. J Hosp Infect 2023; 134:97-107. [PMID: 36805085 PMCID: PMC9933573 DOI: 10.1016/j.jhin.2023.01.018] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2022] [Revised: 01/18/2023] [Accepted: 01/23/2023] [Indexed: 02/18/2023]
Abstract
BACKGROUND The risk factors for coronavirus disease (COVID-19) among healthcare workers (HCWs) might have changed since the emergence of the highly immune evasive Omicron variant. AIM To compare the risk factors for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among HCWs during the Delta- and Omicron-predominant periods. METHODS Using data from repeated serosurveys among the staff of a medical research centre in Tokyo, two cohorts were established: Delta period cohort (N = 858) and Omicron period cohort (N = 652). The potential risk factors were assessed using a questionnaire. Acute/current or past SARS-CoV-2 infection was identified by polymerase chain reaction or anti-nucleocapsid antibody tests, respectively. Poisson regression was used to calculate the risk ratio (RR) of infection risk. FINDINGS The risk of SARS-CoV-2 infection during the early Omicron-predominant period was 3.4-fold higher than during the Delta-predominant period. Neither working in a COVID-19-related department nor having a higher degree of occupational exposure to SARS-CoV-2 was associated with an increased infection risk during both periods. During the Omicron-predominant period, infection risk was higher among those who spent ≥30 min in closed spaces, crowded spaces, and close-contact settings without wearing mask (≥3 times versus never: RR: 6.62; 95% confidence interval: 3.01-14.58), whereas no such association was found during the Delta period. CONCLUSION Occupational exposure to COVID-19-related work was not associated with the risk of SARS-CoV-2 infection in the Delta or Omicron period, whereas high-risk behaviours were associated with an increased infection risk during the Omicron period.
Collapse
Affiliation(s)
- Y Li
- Department of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan
| | - S Yamamoto
- Department of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan
| | - Y Oshiro
- Department of Laboratory Testing, Center Hospital of the National Center for Global Health and Medicine, Tokyo, Japan
| | - N Inamura
- Department of Laboratory Testing, Center Hospital of the National Center for Global Health and Medicine, Tokyo, Japan
| | - T Nemoto
- Department of Laboratory Testing, Center Hospital of the National Center for Global Health and Medicine, Tokyo, Japan
| | - K Horii
- Infection Control Office, Center Hospital of the National Center for Global Health and Medicine, Tokyo, Japan
| | - J S Takeuchi
- Department Academic-Industrial Partnerships Promotion, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan
| | - T Mizoue
- Department of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan.
| | - M Konishi
- Department of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan
| | - M Ozeki
- Department of Laboratory Testing, Center Hospital of the National Center for Global Health and Medicine, Tokyo, Japan
| | - H Sugiyama
- Center Hospital of the National Center for Global Health and Medicine, Tokyo, Japan
| | - W Sugiura
- Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan
| | - N Ohmagari
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| |
Collapse
|
4
|
Yamamoto S, Mizoue N, Mizoue T, Konishi M, Horii K, Sugiyama H, Ohmagari N. Living with school-age children and absence among staff of a tertiary hospital during the Omicron epidemic in Tokyo. J Hosp Infect 2022; 130:151-153. [PMID: 35995338 PMCID: PMC9389519 DOI: 10.1016/j.jhin.2022.08.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2022] [Accepted: 08/06/2022] [Indexed: 12/01/2022]
Affiliation(s)
- S. Yamamoto
- Department of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan
| | - N. Mizoue
- Department of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan
| | - T. Mizoue
- Department of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan,Corresponding author. Address: Department of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine, 1-21-1, Toyama, Shinjuku-ku, Tokyo, 162-8655, Japan. Tel.: +81 3 3202 7181
| | - M. Konishi
- Department of Epidemiology and Prevention, Center for Clinical Sciences, National Center for Global Health and Medicine, Tokyo, Japan
| | - K. Horii
- Infection Control Office, Center Hospital of the National Center for the Global Health and Medicine, Tokyo, Japan
| | - H. Sugiyama
- Center Hospital of the National Center for the Global Health and Medicine, Tokyo, Japan
| | - N. Ohmagari
- Disease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan
| |
Collapse
|
5
|
Konishi M, Mizushima I, Kawano M, Murayama T, Nakazaki S, Shinoda K, Kido T, Katsuki Y, Fujinaga H, Watanabe T, Motomura H, Matsushita I. POS0675 IMPACT OF PAST USE OF DISEASE MODIFYING ANTI-RHEUMATIC DRUGS ON JAK INHIBITOR TREATMENT FOR RHEUMATOID ARTHRITIS - DATA FROM THE FUKUI ISHIKAWA TOYAMA DATABASE OF RHEUMATOID ARTHRITIS. Ann Rheum Dis 2022. [DOI: 10.1136/annrheumdis-2022-eular.1443] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BackgroundCurrently, five types of Janus kinase inhibitors (JAKis) are used for rheumatoid arthritis (RA) treatment. The number of cases in which multiple JAKis have been prescribed is increasing. However, the real-world efficacy and safety of JAKis and related factors require further evaluation.ObjectivesThe primary objective of this study was to elucidate the impact of past use of disease-modifying anti-rheumatic drugs on RA treatment using JAKis. The secondary objective was to investigate the safety profiles of these agents in a real-world setting.MethodsOf the 303 JAKi-treated patients in the Fukui Ishikawa Toyama Database of RA included in this study, 30 had switched from one JAKi to another (JJ group), 214 switched from a biologic agent to a JAKi (BJ group), and 47 were naïve to either biologics or JAKis (NJ group). We compared baseline factors, treatment response, and JAKi continuation rates among the three groups. Factors related to JAKi discontinuation were assessed using Cox regression analysis. Furthermore, we investigated adverse events and reported them using exposure-adjusted incidence rates (EAIR; incidence rates per 100 patient-years).ResultsData from the 303 cases were analyzed (mean age = 63.6 years; female, 82%; mean RA duration, 176 months). Of the 303 patients, 118, 106, 50, and 29 were treated with tofacitinib, baricitinib, peficitinib, and upadacitinib, respectively, on initial observation. Rate of concomitant use with methotrexate and prednisolone was 52% and 49%, respectively.Regarding efficacy, no significant differences were observed among the three groups in terms of treatment response and JAKi continuation rates, except for the 6-month treatment response between the JJ and NJ groups. Cox regression analysis of the 303 cases revealed that only past use of JAKis during the disease history was significantly associated with JAKi discontinuation. The Kaplan–Meier method showed that patients who previously used JAKis had significantly shorter median JAKi treatment duration than those without such a history (20.9 vs. 54.7 months; p = 0.012). Treatment response was significantly poor in patients who had previously used JAKis, especially 6 months after treatment initiation.In terms of safety, the total exposure period for the 303 cases was 495 person-years, and the total number of adverse events was 161 (EAIR, 32.5). There were 12 cases (EAIR, 2.5) of serious infections, 23 cases (EAIR, 5.1) of herpes zoster, 7 cases (EAIR, 1.4) of malignant tumors, and 4 cases (EAIR, 0.8) of MACE. Adverse events led to JAKi discontinuation in 34 patients (EAIR, 6.9); the main causes of adverse events leading to treatment discontinuation were infectious diseases in 10 cases (EAIR, 2) and neoplasms in 4 cases (EAIR, 0.8). Within 1 year of initiating JAKi therapy, 21 patients discontinued treatment owing to adverse events, which accounted for 27% of the reasons for treatment discontinuation.We also investigated cases of JAKi dose reduction, observed in 42 of the 303 cases. Among them, 10 patients required a re-increase in the JAKi dose, and 13 patients (56.5%) were able to maintain the reduced dose for more than 1 year. The remaining 19 patients were excluded from the analysis because the treatment duration at the lower dose had not exceeded 1 year at the time of data extraction. No difference in disease activity at the time of dose reduction was observed between those who maintained the new dose and those who did not (mean DAS28-CRP: 1.48 ± 0.26 vs. 1.89 ± 0.62).ConclusionPast use of JAKis may contribute to decreased response and continuation rates for JAKi treatment. In this study, conducted in Japan, development of herpes zoster was found to the most frequent adverse event among the priority survey items.AcknowledgementsI have no acknowledgements to declare.Disclosure of InterestsNone declared
Collapse
|
6
|
Satou R, Matsuzawa Y, Akiyama E, Konishi M, Yoshii T, Nakahashi H, Minamimoto Y, Okada K, Maejima N, Iwahashi N, Hibi K, Kosuge M, Ebina T, Tamura K, Kimura K. Inflammation-frailty linkage and its long-term prognostic impact in patients with acute coronary syndrome. Eur Heart J 2021. [DOI: 10.1093/eurheartj/ehab724.1298] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Introduction
Chronic inflammation has been receiving considerable attention as an emerging risk factor for cardiovascular disease. In contrast, with the aging of the population, frailty has been also attracting a great deal of attention as the residual risk for cardiovascular disease. Although inflammation and frailty exacerbate each other and have an adverse effect on many diseases, the relationship between chronic inflammation and frailty and the impact of these combination on long-term prognosis in patients with acute coronary syndrome (ACS) are not elucidated.
Purpose
The aims of this study were to determine the association between chronic inflammation and frailty and its impact on long-term cardiovascular outcomes in patients with ACS.
Methods
A total of 482 consecutive ACS patients with obstructive coronary artery disease (age 66±12 years, male 81%) were enrolled in this observational study. We evaluated patients' gait speed as a measure of frailty before discharge. C-reactive protein (CRP) levels at 1 month after discharge were also evaluated as inflammation in the chronic phase. According to commonly used criteria of the residual inflammation (CRP>0.2 mg/dL) and the definition of the European Working Group for Sarcopenia (gait speed ≤0.8 m/sec), patients were stratified by 4 subgroups: low/high CRP with slow/normal gait speed. The primary endpoint was composite outcomes of cardiovascular death, myocardial infarction and ischemic stroke.
Results
While there was no significant association between CRP levels and gait speed in all patients, a significant negative association between two variables was observed in the high CRP group (Spearman's ρ = −0.31, p=0.001). During the median follow-up of 6 years, primary endpoints have occurred in 82 patients. Overall, event-free rates differed significantly among the 4 groups, demonstrating the lowest event-free rate in the patients with high CRP and slow gait speed (p<0.0001; Figure). In the multivariate analysis, high CRP (adjusted HR 1.99, 95% CI 1.14–3.46, p=0.02) and slow gait speed (adjusted HR 1.82, 95% CI 1.09–3.04, p=0.02) were independently and significantly associated with the primary endpoint. Moreover, the patients with both high CRP and slow gait speed had a 2.6-fold higher risk of cardiovascular events compared to others (adjusted HR 2.62, 95% CI 1.36–5.05, p=0.004).
Conclusion
In the patients with ACS, CRP levels and gait speed were negatively associated in the high CRP group. Chronic inflammation and frailty were both associated with poor prognosis in ACS and in particular, the combination of these factors was strongly associated with poor prognosis.
Funding Acknowledgement
Type of funding sources: None. Figure 1
Collapse
Affiliation(s)
- R Satou
- Yokohama City University Medical Center, division of cardiology, Yokohama, Japan
| | - Y Matsuzawa
- Yokohama City University Medical Center, division of cardiology, Yokohama, Japan
| | - E Akiyama
- Yokohama City University Medical Center, division of cardiology, Yokohama, Japan
| | - M Konishi
- Yokohama City University, Department of Medical Science and Cardiorenal Medicine, Yokohama, Japan
| | - T Yoshii
- Yokohama City University Medical Center, division of cardiology, Yokohama, Japan
| | - H Nakahashi
- Yokohama City University Medical Center, division of cardiology, Yokohama, Japan
| | - Y Minamimoto
- Yokohama City University Medical Center, division of cardiology, Yokohama, Japan
| | - K Okada
- Yokohama City University Medical Center, division of cardiology, Yokohama, Japan
| | - N Maejima
- Yokohama City University Medical Center, division of cardiology, Yokohama, Japan
| | - N Iwahashi
- Yokohama City University Medical Center, division of cardiology, Yokohama, Japan
| | - K Hibi
- Yokohama City University Medical Center, division of cardiology, Yokohama, Japan
| | - M Kosuge
- Yokohama City University Medical Center, division of cardiology, Yokohama, Japan
| | - T Ebina
- Yokohama City University Medical Center, division of cardiology, Yokohama, Japan
| | - K Tamura
- Yokohama City University, Department of Medical Science and Cardiorenal Medicine, Yokohama, Japan
| | - K Kimura
- Yokohama City University Medical Center, division of cardiology, Yokohama, Japan
| |
Collapse
|
7
|
Okamura M, Konishi M, Saigusa Y, Ando S, Nakayama M, Komura N, Sugano T, Tamaura K, Nakamura T. Impact of grip strength and balance function on the exercise capacity in pulmonary hypertension. Eur J Prev Cardiol 2021. [DOI: 10.1093/eurjpc/zwab061.125] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: None.
【Background】
Patients with pulmonary hypertension (PH) suffer from poor exercise capacity due to impaired oxygenation or reduced cardiac output. However, the relationship between exercise capacity and physical functions remains unclear.
【Purpose】
The purpose of this study is to investigate the relationship between exercise capacity and physical functions in pulmonary hypertension.
【Methods】
From February 2018 to June 2020, 94 patients (61.3 ± 14.7 years old, 69.1% females) with group 1/3/4/5 PH underwent cardiac catheterization, 6-minute walking distance (6MWD), and physical function measurements simultaneously. The physical functions was measured using muscle strength (grip strength, knee extension muscle strength), balance function (one leg standing time), and short physical performance battery (SPPB). Exercise capacity was measured by 6MWD.
【Results】
The study cohort consists of 22/8/60/4 (23.4%/8.5%/63.8%/4.3%) patients with group 1/3/4/5 PH, respectively. The average age of each group was 50.7/64.7/63.1/66.0 years old, respectively. A total of 194 measurements of physical functions were evaluated from 94 patients and employed in multivariate logistic regression analysis using adaptive-LASSO methods with the 6MWD (476.2 ± 107.5m) as a dependent variable. WHO functional class (class II: standardized β=-0.35, 95% confidence interval (CI) [-0.54 - -0.16], p < 0.001), class III: β=-0.60, 95%CI [-0.90 - -0.30], p < 0.001), mixed venous oxygen saturation (SvO2: β=0.11, 95%CI [0.03 - 0.19], p = 0.008), pulmonary vascular resistance (PVR: β=-0.16, 95%CI [-0.25 - -0.07], p < 0.001), grip strength (β=0.20, 95%CI [0.09 - 0.31], p < 0.001), one leg standing time (β=0.10, 95%CI [0.00 - 0.20], p = 0.049) , and 4m gait speed test (β=-0.28, 95%CI [-0.36 - -0.19], p < 0.001) were associated with 6MWD.
【Conclusions】
Grip strength and balance function, as well as SvO2 and PVR, were associated with the exercise capacity in pulmonary hypertension.
Collapse
Affiliation(s)
- M Okamura
- Yokohama City University Hospital, Department of Rehabilitation, Yokohama, Japan
| | - M Konishi
- Yokohama City University School of Medicine, Department of Medical Science and Cardiorenal Medicine, Yokohama, Japan
| | - Y Saigusa
- Yokohama City University School of Medicine, Department of Biostatistics, Yokohama, Japan
| | - S Ando
- Tokyo University of Science Faculty of Engineering, Department of Information and Computer Technology, Tokyo, Japan
| | - M Nakayama
- Yokohama City University School of Medicine, Department of Medical Science and Cardiorenal Medicine, Yokohama, Japan
| | - N Komura
- Yokohama City University School of Medicine, Department of Medical Science and Cardiorenal Medicine, Yokohama, Japan
| | - T Sugano
- Yokohama City University School of Medicine, Department of Medical Science and Cardiorenal Medicine, Yokohama, Japan
| | - K Tamaura
- Yokohama City University School of Medicine, Department of Medical Science and Cardiorenal Medicine, Yokohama, Japan
| | - T Nakamura
- Yokohama City University School of Medicine, Department of Rehabilitation Medicine, Yokohama, Japan
| |
Collapse
|
8
|
Udagawa T, Okutsu M, Kanamori T, Konishi M, Takase H, Morio T. POS-059 SUCCESSFUL TREATMENT OF REFRACTORY TUBULOINTERSTITIAL NEPHRITIS AND UVEITIS SYNDROME USING MYCOPHENOLATE MOFETIL. Kidney Int Rep 2021. [DOI: 10.1016/j.ekir.2021.03.065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
9
|
Hara S, Shimizu T, Konishi M, Yamamura R, Ikemoto S. Autonomous Mobile Robot for Outdoor Slope Using 2D LiDAR with Uniaxial Gimbal Mechanism. JRM 2020. [DOI: 10.20965/jrm.2020.p1173] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
The Nakanoshima Challenge is a contest for developing sophisticated navigation systems of robots for collecting garbage in outdoor public spaces. In this study, a robot named Navit(oo)n is designed, and its performance in public spaces such as city parks is evaluated. Navit(oo)n contains two 2D LiDAR scanners with uniaxial gimbal mechanism, improving self-localization robustness on a slope. The gimbal mechanism adjusts the angle of the LiDAR scanner, preventing erroneous ground detection. We evaluate the navigation performance of Navit(oo)n in the Nakanoshima and its Extra Challenges.
Collapse
|
10
|
Saito K, Matsue Y, Kamiya K, Saito H, Ogasahara Y, Kitai T, Konishi M, Maekawa E, Iwata K, Jujo K, Wada H, Kasai T, Nagamatsu H, Momomura S, Kagiyama N. Prognostic significance of 2019 Asian Working Group for Sarcopenia update on definition of sarcopenia. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.1078] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background/Introduction
Sarcopenia plays a major role in the pathophysiology of frailty and is associated with worse outcome in the elderly population including patients with heart failure. A recent update of the most common definition of sarcopenia in Asia, Asian Working Group for Sarcopenia (AWGS2019), included significant changes in the diagnostic algorithm with newly dividing sarcopenia into severe and “non-severe” sarcopenia.
Purpose
The objective of this study was to evaluate the differences between AWGS2014 and AWGS2019 in patients with heart failure.
Methods
In the multicenter prospective FRAGILE-HF registry, which included elderly (≥65 years old) patients who were hospitalized with heart failure, we studied 865 patients (80±8 years old, 42% female). All-cause death in 1-year follow-up was tracked.
Results
Based on the original version of AWGS (AWGS2014), 183 patients (21%) were diagnosed with sarcopenia, which was associated with higher age, lower physical performance, less muscle mass, and greater heart failure risk (all p<0.001) as well as higher rate of all-cause death (HR 1.90, p=0.004 after adjustment by multivariable regression). Those patients with sarcopenia by AWGS2014 were reclassified mainly to severe sarcopenia (155, 84.7%) by AWGS2019, and 25 (13.7%) and 2 (1.1%) were classified into sarcopenia and non-sarcopenia. Meanwhile, 24 (3.5%) and 4 (0.6%) of patients without sarcopenia by AWGS2014 were reclassified into sarcopenia and severe sarcopenia, respectively. Although severe sarcopenia by AWGS2019 was associated with higher age, lower physical performance, less muscle mass, and greater heart failure risk (all p<0.001), patients with “non-severe” sarcopenia was rather younger (p<0.001) and had better physical performance (p=0.021) despite less muscle mass (p<0.001) than those without sarcopenia. Multivariate Cox analysis demonstrated severe sarcopenia by AWGS2019 was an independent prognostic factor (HR 1.77, p=0.014), but “non-severe” sarcopenia was not (HR 1.52, p=0.37). The prognosis of patients who were reclassified from non-sarcopenia to sarcopenia or severe sarcopenia were comparable to those remained non-sarcopenia. When added to other risk factors, the prognostic predictability of AWGS2019 was significantly lower than AWGS2014 (net reclassification improvement −0.26, p=0.025).
Conclusions
About a half of “non-severe” sarcopenia in AWGS2019 were patients without sarcopenia in AWGS2014. The prognosis of such patients who were newly diagnosed as sarcopenia was good, resulting in low overall prognostic predictability of AWGS2019. A further consideration for diagnostic algorithms of sarcopenia may be warranted in patients with heart failure.
Funding Acknowledgement
Type of funding source: Foundation. Main funding source(s): Japan Heart Foundation
Collapse
Affiliation(s)
- K Saito
- The Sakakibara Heart Institute of Okayama, Cardiac rehabilitation, Okayama, Japan
| | - Y Matsue
- Juntendo University Graduate School of Medicine, Tokyo, Japan
| | - K Kamiya
- Kitasato University Graduate School of Medical Sciences, Sagamihara, Japan
| | - H Saito
- Kameda Medical Center, Chiba, Japan
| | - Y Ogasahara
- The Sakakibara Heart Institute of Okayama, Okayama, Japan
| | - T Kitai
- Kobe City Medical Center General Hospital, Kobe, Japan
| | - M Konishi
- Yokohama City University Medical Center, Yokohama, Japan
| | - E Maekawa
- Kitasato University Graduate School of Medical Sciences, Sagamihara, Japan
| | - K Iwata
- Kobe City Medical Center General Hospital, Kobe, Japan
| | - K Jujo
- Nishiarai Heart Center, Tokyo, Japan
| | - H Wada
- Jichi Medical University Saitama Medical Center, Saitama, Japan
| | - T Kasai
- Juntendo University Graduate School of Medicine, Tokyo, Japan
| | | | - S Momomura
- Jichi Medical University Saitama Medical Center, Saitama, Japan
| | - N Kagiyama
- West Virginia Institute Heart and Vascular Institute, Morgantown, United States of America
| |
Collapse
|
11
|
Konishi M, Kagiyama N, Saito H, Saito K, Ogasahara Y, Maekawa E, Kitai T, Momomura S, Tamura K, Kimura K, Kamiya K, Matsue Y. Negative impact of skeletal muscle impairment in older patients with heart failure with reduced versus preserved ejection fraction. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.1143] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background/Introduction
Reduced functional capacity is an important phenotype of heart failure (HF), even though it may be considered multifactorial, especially in HF with preserved ejection fraction (HFpEF). Impairment in skeletal muscle may be one of extra-cardiac factors for reduced functional capacity and subsequent poor outcome.
Purpose
We sought to investigate the impact of the impairment in skeletal muscle, defined by the cut-offs proposed by the international consensus, on functional capacity and clinical outcome, in HF patients with preserved and reduced EF (HFrEF).
Methods
This is a multicenter prospective study including 1317 consecutive older (≥65 years) hospitalized patients with HF [HFpEF (ejection fraction ≥45%, n=675, 82±7 years, 46.4% male) and HFrEF (ejection fraction <45%, n=642, 78±8 years, 68.4% male)].
Results
HFrEF patients were more likely to have low skeletal muscle mass measured by bioelectrical impedance analysis (30.9% vs 22.1%, p=0.003) whereas less likely to have low muscle strength (handgrip strength; 62.9% vs 73.8%, p<0.001) than HFpEF, resulting in similar prevalence of sarcopenia between the two groups (21.6% vs 18.1%, p=0.19). In HFrEF, presence of sarcopenia was an independent predictor of reduced functional capacity assessed by a 6-minute walk distance (standardized beta=−0.093, p=0.039 in multivariate linear regression analysis) and 1-year mortality (adjusted hazard ratio (aHR) and 95% CI; 2.14 (1.22–3.70), p=0.009 in multivariate Cox-regression analysis). In patients with HFpEF, sarcopenia could predict mortality (aHR and 95% CI; 2.23 (1.23–3.91), p=0.009), though its association with reduced functional capacity was not significant after multivariate adjustment (standardized beta=−0.059, p=0.20). Kaplan-Meier survival curves in HFpEF and HFrEF are shown (Figure).
Conclusion(s)
In older patients with HF, sarcopenia was similarly contributed to mortality in HFpEF and HFrEF whereas its influence on functional capacity was pronounced in HFrEF.
Funding Acknowledgement
Type of funding source: Private grant(s) and/or Sponsorship. Main funding source(s): Japan Heart Foundation Research Grant
Collapse
Affiliation(s)
- M Konishi
- Yokohama City University Hospital, Yokohama, Japan
| | - N Kagiyama
- The Sakakibara Heart Institute of Okayama, Okayama, Japan
| | - H Saito
- Kameda Medical Center, Kamogawa, Japan
| | - K Saito
- The Sakakibara Heart Institute of Okayama, Okayama, Japan
| | - Y Ogasahara
- The Sakakibara Heart Institute of Okayama, Okayama, Japan
| | - E Maekawa
- Kitasato University School of Medicine, Sagamihara, Japan
| | - T Kitai
- Kobe City Medical Center General Hospital, Kobe, Japan
| | - S Momomura
- Jichi Medical University Saitama Medical Center, Saitama, Japan
| | - K Tamura
- Yokohama City University Hospital, Yokohama, Japan
| | - K Kimura
- Yokohama City University Medical Center, Yokohama, Japan
| | - K Kamiya
- Kitasato University School of Medicine, Sagamihara, Japan
| | - Y Matsue
- Juntendo University School of Medicine, Tokyo, Japan
| |
Collapse
|
12
|
Jujo K, Kagiyama N, Kamiya K, Saito H, Saito K, Ogasahara Y, Maekawa E, Konishi M, Kitai T, Iwata K, Wada H, Kasai T, Nagamatsu H, Ozawa T, Matsue Y. Social frailty provides additive prognostic impact on one-year outcome in aged patients with congestive heart failure. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.1152] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Frailty is associated with multisystem declines in physiologic reserve and increased vulnerability to stressors, resulting in increased risks of adverse clinical outcomes in patients with heart failure (HF). Although frailty is conceptualized as an accumulation of deficits in multiple areas, most of the studies have focused mainly on physical frailty, and the social domains is one of the least investigated area.
Objectives
We prospectively evaluated the incidence and prognostic implication of social frailty (SF) in older patients with HF.
Methods
The FRAGILE-HF is a multicenter, prospective cohort study including patients hospitalized for HF and aged ≥65 years old. We defined SF by Makizako's 5 items, which are 5 questions proposed and validated to be associated with future disability. The primary endpoint of this study was a composite of death from any cause and rehospitalization due to HF. The impact of SF on all-cause mortality alone was also evaluated.
Results
Among 1,240 hospitalized HF patients, 5 simple questions revealed that 825 (66.5%) were in SF. During 1-year observation period after the discharge, the combined endpoint was observed in 399 (32.2%) patients, and 145 (11.7%) patients died. Kaplan-Meier analysis showed that SF patients had significantly higher rates of both the combined endpoint and all-cause mortality than those without SF (Log-rank test: p<0.05 for both, Figures). Moreover, SF remained independently associated with higher event rate of the combined endpoint (hazard ratio: 1.30; 95% confidence interval: 1.02 to 1.66; p=0.038) and all-cause mortality (hazard ratio: 1.53; 95% confidence interval: 1.01 to 2.30; p=0.044), even after adjusting for other covariates. Significant incremental prognostic value was shown when information on social frailty was added to known risk factors for combined endpoint (NRI: 0.189, 95% confidence interval: 0.063–0.316, p=0.003) and all-cause mortality (NRI: 0.234, 95% confidence interval: 0.073–0.395, p=0.004).
Conclusions
Among older hospitalized patients with heart failure, two-thirds of the population was with SF. Evaluating SF provides additive prognostic information in elderly patients with heart failure.
Funding Acknowledgement
Type of funding source: Private grant(s) and/or Sponsorship. Main funding source(s): Novartis Pharma Research Grants, Japan Heart Foundation Research Grant
Collapse
Affiliation(s)
- K Jujo
- Tokyo Women's Medical University, Tokyo, Japan
| | - N Kagiyama
- West Virginia Institute Heart and Vascular Institute, Morgantown, United States of America
| | - K Kamiya
- Kitasato University, Rehabilitation, Tokyo, Japan
| | - H Saito
- Kameda Medical Center, Chiba, Japan
| | - K Saito
- The Sakakibara Heart Institute of Okayama, Okayama, Japan
| | - Y Ogasahara
- The Sakakibara Heart Institute of Okayama, Okayama, Japan
| | - E Maekawa
- Kitasato University, Nursing, Tokyo, Japan
| | - M Konishi
- Yokohama City University Medical Center, Yokohama, Japan
| | - T Kitai
- Kobe City Medical Center General Hospital, Kobe, Japan
| | - K Iwata
- Kobe City Medical Center General Hospital, Kobe, Japan
| | - H Wada
- Jichi Medical University Saitama Medical Center, Saitama, Japan
| | - T Kasai
- Juntendo University School of Medicine, Tokyo, Japan
| | - H Nagamatsu
- Tokai University School of Medicine, Kanagawa, Japan
| | - T Ozawa
- Odawara Municipal Hospital, Rehabilitation, Kanagawa, Japan
| | - Y Matsue
- Juntendo University School of Medicine, Tokyo, Japan
| |
Collapse
|
13
|
Satou R, Matsuzawa Y, Akiyama E, Konishi M, Yoshii T, Okada K, Maejima N, Iwahashi N, Hibi K, Kosuge M, Ebina T, Tamura K, Kimura K. Low-density lipoprotein cholesterol levels on admission and long-term outcomes in statin-naive patients with acute coronary syndrome. Eur Heart J 2020. [DOI: 10.1093/ehjci/ehaa946.1647] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Introduction
Dyslipidemia, especially an increase in the low-density lipoprotein cholesterol (LDL-C) has been established as one of the most important risk factors for atherosclerotic cardiovascular diseases. In contrast, some recent studies have shown that the low LDL-C level was associated with short-term poor prognosis in patients with cardiovascular disease, and this is so-called “cholesterol paradox”. However, there is few data evaluating the effects on long-term outcome of “cholesterol paradox” in patients with acute coronary syndrome (ACS).
Purpose
The purpose of this study was to examine whether the low LDL-C level on admission affect long-term prognosis in patients with ACS.
Methods
A total of 434 ACS patients who survived to hospital discharge were enrolled in this study. All patients were statin-naïve on admission, and were received statin therapy after hospitalization. Patients were divided into the low LDL-C (≤114 mg/dl) and high LDL-C (>114 mg/dl) groups using the first tertile of the LDL-C level on admission. The primary endpoint was composite outcomes of all-cause death, myocardial infarction, ischemic stroke, hospitalization for congestive heart failure and unplanned revascularization.
Results
During a median follow-up period of 5.5 years, primary endpoint occurred in 117 patients. Overall, event-free rates differed significantly between the low and high LDL-C groups, demonstrating the lower event-free rate in patients with the low LDL-C group (38.9% in low LDL-C group versus 20.7% in high LDL-C group, p=0.0002; Figure). Even after adjustment for age, sex, body mass index, and various classical risk factors, the low LDL-C group was significantly at higher risk for primary composite outcomes compared to the high LDL-C group (adjusted hazard ratio 1.65, 95%-confidence interval 1.10–2.49, p=0.02).
Conclusion
In patients with ACS, the low LDL-C level on admission was significantly associated with long-term worse prognosis, regardless of statin therapy at discharge. In ACS patients with low LDL-C level, it might be necessary for elucidating the residual risk for secondary adverse event to improve their prognosis.
Funding Acknowledgement
Type of funding source: None
Collapse
Affiliation(s)
- R Satou
- Yokohama City University Medical Center, division of cardiology, Yokohama, Japan
| | - Y Matsuzawa
- Yokohama City University Medical Center, division of cardiology, Yokohama, Japan
| | - E Akiyama
- Yokohama City University Medical Center, division of cardiology, Yokohama, Japan
| | - M Konishi
- Yokohama City University, Department of Medical Science and Cardiorenal Medicine, Yokohama, Japan
| | - T Yoshii
- Yokohama City University Medical Center, division of cardiology, Yokohama, Japan
| | - K Okada
- Yokohama City University Medical Center, division of cardiology, Yokohama, Japan
| | - N Maejima
- Yokohama City University Medical Center, division of cardiology, Yokohama, Japan
| | - N Iwahashi
- Yokohama City University Medical Center, division of cardiology, Yokohama, Japan
| | - K Hibi
- Yokohama City University Medical Center, division of cardiology, Yokohama, Japan
| | - M Kosuge
- Yokohama City University Medical Center, division of cardiology, Yokohama, Japan
| | - T Ebina
- Yokohama City University Medical Center, division of cardiology, Yokohama, Japan
| | - K Tamura
- Yokohama City University, Department of Medical Science and Cardiorenal Medicine, Yokohama, Japan
| | - K Kimura
- Yokohama City University, Department of Medical Science and Cardiorenal Medicine, Yokohama, Japan
| |
Collapse
|
14
|
Edeline J, Hirano S, Bertaut A, Konishi M, Benabdelghani M, Uesaka K, Watelet J, Ohtsuka M, Hammel P, Kaneoka Y, Joly JP, Yamamoto M, Jouffroy C, Ambo Y, Louvet C, Ando M, Malka D, Nagino M, Phelip J, Ebata T. 55P Adjuvant gemcitabine-based chemotherapy for biliary tract cancer: Pooled analysis of the BCAT and PRODIGE-12 studies. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.033] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
15
|
Sugihara T, Hasegawa H, Uchida HA, Yoshifuji H, Watanabe Y, Amiya E, Maejima Y, Konishi M, Murakawa Y, Ogawa N, Furuta S, Katsumata Y, Komagata Y, Naniwa T, Okazaki T, Tanaka Y, Takeuchi T, Nakaoka Y, Arimura Y, Harigai M, Isobe M. Associated factors of poor treatment outcomes in patients with giant cell arteritis: clinical implication of large vessel lesions. Arthritis Res Ther 2020; 22:72. [PMID: 32264967 PMCID: PMC7137303 DOI: 10.1186/s13075-020-02171-6] [Citation(s) in RCA: 26] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/25/2020] [Accepted: 03/30/2020] [Indexed: 12/17/2022] Open
Abstract
Background Relapses frequently occur in giant cell arteritis (GCA), and long-term glucocorticoid therapy is required. The identification of associated factors with poor treatment outcomes is important to decide the treatment algorithm of GCA. Methods We enrolled 139 newly diagnosed GCA patients treated with glucocorticoids between 2007 and 2014 in a retrospective, multi-center registry. Patients were diagnosed with temporal artery biopsy, 1990 American College of Rheumatology classification criteria, or large vessel lesions (LVLs) detected by imaging based on the modified classification criteria. Poor treatment outcomes (non-achievement of clinical remission by week 24 or relapse during 52 weeks) were evaluated. Clinical remission was defined as the absence of clinical signs and symptoms in cranial and large vessel areas, polymyalgia rheumatica (PMR), and elevation of C-reactive protein (CRP) levels. A patient was determined to have a relapse if he/she had either one of the signs and symptoms that newly appeared or worsened after achieving clinical remission. Re-elevation of CRP without clinical manifestations was considered as a relapse if other causes such as infection were excluded and the treatment was intensified. Associated factors with poor treatment outcomes were analyzed by using the Cox proportional hazard model. Results Cranial lesions, PMR, and LVLs were detected in 77.7%, 41.7%, and 52.5% of the enrolled patients, respectively. Treatment outcomes were evaluated in 119 newly diagnosed patients who were observed for 24 weeks or longer. The mean initial dose of prednisolone was 0.76 mg/kg/day, and 29.4% received any concomitant immunosuppressive drugs at baseline. Overall, 41 (34.5%) of the 119 patients had poor treatment outcomes; 13 did not achieve clinical remission by week 24, and 28 had a relapse after achieving clinical remission. Cumulative rates of the events of poor treatment outcomes in patients with and without LVLs were 47.5% and 17.7%, respectively. A multivariable model showed the presence of LVLs at baseline was significantly associated with poor treatment outcomes (adjusted hazard ratio [HR] 3.54, 95% CI 1.52–8.24, p = 0.003). Cranial lesions and PMR did not increase the risk of poor treatment outcomes. Conclusion The initial treatment intensity in the treatment algorithm of GCA could be determined based upon the presence or absence of LVLs detected by imaging at baseline.
Collapse
Affiliation(s)
- Takahiko Sugihara
- Department of Lifetime Clinical Immunology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8519, Japan. .,Department of Rheumatology, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan. .,Department of Medicine and Rheumatology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan.
| | - Hitoshi Hasegawa
- Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, Matsuyama, Ehime, Japan
| | - Haruhito A Uchida
- Department of Chronic Kidney Disease and Cardiovascular Disease, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
| | - Hajime Yoshifuji
- Department of Rheumatology and Clinical Immunology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
| | - Yoshiko Watanabe
- First Department of Physiology, Kawasaki Medical School, Kurashiki, Japan
| | - Eisuke Amiya
- Department of Cardiovascular Medicine, Graduate School of Medicine, Department of Therapeutic Strategy for Heart Failure, The University of Tokyo, Tokyo, Japan
| | - Yasuhiro Maejima
- Department of Cardiovascular Medicine, Tokyo Medical and Dental University, Tokyo, Japan
| | - Masanori Konishi
- Department of Cardiovascular Medicine, Tokyo Medical and Dental University, Tokyo, Japan
| | - Yohko Murakawa
- Department of Rheumatology, Shimane University Faculty of Medicine, Izumo, Japan
| | - Noriyoshi Ogawa
- Department of Internal Medicine 3, Hamamatsu University School of Medicine, Hamamatsu, Japan
| | - Shunsuke Furuta
- Department of Allergy and Clinical Immunology, Chiba University Hospital, Chiba, Japan
| | - Yasuhiro Katsumata
- Department of Rheumatology, Tokyo Women's Medical University School of Medicine, Tokyo, Japan
| | - Yoshinori Komagata
- Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan
| | - Taio Naniwa
- Division of Rheumatology, Department of Internal Medicine, Nagoya City University Hospital, Nagoya, Japan.,Department of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Japan
| | - Takahiro Okazaki
- Division of Rheumatology & Allergology, Department of Internal Medicine, St. Marianna University School of Medicine, Kawasaki, Japan.,National Hospital Organization, Shizuoka Medical Center, Shimizu, Japan
| | - Yoshiya Tanaka
- The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan
| | - Tsutomu Takeuchi
- Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan
| | - Yoshikazu Nakaoka
- Department of Cardiovascular Medicine, Osaka University Graduate School of Medicine, Suita, Japan.,Department of Vascular Physiology, National Cerebral and Cardiovascular Center Research Institute, Suita, Japan
| | - Yoshihiro Arimura
- Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan.,Kichijoji Asahi Hospital, Tokyo, Japan
| | - Masayoshi Harigai
- Department of Rheumatology, Tokyo Women's Medical University School of Medicine, Tokyo, Japan
| | - Mitsuaki Isobe
- Department of Cardiovascular Medicine, Tokyo Medical and Dental University, Tokyo, Japan.,Sakakibara Heart Institute, Tokyo, Japan
| | | |
Collapse
|
16
|
Miki M, Takao S, Konishi M, Shigeoka Y, Miyashita M, Suwa H, Imamura M, Okuno T, Hirokaga K, Miyoshi Y, Murase K, Yanai A, Yamagami K, Akazawa K. Investigation of the use of a novel S-1 administration method for treating metastatic and recurrent breast cancer. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz418.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
17
|
Satou R, Akiyama E, Konishi M, Matsuzawa Y, Kimura Y, Okada K, Maejima N, Iwahashi N, Hibi K, Kosuge M, Ebina T, Tamura K, Kimura K. P5483Prognostic impact of skeletal muscle, fat, and bone mass in male patients with ST-segment elevation myocardial infarction. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz746.0437] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
Muscle, fat and bone mass may play some roles to keep physical activity and favorable outcome in patients with cardiovascular diseases. However, there is a paucity of data regarding the effects on the prognosis of skeletal muscle, fat, and bone mass in patients with ST-segment elevation myocardial infarction (STEMI).
Purpose
Our purpose was to examine whether skeletal muscle, fat, and bone mass each affect the prognosis after STEMI.
Methods
A total of 354 male patients with STEMI were enrolled in this study. Dual-energy X-ray absorptiometry scan was performed before discharge. All patients were followed up for the primary composite outcome of all-cause death, nonfatal myocardial infarction, nonfatal ischemic stroke, hospitalization for congestive heart failure, and unplanned revascularization.
Results
During a median follow-up of 32 months, 57 patients experienced primary composite outcome. Each of skeletal muscle, fat, and bone mass were indexed by height squared (kg/m2) and divided into two groups using the cut-off value obtained from the maximum Youden index to predict the primary composite outcome. The event rate was significantly higher in patients with low appendicular skeletal muscle mass index (ASMI) (29.2% vs 11.7%, p<0.001), low fat mass index (FMI) (22.9% vs 13.3%, p=0.030), and low bone mass index (23.8% vs 11.6%, p=0.002). After adjustment for age, renal function, diabetes mellitus, infarct size, Killip classification, and body mass index, low ASMI but not FMI (p=0.150) and bone mass index (p=0.159) was independently and significantly associated with the primary composite outcome (adjusted hazard ratio 2.12, 95%-confidence interval 1.05–4.31, p=0.035).
Conclusions
Index about muscle mass rather than fat and bone mass have prognostic impact in male patients with STEMI.
Collapse
Affiliation(s)
- R Satou
- Yokohama City University Medical Center, division of cardiology, Yokohama, Japan
| | - E Akiyama
- Yokohama City University Medical Center, division of cardiology, Yokohama, Japan
| | - M Konishi
- Yokohama City University Medical Center, division of cardiology, Yokohama, Japan
| | - Y Matsuzawa
- Yokohama City University Medical Center, division of cardiology, Yokohama, Japan
| | - Y Kimura
- Yokohama City University Medical Center, division of cardiology, Yokohama, Japan
| | - K Okada
- Yokohama City University Medical Center, division of cardiology, Yokohama, Japan
| | - N Maejima
- Yokohama City University Medical Center, division of cardiology, Yokohama, Japan
| | - N Iwahashi
- Yokohama City University Medical Center, division of cardiology, Yokohama, Japan
| | - K Hibi
- Yokohama City University Medical Center, division of cardiology, Yokohama, Japan
| | - M Kosuge
- Yokohama City University Medical Center, division of cardiology, Yokohama, Japan
| | - T Ebina
- Yokohama City University Medical Center, division of cardiology, Yokohama, Japan
| | - K Tamura
- Yokohama City University, Department of Medical Science and Cardiorenal Medicine, Yokohama, Japan
| | - K Kimura
- Yokohama City University Medical Center, division of cardiology, Yokohama, Japan
| |
Collapse
|
18
|
Kobayashi S, Takahashi S, Kojima M, Sugimoto M, Konishi M, Ito M, Yoshino T, Gotohda N, Taniguchi H. Clinical impact of BRAF V600E mutations in patients (pts) with resectable solitary colorectal liver metastases (CRLM). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz246.076] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
19
|
Akiyama E, Konishi M, Okumura T, Kida K, Oishi S, Suzuki S, Yamamoto M, Kitai T, Matsue Y. 428In-hospital coronary angiography is associated with increased evidence based medications and better survival in patients hospitalized with acute heart failure - results from REALITY-AHF. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz747.0106] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Coronary artery disease is a major cause of heart failure (HF). Urgent coronary angiography (CAG) is recommended for patients with acute HF (AHF) complicated with acute coronary syndrome (ACS); however, clinical usefulness of in-hospital CAG in AHF patients without ACS remains unknown.
Purpose
To investigate the association between in-hospital CAG and all-cause mortality at 1-year after hospital discharge and effects of medications at discharge on this association.
Methods
From the REALITY-AHF study, 1344 patients hospitalized with AHF were enrolled in this study and followed up for 1-year after hospital discharge.
Results
In-hospital CAG was undergone in 511 patients (38%). CAG group had a significantly lower 1-year mortality compared with non-CAG group (unadjusted hazard ratio [HR]; 0.30, 95%-confidence interval [CI] 0.21–0.43, P<0.001, after adjustment for MAGGIC score; HR 0.45, 95%-CI 0.29–0.70, P<0.001, in propensity-score matched 296 pairs; HR 0.60, 95%-CI 0.37–0.98, P=0.04). At discharge, aspirin, statins and beta blockers were prescribed more in CAG group compared with non-CAG group (aspirin 46% versus 30%, P<0.001, statins 51% versus 35%, P<0.001, and beta blockers 76% versus 65%, P=0.007). The prescription of aspirin or statins at discharge was associated with a better 1-year survival in patients with multivessel disease (P<0.001), but not in patients without significant stenosis or single vessel disease (P=0.95) (Figure).
CAG results, medications and mortality
Conclusions
In patients hospitalized with AHF, in-hospital CAG was associated with increased evidence based medications at discharge and a better long-term survival. Aspirin and statins at discharge might improve outcomes in AHF patients with multivessel disease.
Acknowledgement/Funding
This study was funded by The Cardiovascular Research Fund, Tokyo, Japan.
Collapse
Affiliation(s)
- E Akiyama
- Yokohama City University Medical Center, Yokohama, Japan
| | - M Konishi
- Yokohama City University Medical Center, Yokohama, Japan
| | | | - K Kida
- St. Marianna University, Kawasaki, Japan
| | - S Oishi
- Himeji Cardiovascular Center, Himeji, Japan
| | - S Suzuki
- Fukushima Medical University, Fukushima, Japan
| | | | - T Kitai
- Kobe City Medical Center General Hospital, Kobe, Japan
| | - Y Matsue
- Juntendo University, Tokyo, Japan
| |
Collapse
|
20
|
Konishi M, Akiyama E, Matsuzawa Y, Sato R, Kikuchi S, Nakahashi H, Maejima N, Iwahashi N, Hibi K, Kosuge M, Tamura K, Kimura K. 218Different impact of muscle, fat, and bone mass in heart failure with reduced and preserved ejection fraction. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz747.0059] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
Low muscle mass with or without fat mass is a main component of cachexia in heart failure (HF) and associated with poor prognosis. There is a paucity of data, however, regarding prognostic impact of each component of body composition (i.e., muscle, fat, and bone mass).
Purpose
We hypothesized that muscle, fat, and bone mass have different impact on prognosis in HF.
Methods
We retrospectively analyzed 418 patients admitted with a diagnosis of HF (71±13 years, 59% male, 46 and 54% with preserved/mid-range (left ventricular ejection fraction (LVEF) ≥40%) and reduced (<40%) LVEF), respectively). Dual-energy X-ray absorptiometry was performed at stable state after decongestion therapy.
Results
Mean appendicular skeletal mass index (ASMI) was 6.9±1.2 kg/m2 in men and 5.6±0.9 in women, so that 55% of patients had low muscle mass categorized by the Asian Working Group of Sarcopenia. During median follow-up of 502 days, 163 (39.0%) patients experienced primary outcome defined as death or heart failure hospitalization. Using optimal cut-off of each body component chosen on the basis of a receiver operating characteristic curve and the Youden method, we demonstrated that lower ASMI defined by the cut-off of 6.5 kg/m2 in male and 5.2 in female (adjusted hazard ratio (HR): 1.768, 95% CI: 1.210–2.581, p=0.003) and bone mass (adjusted HR: 1.498, 95% CI: 1.051–2.152, p=0.025), but not lower fat mass (p=0.34), were associated with elevated risk of primary outcome after multivariate adjustment. Kaplan-Meier curves with p value by Log-rank test were shown in figure. In subgroup analysis, negative impact of lower ASMI was significant regardless of sex and LVEF category, whereas negative impact of low bone mass was significant only in 78 female patients with reduced LVEF.
Figure 1
Conclusions
Indices about muscle and bone mass rather than fat mass had prognostic impact in HF. The impact of each body component may different according to sex and LVEF.
Collapse
Affiliation(s)
- M Konishi
- Yokohama City University Medical Center, Yokohama, Japan
| | - E Akiyama
- Yokohama City University Medical Center, Yokohama, Japan
| | - Y Matsuzawa
- Yokohama City University Medical Center, Yokohama, Japan
| | - R Sato
- Yokohama City University Medical Center, Yokohama, Japan
| | - S Kikuchi
- Yokohama City University Medical Center, Yokohama, Japan
| | - H Nakahashi
- Yokohama City University Medical Center, Yokohama, Japan
| | - N Maejima
- Yokohama City University Medical Center, Yokohama, Japan
| | - N Iwahashi
- Yokohama City University Medical Center, Yokohama, Japan
| | - K Hibi
- Yokohama City University Medical Center, Yokohama, Japan
| | - M Kosuge
- Yokohama City University Medical Center, Yokohama, Japan
| | - K Tamura
- Yokohama City University, Yokohama, Japan
| | - K Kimura
- Yokohama City University Medical Center, Yokohama, Japan
| |
Collapse
|
21
|
Satou R, Akiyama E, Konishi M, Matsuzawa Y, Kimura Y, Okada K, Maejima N, Iwahashi N, Hibi K, Kosuge M, Ebina T, Tamura K, Kimura K. P2657Prognostic impact of skeletal muscle mass in upper and lower extremities in patients with ST-segment elevation myocardial infarction. Eur Heart J 2019. [DOI: 10.1093/eurheartj/ehz748.0978] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Abstract
Introduction
Sarcopenia, characterized by the loss of skeletal muscle mass and muscle strength, has been demonstrated the importance in cardiovascular diseases including ST-segment elevation myocardial infarction (STEMI). However, there is few data comparing the effects on the prognosis of skeletal muscle mass of upper and lower extremities in STEMI patients.
Purpose
Our purpose was to examine whether skeletal muscle mass of upper and lower extremities affect the prognosis after STEMI.
Methods
A total of 432 patients with STEMI were enrolled in this study. Dual-energy X-ray absorptiometry scan was performed before discharge. Each of upper and lower extremity skeletal muscle masses was indexed by height squared (kg/m2), and divided into two groups using the first quartile value for each sex. All patients were followed up for the primary composite outcome of all-cause death, nonfatal myocardial infarction, nonfatal ischemic stroke, hospitalization for congestive heart failure, and unplanned revascularization.
Results
During a median follow-up of 32 months, 68 patients experienced primary composite outcome. The event rate was significantly higher in patients with low-lower extremity skeletal muscle mass index (LESMI) than in those with high-LESMI (24.3% vs 12.9%, log-rank p<0.001), as well as in those with low-upper extremity muscle mass index than in those with high-upper extremity muscle mass index (UESMI) (19.6% vs 14.5%, log-rank p=0.047). However, after adjustment for age, gender, renal function, diabetes mellitus, infarct size, body mass index, and body fat percentage, only low-LESMI was independently and significantly associated with the primary composite outcome (adjusted hazard ratio for LESMI 2.11, 95%-confidence interval 1.06–4.14, p=0.034, adjusted hazard ratio for UESMI 1.04, 95%-confidence interval 0.52–2.08, p=0.906,).
Conclusions
Decreased muscle mass of lower extremity, rather than upper extremity, might have prognostic impact in patients with STEMI.
Collapse
Affiliation(s)
- R Satou
- Yokohama City University Medical Center, division of cardiology, Yokohama, Japan
| | - E Akiyama
- Yokohama City University Medical Center, division of cardiology, Yokohama, Japan
| | - M Konishi
- Yokohama City University Medical Center, division of cardiology, Yokohama, Japan
| | - Y Matsuzawa
- Yokohama City University Medical Center, division of cardiology, Yokohama, Japan
| | - Y Kimura
- Yokohama City University Medical Center, division of cardiology, Yokohama, Japan
| | - K Okada
- Yokohama City University Medical Center, division of cardiology, Yokohama, Japan
| | - N Maejima
- Yokohama City University Medical Center, division of cardiology, Yokohama, Japan
| | - N Iwahashi
- Yokohama City University Medical Center, division of cardiology, Yokohama, Japan
| | - K Hibi
- Yokohama City University Medical Center, division of cardiology, Yokohama, Japan
| | - M Kosuge
- Yokohama City University Medical Center, division of cardiology, Yokohama, Japan
| | - T Ebina
- Yokohama City University Medical Center, division of cardiology, Yokohama, Japan
| | - K Tamura
- Yokohama City University, Department of Medical Science and Cardiorenal Medicine, Yokohama, Japan
| | - K Kimura
- Yokohama City University Medical Center, division of cardiology, Yokohama, Japan
| |
Collapse
|
22
|
Hayashi M, Nakazawa K, Hasegawa Y, Horiguchi J, Miura D, Ishikawa T, Takao S, Kim SJ, Yamagami K, Miyashita M, Konishi M, Shigeoka Y, Suzuki M, Taguchi T, Kubota T, Tanino Y, Yamada K, Kimura K, Akazawa K, Kohno N. Abstract P1-11-07: Risk analysis for chemotherapy induced nausea and vomiting (CINV) in patients receiving FEC100 treatment. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-p1-11-07] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
BACKGROUND:
Anthracycline-containing regimens are standard treatment options in adjuvant and neoadjuvant chemotherapy in breast cancer. Chemotherapy-induced nausea and vomiting (CINV) is experienced frequently in patients receiving these regimens, but the risk factors for CINV are unknown.
OBJECTIVE:
The aim of this study was to investigate risk factors for CINV in anthracycline-containing regimens retrospectively.
METHODS:
Data were collected from the JONIE study, which was conducted in order to estimate the efficacy of zoledronic acid in a neoadjuvant setting from March 2010 to June 2012 (UMIN000003261). A total of 180 patients were recruited, and we used CINV data from the first cycle of FEC100 treatment and patient backgrounds. As the protocol regulation allowed the use of antiemetic drugs,in the first cycle of the FEC100 regimen, patients received various types of antiemetic agents, which we classified into four groups: Dexamethasone (DEX)+5-HT3 receptor antagonist (5-HT3)+neurokinin-1 receptor antagonist (NK1) (DEX+5-HT3+NK1) group; Dexamethasone (DEX)+5-HT3 receptor antagonist (5-HT3) (DEX+5HT3) group; Dexamethasone (DEX)+5-HT3 receptor antagonist (5-HT3)+dopamine receptor antagonist (DRA) (DEX+5HT3+DRA) group; and Dexamethasone (DEX)+5-HT3 receptor antagonist (5-HT3)+neurokinin-1 receptor antagonist (NK1)+ dopamine receptor antagonist (DRA) (DEX+5-HT3+NK1+DRA) group. Risk factors were selected from patient backgrounds and the combinations of antiemetic drugs. In patient backgrounds, the body mass index (BMI) was stratified into 3 categories: Less than 18.5 (underweight group); equal to or more than 18.5 but less than 25 (standard BMI group); and equal to or more than 25 (overweight group). The risks for CINV were analyzed by univariate and multivariate analyses. P values of less than 0.05 were defined as significant.
RESULTS:
In a univariate analysis of nausea, the body mass index (BMI) was the only significant factor (P<0.05). On the other hand, BMI and the combination of antiemetic drugs were significant factors in vomiting. (P<0.05 and 0.005, respectively). In a multivariate analysis of nausea, the P value for BMI was 0.02. The odds ratio for the underweight group was 7.745 (confidence interval: 2.171 to 27.634) compared with the standard BMI group. In a multivariate analysis of vomiting, BMI and the combination of antiemetic drugs were significant risk factors (P=0.025 and 0.023, respectively). The odds ratio for the underweight group was 3.481 (confidence interval: 1.183 to 10.241)compared with the standard BMI group. Furthermore, the odds ratios in the DEX+5-HT3+DRA and DEX+5HT3 groups were 5.005 (confidence interval: 1.543 to 16.239) and 4.178 (confidence interval: 1.428 to 12.222), respectively, compared with the DEX+5-HT3+NK1 group, which was consistent with the CINV guidelines in 2011.
CONCLUSIONS:
This study revealed that BMI was the most important risk factor for nausea, and that BMI and the combination of antiemetic drugs were risk factors for vomiting. Underweight-patients tend to have CINV in anthracycline-containing regimen. The DEX+5-HT3+NK1 group was the best antiemetic drug combination. These result show that following the CINV guideline treatment is mandatory in order to prevent CINV.
Citation Format: Hayashi M, Nakazawa K, Hasegawa Y, Horiguchi J, Miura D, Ishikawa T, Takao S, Kim SJ, Yamagami K, Miyashita M, Konishi M, Shigeoka Y, Suzuki M, Taguchi T, Kubota T, Tanino Y, Yamada K, Kimura K, Akazawa K, Kohno N. Risk analysis for chemotherapy induced nausea and vomiting (CINV) in patients receiving FEC100 treatment [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr P1-11-07.
Collapse
Affiliation(s)
- M Hayashi
- Dokkyo Medical University, 880 Kitakobayashi, Mibu, Tochigi, Japan; Niigata University, 951 Asahimachi, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; International University of Health and Welfare, 4-3 Kozunomori, Narita, Chiba, Japan; Akasaka Miura Clinic, 2-11-15 Akasaka, Minato-ku, Tokyo, Japan; Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, Japan; Hyogo Cancer Center, 13-70, Kitaoji-machi, Akashi, Hyogo, Japan; Oaska University, 2-2 Yamadagaoka, Suita, Osaka, Japan; Shinko Hospital, 1-4-47, Wakihama-cho, Kobe, Hyogo, Japan; Konan Hospital, 1-5-16 Kamokogahara, Kobe, Hyogo, Japan; Hyogo Prefectural Nishinomiya Hospital, 13-9 Rokujinji-machi, Nishinomiya, Hyogo, Japan; Yodogawa Christian Hospital, 1-7-50 Kunijima, Higashi Yodogawa, Osaka, Japan; National Hospital Organization Chiba Medical Center, 4-1-2 Tsubakimori, Chiba, Japan; Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji, Kyoto, Japan; Kamiiida Daiichi General Hospital, 2-70 Ka
| | - K Nakazawa
- Dokkyo Medical University, 880 Kitakobayashi, Mibu, Tochigi, Japan; Niigata University, 951 Asahimachi, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; International University of Health and Welfare, 4-3 Kozunomori, Narita, Chiba, Japan; Akasaka Miura Clinic, 2-11-15 Akasaka, Minato-ku, Tokyo, Japan; Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, Japan; Hyogo Cancer Center, 13-70, Kitaoji-machi, Akashi, Hyogo, Japan; Oaska University, 2-2 Yamadagaoka, Suita, Osaka, Japan; Shinko Hospital, 1-4-47, Wakihama-cho, Kobe, Hyogo, Japan; Konan Hospital, 1-5-16 Kamokogahara, Kobe, Hyogo, Japan; Hyogo Prefectural Nishinomiya Hospital, 13-9 Rokujinji-machi, Nishinomiya, Hyogo, Japan; Yodogawa Christian Hospital, 1-7-50 Kunijima, Higashi Yodogawa, Osaka, Japan; National Hospital Organization Chiba Medical Center, 4-1-2 Tsubakimori, Chiba, Japan; Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji, Kyoto, Japan; Kamiiida Daiichi General Hospital, 2-70 Ka
| | - Y Hasegawa
- Dokkyo Medical University, 880 Kitakobayashi, Mibu, Tochigi, Japan; Niigata University, 951 Asahimachi, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; International University of Health and Welfare, 4-3 Kozunomori, Narita, Chiba, Japan; Akasaka Miura Clinic, 2-11-15 Akasaka, Minato-ku, Tokyo, Japan; Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, Japan; Hyogo Cancer Center, 13-70, Kitaoji-machi, Akashi, Hyogo, Japan; Oaska University, 2-2 Yamadagaoka, Suita, Osaka, Japan; Shinko Hospital, 1-4-47, Wakihama-cho, Kobe, Hyogo, Japan; Konan Hospital, 1-5-16 Kamokogahara, Kobe, Hyogo, Japan; Hyogo Prefectural Nishinomiya Hospital, 13-9 Rokujinji-machi, Nishinomiya, Hyogo, Japan; Yodogawa Christian Hospital, 1-7-50 Kunijima, Higashi Yodogawa, Osaka, Japan; National Hospital Organization Chiba Medical Center, 4-1-2 Tsubakimori, Chiba, Japan; Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji, Kyoto, Japan; Kamiiida Daiichi General Hospital, 2-70 Ka
| | - J Horiguchi
- Dokkyo Medical University, 880 Kitakobayashi, Mibu, Tochigi, Japan; Niigata University, 951 Asahimachi, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; International University of Health and Welfare, 4-3 Kozunomori, Narita, Chiba, Japan; Akasaka Miura Clinic, 2-11-15 Akasaka, Minato-ku, Tokyo, Japan; Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, Japan; Hyogo Cancer Center, 13-70, Kitaoji-machi, Akashi, Hyogo, Japan; Oaska University, 2-2 Yamadagaoka, Suita, Osaka, Japan; Shinko Hospital, 1-4-47, Wakihama-cho, Kobe, Hyogo, Japan; Konan Hospital, 1-5-16 Kamokogahara, Kobe, Hyogo, Japan; Hyogo Prefectural Nishinomiya Hospital, 13-9 Rokujinji-machi, Nishinomiya, Hyogo, Japan; Yodogawa Christian Hospital, 1-7-50 Kunijima, Higashi Yodogawa, Osaka, Japan; National Hospital Organization Chiba Medical Center, 4-1-2 Tsubakimori, Chiba, Japan; Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji, Kyoto, Japan; Kamiiida Daiichi General Hospital, 2-70 Ka
| | - D Miura
- Dokkyo Medical University, 880 Kitakobayashi, Mibu, Tochigi, Japan; Niigata University, 951 Asahimachi, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; International University of Health and Welfare, 4-3 Kozunomori, Narita, Chiba, Japan; Akasaka Miura Clinic, 2-11-15 Akasaka, Minato-ku, Tokyo, Japan; Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, Japan; Hyogo Cancer Center, 13-70, Kitaoji-machi, Akashi, Hyogo, Japan; Oaska University, 2-2 Yamadagaoka, Suita, Osaka, Japan; Shinko Hospital, 1-4-47, Wakihama-cho, Kobe, Hyogo, Japan; Konan Hospital, 1-5-16 Kamokogahara, Kobe, Hyogo, Japan; Hyogo Prefectural Nishinomiya Hospital, 13-9 Rokujinji-machi, Nishinomiya, Hyogo, Japan; Yodogawa Christian Hospital, 1-7-50 Kunijima, Higashi Yodogawa, Osaka, Japan; National Hospital Organization Chiba Medical Center, 4-1-2 Tsubakimori, Chiba, Japan; Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji, Kyoto, Japan; Kamiiida Daiichi General Hospital, 2-70 Ka
| | - T Ishikawa
- Dokkyo Medical University, 880 Kitakobayashi, Mibu, Tochigi, Japan; Niigata University, 951 Asahimachi, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; International University of Health and Welfare, 4-3 Kozunomori, Narita, Chiba, Japan; Akasaka Miura Clinic, 2-11-15 Akasaka, Minato-ku, Tokyo, Japan; Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, Japan; Hyogo Cancer Center, 13-70, Kitaoji-machi, Akashi, Hyogo, Japan; Oaska University, 2-2 Yamadagaoka, Suita, Osaka, Japan; Shinko Hospital, 1-4-47, Wakihama-cho, Kobe, Hyogo, Japan; Konan Hospital, 1-5-16 Kamokogahara, Kobe, Hyogo, Japan; Hyogo Prefectural Nishinomiya Hospital, 13-9 Rokujinji-machi, Nishinomiya, Hyogo, Japan; Yodogawa Christian Hospital, 1-7-50 Kunijima, Higashi Yodogawa, Osaka, Japan; National Hospital Organization Chiba Medical Center, 4-1-2 Tsubakimori, Chiba, Japan; Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji, Kyoto, Japan; Kamiiida Daiichi General Hospital, 2-70 Ka
| | - S Takao
- Dokkyo Medical University, 880 Kitakobayashi, Mibu, Tochigi, Japan; Niigata University, 951 Asahimachi, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; International University of Health and Welfare, 4-3 Kozunomori, Narita, Chiba, Japan; Akasaka Miura Clinic, 2-11-15 Akasaka, Minato-ku, Tokyo, Japan; Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, Japan; Hyogo Cancer Center, 13-70, Kitaoji-machi, Akashi, Hyogo, Japan; Oaska University, 2-2 Yamadagaoka, Suita, Osaka, Japan; Shinko Hospital, 1-4-47, Wakihama-cho, Kobe, Hyogo, Japan; Konan Hospital, 1-5-16 Kamokogahara, Kobe, Hyogo, Japan; Hyogo Prefectural Nishinomiya Hospital, 13-9 Rokujinji-machi, Nishinomiya, Hyogo, Japan; Yodogawa Christian Hospital, 1-7-50 Kunijima, Higashi Yodogawa, Osaka, Japan; National Hospital Organization Chiba Medical Center, 4-1-2 Tsubakimori, Chiba, Japan; Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji, Kyoto, Japan; Kamiiida Daiichi General Hospital, 2-70 Ka
| | - SJ Kim
- Dokkyo Medical University, 880 Kitakobayashi, Mibu, Tochigi, Japan; Niigata University, 951 Asahimachi, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; International University of Health and Welfare, 4-3 Kozunomori, Narita, Chiba, Japan; Akasaka Miura Clinic, 2-11-15 Akasaka, Minato-ku, Tokyo, Japan; Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, Japan; Hyogo Cancer Center, 13-70, Kitaoji-machi, Akashi, Hyogo, Japan; Oaska University, 2-2 Yamadagaoka, Suita, Osaka, Japan; Shinko Hospital, 1-4-47, Wakihama-cho, Kobe, Hyogo, Japan; Konan Hospital, 1-5-16 Kamokogahara, Kobe, Hyogo, Japan; Hyogo Prefectural Nishinomiya Hospital, 13-9 Rokujinji-machi, Nishinomiya, Hyogo, Japan; Yodogawa Christian Hospital, 1-7-50 Kunijima, Higashi Yodogawa, Osaka, Japan; National Hospital Organization Chiba Medical Center, 4-1-2 Tsubakimori, Chiba, Japan; Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji, Kyoto, Japan; Kamiiida Daiichi General Hospital, 2-70 Ka
| | - K Yamagami
- Dokkyo Medical University, 880 Kitakobayashi, Mibu, Tochigi, Japan; Niigata University, 951 Asahimachi, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; International University of Health and Welfare, 4-3 Kozunomori, Narita, Chiba, Japan; Akasaka Miura Clinic, 2-11-15 Akasaka, Minato-ku, Tokyo, Japan; Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, Japan; Hyogo Cancer Center, 13-70, Kitaoji-machi, Akashi, Hyogo, Japan; Oaska University, 2-2 Yamadagaoka, Suita, Osaka, Japan; Shinko Hospital, 1-4-47, Wakihama-cho, Kobe, Hyogo, Japan; Konan Hospital, 1-5-16 Kamokogahara, Kobe, Hyogo, Japan; Hyogo Prefectural Nishinomiya Hospital, 13-9 Rokujinji-machi, Nishinomiya, Hyogo, Japan; Yodogawa Christian Hospital, 1-7-50 Kunijima, Higashi Yodogawa, Osaka, Japan; National Hospital Organization Chiba Medical Center, 4-1-2 Tsubakimori, Chiba, Japan; Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji, Kyoto, Japan; Kamiiida Daiichi General Hospital, 2-70 Ka
| | - M Miyashita
- Dokkyo Medical University, 880 Kitakobayashi, Mibu, Tochigi, Japan; Niigata University, 951 Asahimachi, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; International University of Health and Welfare, 4-3 Kozunomori, Narita, Chiba, Japan; Akasaka Miura Clinic, 2-11-15 Akasaka, Minato-ku, Tokyo, Japan; Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, Japan; Hyogo Cancer Center, 13-70, Kitaoji-machi, Akashi, Hyogo, Japan; Oaska University, 2-2 Yamadagaoka, Suita, Osaka, Japan; Shinko Hospital, 1-4-47, Wakihama-cho, Kobe, Hyogo, Japan; Konan Hospital, 1-5-16 Kamokogahara, Kobe, Hyogo, Japan; Hyogo Prefectural Nishinomiya Hospital, 13-9 Rokujinji-machi, Nishinomiya, Hyogo, Japan; Yodogawa Christian Hospital, 1-7-50 Kunijima, Higashi Yodogawa, Osaka, Japan; National Hospital Organization Chiba Medical Center, 4-1-2 Tsubakimori, Chiba, Japan; Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji, Kyoto, Japan; Kamiiida Daiichi General Hospital, 2-70 Ka
| | - M Konishi
- Dokkyo Medical University, 880 Kitakobayashi, Mibu, Tochigi, Japan; Niigata University, 951 Asahimachi, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; International University of Health and Welfare, 4-3 Kozunomori, Narita, Chiba, Japan; Akasaka Miura Clinic, 2-11-15 Akasaka, Minato-ku, Tokyo, Japan; Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, Japan; Hyogo Cancer Center, 13-70, Kitaoji-machi, Akashi, Hyogo, Japan; Oaska University, 2-2 Yamadagaoka, Suita, Osaka, Japan; Shinko Hospital, 1-4-47, Wakihama-cho, Kobe, Hyogo, Japan; Konan Hospital, 1-5-16 Kamokogahara, Kobe, Hyogo, Japan; Hyogo Prefectural Nishinomiya Hospital, 13-9 Rokujinji-machi, Nishinomiya, Hyogo, Japan; Yodogawa Christian Hospital, 1-7-50 Kunijima, Higashi Yodogawa, Osaka, Japan; National Hospital Organization Chiba Medical Center, 4-1-2 Tsubakimori, Chiba, Japan; Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji, Kyoto, Japan; Kamiiida Daiichi General Hospital, 2-70 Ka
| | - Y Shigeoka
- Dokkyo Medical University, 880 Kitakobayashi, Mibu, Tochigi, Japan; Niigata University, 951 Asahimachi, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; International University of Health and Welfare, 4-3 Kozunomori, Narita, Chiba, Japan; Akasaka Miura Clinic, 2-11-15 Akasaka, Minato-ku, Tokyo, Japan; Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, Japan; Hyogo Cancer Center, 13-70, Kitaoji-machi, Akashi, Hyogo, Japan; Oaska University, 2-2 Yamadagaoka, Suita, Osaka, Japan; Shinko Hospital, 1-4-47, Wakihama-cho, Kobe, Hyogo, Japan; Konan Hospital, 1-5-16 Kamokogahara, Kobe, Hyogo, Japan; Hyogo Prefectural Nishinomiya Hospital, 13-9 Rokujinji-machi, Nishinomiya, Hyogo, Japan; Yodogawa Christian Hospital, 1-7-50 Kunijima, Higashi Yodogawa, Osaka, Japan; National Hospital Organization Chiba Medical Center, 4-1-2 Tsubakimori, Chiba, Japan; Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji, Kyoto, Japan; Kamiiida Daiichi General Hospital, 2-70 Ka
| | - M Suzuki
- Dokkyo Medical University, 880 Kitakobayashi, Mibu, Tochigi, Japan; Niigata University, 951 Asahimachi, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; International University of Health and Welfare, 4-3 Kozunomori, Narita, Chiba, Japan; Akasaka Miura Clinic, 2-11-15 Akasaka, Minato-ku, Tokyo, Japan; Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, Japan; Hyogo Cancer Center, 13-70, Kitaoji-machi, Akashi, Hyogo, Japan; Oaska University, 2-2 Yamadagaoka, Suita, Osaka, Japan; Shinko Hospital, 1-4-47, Wakihama-cho, Kobe, Hyogo, Japan; Konan Hospital, 1-5-16 Kamokogahara, Kobe, Hyogo, Japan; Hyogo Prefectural Nishinomiya Hospital, 13-9 Rokujinji-machi, Nishinomiya, Hyogo, Japan; Yodogawa Christian Hospital, 1-7-50 Kunijima, Higashi Yodogawa, Osaka, Japan; National Hospital Organization Chiba Medical Center, 4-1-2 Tsubakimori, Chiba, Japan; Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji, Kyoto, Japan; Kamiiida Daiichi General Hospital, 2-70 Ka
| | - T Taguchi
- Dokkyo Medical University, 880 Kitakobayashi, Mibu, Tochigi, Japan; Niigata University, 951 Asahimachi, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; International University of Health and Welfare, 4-3 Kozunomori, Narita, Chiba, Japan; Akasaka Miura Clinic, 2-11-15 Akasaka, Minato-ku, Tokyo, Japan; Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, Japan; Hyogo Cancer Center, 13-70, Kitaoji-machi, Akashi, Hyogo, Japan; Oaska University, 2-2 Yamadagaoka, Suita, Osaka, Japan; Shinko Hospital, 1-4-47, Wakihama-cho, Kobe, Hyogo, Japan; Konan Hospital, 1-5-16 Kamokogahara, Kobe, Hyogo, Japan; Hyogo Prefectural Nishinomiya Hospital, 13-9 Rokujinji-machi, Nishinomiya, Hyogo, Japan; Yodogawa Christian Hospital, 1-7-50 Kunijima, Higashi Yodogawa, Osaka, Japan; National Hospital Organization Chiba Medical Center, 4-1-2 Tsubakimori, Chiba, Japan; Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji, Kyoto, Japan; Kamiiida Daiichi General Hospital, 2-70 Ka
| | - T Kubota
- Dokkyo Medical University, 880 Kitakobayashi, Mibu, Tochigi, Japan; Niigata University, 951 Asahimachi, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; International University of Health and Welfare, 4-3 Kozunomori, Narita, Chiba, Japan; Akasaka Miura Clinic, 2-11-15 Akasaka, Minato-ku, Tokyo, Japan; Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, Japan; Hyogo Cancer Center, 13-70, Kitaoji-machi, Akashi, Hyogo, Japan; Oaska University, 2-2 Yamadagaoka, Suita, Osaka, Japan; Shinko Hospital, 1-4-47, Wakihama-cho, Kobe, Hyogo, Japan; Konan Hospital, 1-5-16 Kamokogahara, Kobe, Hyogo, Japan; Hyogo Prefectural Nishinomiya Hospital, 13-9 Rokujinji-machi, Nishinomiya, Hyogo, Japan; Yodogawa Christian Hospital, 1-7-50 Kunijima, Higashi Yodogawa, Osaka, Japan; National Hospital Organization Chiba Medical Center, 4-1-2 Tsubakimori, Chiba, Japan; Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji, Kyoto, Japan; Kamiiida Daiichi General Hospital, 2-70 Ka
| | - Y Tanino
- Dokkyo Medical University, 880 Kitakobayashi, Mibu, Tochigi, Japan; Niigata University, 951 Asahimachi, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; International University of Health and Welfare, 4-3 Kozunomori, Narita, Chiba, Japan; Akasaka Miura Clinic, 2-11-15 Akasaka, Minato-ku, Tokyo, Japan; Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, Japan; Hyogo Cancer Center, 13-70, Kitaoji-machi, Akashi, Hyogo, Japan; Oaska University, 2-2 Yamadagaoka, Suita, Osaka, Japan; Shinko Hospital, 1-4-47, Wakihama-cho, Kobe, Hyogo, Japan; Konan Hospital, 1-5-16 Kamokogahara, Kobe, Hyogo, Japan; Hyogo Prefectural Nishinomiya Hospital, 13-9 Rokujinji-machi, Nishinomiya, Hyogo, Japan; Yodogawa Christian Hospital, 1-7-50 Kunijima, Higashi Yodogawa, Osaka, Japan; National Hospital Organization Chiba Medical Center, 4-1-2 Tsubakimori, Chiba, Japan; Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji, Kyoto, Japan; Kamiiida Daiichi General Hospital, 2-70 Ka
| | - K Yamada
- Dokkyo Medical University, 880 Kitakobayashi, Mibu, Tochigi, Japan; Niigata University, 951 Asahimachi, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; International University of Health and Welfare, 4-3 Kozunomori, Narita, Chiba, Japan; Akasaka Miura Clinic, 2-11-15 Akasaka, Minato-ku, Tokyo, Japan; Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, Japan; Hyogo Cancer Center, 13-70, Kitaoji-machi, Akashi, Hyogo, Japan; Oaska University, 2-2 Yamadagaoka, Suita, Osaka, Japan; Shinko Hospital, 1-4-47, Wakihama-cho, Kobe, Hyogo, Japan; Konan Hospital, 1-5-16 Kamokogahara, Kobe, Hyogo, Japan; Hyogo Prefectural Nishinomiya Hospital, 13-9 Rokujinji-machi, Nishinomiya, Hyogo, Japan; Yodogawa Christian Hospital, 1-7-50 Kunijima, Higashi Yodogawa, Osaka, Japan; National Hospital Organization Chiba Medical Center, 4-1-2 Tsubakimori, Chiba, Japan; Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji, Kyoto, Japan; Kamiiida Daiichi General Hospital, 2-70 Ka
| | - K Kimura
- Dokkyo Medical University, 880 Kitakobayashi, Mibu, Tochigi, Japan; Niigata University, 951 Asahimachi, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; International University of Health and Welfare, 4-3 Kozunomori, Narita, Chiba, Japan; Akasaka Miura Clinic, 2-11-15 Akasaka, Minato-ku, Tokyo, Japan; Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, Japan; Hyogo Cancer Center, 13-70, Kitaoji-machi, Akashi, Hyogo, Japan; Oaska University, 2-2 Yamadagaoka, Suita, Osaka, Japan; Shinko Hospital, 1-4-47, Wakihama-cho, Kobe, Hyogo, Japan; Konan Hospital, 1-5-16 Kamokogahara, Kobe, Hyogo, Japan; Hyogo Prefectural Nishinomiya Hospital, 13-9 Rokujinji-machi, Nishinomiya, Hyogo, Japan; Yodogawa Christian Hospital, 1-7-50 Kunijima, Higashi Yodogawa, Osaka, Japan; National Hospital Organization Chiba Medical Center, 4-1-2 Tsubakimori, Chiba, Japan; Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji, Kyoto, Japan; Kamiiida Daiichi General Hospital, 2-70 Ka
| | - K Akazawa
- Dokkyo Medical University, 880 Kitakobayashi, Mibu, Tochigi, Japan; Niigata University, 951 Asahimachi, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; International University of Health and Welfare, 4-3 Kozunomori, Narita, Chiba, Japan; Akasaka Miura Clinic, 2-11-15 Akasaka, Minato-ku, Tokyo, Japan; Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, Japan; Hyogo Cancer Center, 13-70, Kitaoji-machi, Akashi, Hyogo, Japan; Oaska University, 2-2 Yamadagaoka, Suita, Osaka, Japan; Shinko Hospital, 1-4-47, Wakihama-cho, Kobe, Hyogo, Japan; Konan Hospital, 1-5-16 Kamokogahara, Kobe, Hyogo, Japan; Hyogo Prefectural Nishinomiya Hospital, 13-9 Rokujinji-machi, Nishinomiya, Hyogo, Japan; Yodogawa Christian Hospital, 1-7-50 Kunijima, Higashi Yodogawa, Osaka, Japan; National Hospital Organization Chiba Medical Center, 4-1-2 Tsubakimori, Chiba, Japan; Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji, Kyoto, Japan; Kamiiida Daiichi General Hospital, 2-70 Ka
| | - N Kohno
- Dokkyo Medical University, 880 Kitakobayashi, Mibu, Tochigi, Japan; Niigata University, 951 Asahimachi, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Aomori, Japan; International University of Health and Welfare, 4-3 Kozunomori, Narita, Chiba, Japan; Akasaka Miura Clinic, 2-11-15 Akasaka, Minato-ku, Tokyo, Japan; Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, Japan; Hyogo Cancer Center, 13-70, Kitaoji-machi, Akashi, Hyogo, Japan; Oaska University, 2-2 Yamadagaoka, Suita, Osaka, Japan; Shinko Hospital, 1-4-47, Wakihama-cho, Kobe, Hyogo, Japan; Konan Hospital, 1-5-16 Kamokogahara, Kobe, Hyogo, Japan; Hyogo Prefectural Nishinomiya Hospital, 13-9 Rokujinji-machi, Nishinomiya, Hyogo, Japan; Yodogawa Christian Hospital, 1-7-50 Kunijima, Higashi Yodogawa, Osaka, Japan; National Hospital Organization Chiba Medical Center, 4-1-2 Tsubakimori, Chiba, Japan; Kyoto Prefectural University of Medicine, 465 Kajii-cho, Kawaramachi-Hirokoji, Kyoto, Japan; Kamiiida Daiichi General Hospital, 2-70 Ka
| |
Collapse
|
23
|
Ebata T, Hirano S, Konishi M, Uesaka K, Tsuchiya Y, Ohtsuka M, Kaneoka Y, Yamamoto M, Ambo Y, Shimizu Y, Ozawa F, Fukutomi A, Ando M, Nimura Y, Nagino M. Randomized clinical trial of adjuvant gemcitabine chemotherapy versus observation in resected bile duct cancer. Br J Surg 2018; 105:192-202. [PMID: 29405274 DOI: 10.1002/bjs.10776] [Citation(s) in RCA: 227] [Impact Index Per Article: 37.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/07/2017] [Revised: 10/30/2017] [Accepted: 11/01/2017] [Indexed: 02/06/2023]
Abstract
BACKGROUND Although some retrospective studies have suggested the value of adjuvant therapy, no recommended standard exists in bile duct cancer. The aim of this study was to test the hypothesis that adjuvant gemcitabine chemotherapy would improve survival probability in resected bile duct cancer. METHODS This was a randomized phase III trial. Patients with resected bile duct cancer were assigned randomly to gemcitabine and observation groups, which were balanced with respect to lymph node status, residual tumour status and tumour location. Gemcitabine was given intravenously at a dose of 1000 mg/m2 , administered on days 1, 8 and 15 every 4 weeks for six cycles. The primary endpoint was overall survival, and secondary endpoints were relapse-free survival, subgroup analysis and toxicity. RESULTS Some 225 patients were included (117 gemcitabine, 108 observation). Baseline characteristics were well balanced between the gemcitabine and observation groups. There were no significant differences in overall survival (median 62·3 versus 63·8 months respectively; hazard ratio 1·01, 95 per cent c.i. 0·70 to 1·45; P = 0·964) and relapse-free survival (median 36·0 versus 39·9 months; hazard ratio 0·93, 0·66 to 1·32; P = 0·693). There were no survival differences between the two groups in subsets stratified by lymph node status and margin status. Although haematological toxicity occurred frequently in the gemcitabine group, most toxicities were transient, and grade 3/4 non-haematological toxicity was rare. CONCLUSION The survival probability in patients with resected bile duct cancer was not significantly different between the gemcitabine adjuvant chemotherapy group and the observation group. Registration number: UMIN 000000820 (http://www.umin.ac.jp/).
Collapse
Affiliation(s)
- T Ebata
- Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - S Hirano
- Department of Gastroenterological Surgery II, Hokkaido University Graduate School of Medicine, Sapporo, Japan
| | - M Konishi
- Department of Hepatobiliary-Pancreatic Surgery, National Cancer Centre Hospital East, Kashiwa, Japan
| | - K Uesaka
- Division of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Centre Hospital, Shizuoka, Japan
| | - Y Tsuchiya
- Department of Surgery, Niigata Cancer Centre Hospital, Niigata, Japan
| | - M Ohtsuka
- Department of General Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan
| | - Y Kaneoka
- Department of Surgery, Ogaki Municipal Hospital, Ogaki, Japan
| | - M Yamamoto
- Department of Surgery, Institute of Gastroenterology, Tokyo Women's Medical University, Tokyo, Japan
| | - Y Ambo
- Department of Surgery, Teine-Keijinkai Hospital, Sapporo, Japan
| | - Y Shimizu
- Department of Gastroenterological Surgery, Aichi Cancer Centre Hospital, Nagoya, Japan
| | - F Ozawa
- Department of Hepato-Biliary-Pancreatic Surgery, Saitama Medical Centre, Saitama Medical University, Saitama, Japan
| | - A Fukutomi
- Division of Gastrointestinal Oncology, Shizuoka Cancer Centre Hospital, Shizuoka, Japan
| | - M Ando
- Centre for Advanced Medicine and Clinical Research, Nagoya University Hospital, Nagoya, Japan
| | - Y Nimura
- Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | - M Nagino
- Division of Surgical Oncology, Department of Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan
| | | |
Collapse
|
24
|
Saito M, Yamamoto-Hanada K, Pak K, Ayabe T, Mezawa H, Ishitsuka K, Konishi M, Yang L, Matsumoto K, Saito H, Ohya Y. Having small-for-gestational-age infants was associated with maternal allergic features in the JECS birth cohort. Allergy 2018; 73:1908-1911. [PMID: 29802633 DOI: 10.1111/all.13490] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- M. Saito
- Medical Support Center for the Japan Environment and Children's Study; National Center for Child Health and Development; Tokyo Japan
| | - K. Yamamoto-Hanada
- Medical Support Center for the Japan Environment and Children's Study; National Center for Child Health and Development; Tokyo Japan
| | - K. Pak
- Department of Clinical Medicine (Biostatistics); Kitasato University School of Pharmacy; Tokyo Japan
| | - T. Ayabe
- Medical Support Center for the Japan Environment and Children's Study; National Center for Child Health and Development; Tokyo Japan
| | - H. Mezawa
- Medical Support Center for the Japan Environment and Children's Study; National Center for Child Health and Development; Tokyo Japan
| | - K. Ishitsuka
- Medical Support Center for the Japan Environment and Children's Study; National Center for Child Health and Development; Tokyo Japan
| | - M. Konishi
- Medical Support Center for the Japan Environment and Children's Study; National Center for Child Health and Development; Tokyo Japan
| | - L. Yang
- Medical Support Center for the Japan Environment and Children's Study; National Center for Child Health and Development; Tokyo Japan
| | - K. Matsumoto
- Medical Support Center for the Japan Environment and Children's Study; National Center for Child Health and Development; Tokyo Japan
| | - H. Saito
- Medical Support Center for the Japan Environment and Children's Study; National Center for Child Health and Development; Tokyo Japan
| | - Y. Ohya
- Medical Support Center for the Japan Environment and Children's Study; National Center for Child Health and Development; Tokyo Japan
| | | |
Collapse
|
25
|
Suzuki K, Iwai H, Yagi M, Fujisawa T, Kanda A, Konishi M, Kobayashi Y, Tomoda K, Yamashita T. Indications for partial parotidectomy using retrograde dissection of the marginal mandibular branch of the facial nerve for benign tumours of the parotid gland. Br J Oral Maxillofac Surg 2018; 56:727-731. [PMID: 30115458 DOI: 10.1016/j.bjoms.2018.08.002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2018] [Accepted: 08/03/2018] [Indexed: 10/28/2022]
Abstract
The aims of this study were to evaluate the efficacy of partial parotidectomy using retrograde dissection of the marginal mandibular branch of the facial nerve for benign tumours of the parotid gland and to establish the indications for its use. We examined 106 consecutive patients with previously untreated benign tumours in the lower portion of the parotid gland who were treated by parotidectomy. The first group (anterograde group, n=52) consisted of those who had standard anterograde parotidectomy. The remaining patients, who underwent retrograde parotidectomy, were further divided into two groups: those in whom the upper edge of the tumour was located below the mastoid tip (below mastoid group, n=46) or those in whom it was above the mastoid tip (above mastoid group, n=8). The operating time was significantly shorter in the below mastoid group (141.2, 127.5, and 98.1minutes, respectively) as was intraoperative blood loss (41.1, 53.0, and 24.4ml, respectively), compared with the other two groups. There was a higher incidence of facial nerve dysfunction in the above mastoid group postoperatively (4/8) than in the other two groups. The results suggested that the presence of a tumour of any size located below the mastoid tip is a good indication for parotidectomy using retrograde dissection of the marginal mandibular branch of the facial nerve.
Collapse
Affiliation(s)
- K Suzuki
- Department of Otolaryngology, Head and Neck Surgery, Kansai Medical University Hospital.
| | - H Iwai
- Department of Otolaryngology, Head and Neck Surgery, Kansai Medical University Hospital
| | - M Yagi
- Department of Otolaryngology, Head and Neck Surgery, Kansai Medical University Hospital
| | - T Fujisawa
- Department of Otolaryngology, Head and Neck Surgery, Kansai Medical University Hospital
| | - A Kanda
- Department of Otolaryngology, Head and Neck Surgery, Kansai Medical University Hospital
| | - M Konishi
- Department of Otolaryngology, Head and Neck Surgery, Kansai Medical University Hospital
| | - Y Kobayashi
- Department of Otolaryngology, Head and Neck Surgery, Kansai Medical University Hospital
| | - K Tomoda
- Department of Otolaryngology, Head and Neck Surgery, Kansai Medical University Hospital
| | - T Yamashita
- Department of Otolaryngology, Head and Neck Surgery, Kansai Medical University Hospital
| |
Collapse
|
26
|
Satou R, Matsuzawa Y, Konishi M, Kawashima C, Okada K, Maejima N, Iwahashi N, Hibi K, Kosuge M, Ebina T, Tamura K, Kimura K. P1729Low skeletal muscle mass is associated with poor cardiovascular outcome in patients after ST-segment elevation myocardial infarction. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy565.p1729] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- R Satou
- Yokohama City University Medical Center, division of cardiology, Yokohama, Japan
| | - Y Matsuzawa
- Yokohama City University Medical Center, division of cardiology, Yokohama, Japan
| | - M Konishi
- Yokohama City University Medical Center, division of cardiology, Yokohama, Japan
| | - C Kawashima
- Yokohama City University Medical Center, division of cardiology, Yokohama, Japan
| | - K Okada
- Yokohama City University Medical Center, division of cardiology, Yokohama, Japan
| | - N Maejima
- Yokohama City University Medical Center, division of cardiology, Yokohama, Japan
| | - N Iwahashi
- Yokohama City University Medical Center, division of cardiology, Yokohama, Japan
| | - K Hibi
- Yokohama City University Medical Center, division of cardiology, Yokohama, Japan
| | - M Kosuge
- Yokohama City University Medical Center, division of cardiology, Yokohama, Japan
| | - T Ebina
- Yokohama City University Medical Center, division of cardiology, Yokohama, Japan
| | - K Tamura
- Yokohama City University, Department of Medical Science and Cardiorenal Medicine, Yokohama, Japan
| | - K Kimura
- Yokohama City University Medical Center, division of cardiology, Yokohama, Japan
| |
Collapse
|
27
|
Nakahashi H, Matsuzawa Y, Hibi K, Iwahashi N, Maejima N, Konishi M, Okada K, Kimura Y, Kosuge M, Tamura K, Kimura K. P5540Microbiota-derived trimethylamine n-oxide as residual risk after ST-elevation myocardial infarction. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy566.p5540] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Affiliation(s)
- H Nakahashi
- Yokohama City University Medical Center, Cardiology, Yokohama, Japan
| | - Y Matsuzawa
- Yokohama City University Medical Center, Cardiology, Yokohama, Japan
| | - K Hibi
- Yokohama City University Medical Center, Cardiology, Yokohama, Japan
| | - N Iwahashi
- Yokohama City University Medical Center, Cardiology, Yokohama, Japan
| | - N Maejima
- Yokohama City University Medical Center, Cardiology, Yokohama, Japan
| | - M Konishi
- Yokohama City University Medical Center, Cardiology, Yokohama, Japan
| | - K Okada
- Yokohama City University Medical Center, Cardiology, Yokohama, Japan
| | - Y Kimura
- Yokohama City University Medical Center, Cardiology, Yokohama, Japan
| | - M Kosuge
- Yokohama City University Medical Center, Cardiology, Yokohama, Japan
| | - K Tamura
- Yokohama City University Graduate School of Medicine, Department of Medical Science and Cardiorenal Medicine, Yokohama, Japan
| | - K Kimura
- Yokohama City University Medical Center, Cardiology, Yokohama, Japan
| |
Collapse
|
28
|
Ito Y, Maejima Y, Tamura N, Shiheido-Watanabe Y, Konishi M, Ashikaga T, Hirao K, Isobe M. Synergistic effects of HMG-CoA reductase inhibitor and angiotensin II receptor blocker on load-induced heart failure. FEBS Open Bio 2018; 8:799-816. [PMID: 29744294 PMCID: PMC5929928 DOI: 10.1002/2211-5463.12416] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2017] [Revised: 02/15/2018] [Accepted: 03/12/2018] [Indexed: 01/19/2023] Open
Abstract
5-Hydroxy-3-methylglutaryl-CoA reductase inhibitors (statins) have beneficial effects in patients with heart failure (HF), regardless of serum cholesterol levels. However, their synergic effects with angiotensin II receptor blocker (ARB) remain to be established. We assessed the existence and potential underlying mechanisms of the effects of combined ARB [losartan (LOS)] and statin [simvastatin (SIM)] on cardiac function in rats and mice with load-induced HF. Salt-loaded Dahl salt-sensitive (DS) rats were treated with vehicle, LOS, SIM, or LOS + SIM for 8 weeks. To mimic load-induced HF in vitro, cultured neonatal rat cardiomyocytes (NRCM) were cyclically stretched. We also investigated the effect of LOS + SIM on pressure overload-induced HF using mice with transverse aortic constriction (TAC). LOS + SIM improved left ventricular (LV) function and reduced LV hypertrophy more than the monotherapies in both salt-loaded DS rats and TAC-operated mice. LV-tissue increases in Rho kinase and matrix metalloproteinase-9 activity were decreased to a greater extent by LOS + SIM than by LOS and SIM monotherapies. Plasma levels of Exp-3174, a LOS metabolite, were higher in LOS + SIM-treated DS rats than in LOS-treated rats. Stretch-induced hypertrophy of NRCM pretreated with SIM + Exp-3174 was significantly attenuated from that with LOS, Exp-3174, SIM, or LOS + SIM. SIM administration significantly enhanced mitophagy in mouse hearts after TAC. However, LOS + SIM reduced mitophagy, and the salutary effect of SIM in mouse hearts after TAC was abolished in AT1R-/- mice. In conclusion, LOS and SIM have beneficial myocardial effects on load-induced HF via differential pleiotropic effects. Thus, combination therapy of these drugs thus has potential as a therapeutic strategy for HF.
Collapse
Affiliation(s)
- Yusuke Ito
- Department of Cardiovascular Medicine Tokyo Medical and Dental University Japan
| | - Yasuhiro Maejima
- Department of Cardiovascular Medicine Tokyo Medical and Dental University Japan
| | - Natsuko Tamura
- Department of Cardiovascular Medicine Tokyo Medical and Dental University Japan
| | | | - Masanori Konishi
- Department of Cardiovascular Medicine Tokyo Medical and Dental University Japan
| | - Takashi Ashikaga
- Department of Cardiovascular Medicine Tokyo Medical and Dental University Japan
| | - Kenzo Hirao
- Department of Cardiovascular Medicine Tokyo Medical and Dental University Japan
| | - Mitsuaki Isobe
- Department of Cardiovascular Medicine Tokyo Medical and Dental University Japan.,Department of Cardiology Sakakibara Heart Institute Tokyo Japan
| |
Collapse
|
29
|
Konishi M, Maejima Y, Ito Y, Yamamoto T, Hirao K, Isobe M. Comparative Effects of Febuxostat Vs Allopurinol for Severe Congestive Heart Failure. J Card Fail 2017. [DOI: 10.1016/j.cardfail.2017.08.431] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
30
|
Maejima Y, Ito Y, Tamura N, Konishi M, Isobe M. P681Blood coagulation factor Xa promotes the progression of atherosclerosis by enhancing inflammasome formation as a consequence of PAR2-mediated autophagy inhibition. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx501.p681] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
31
|
Minamimoto Y, Iwahashi N, Kirigaya J, Takahashi H, Matsuzawa Y, Konishi M, Maejima N, Hibi K, Kosuge M, Ebina T, Kimura K, Tamura K. P4458Glycemic variability influences to bring left ventricular positive and reverse remodeling in patients with ST-segment elevation acute myocardial infarction. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx504.p4458] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
32
|
Minamimoto Y, Iwahashi N, Nakahashi H, Matsuzawa Y, Konishi M, Maejima N, Hibi K, Kosuge M, Ebina T, Kimura K, Tamura K. P55398-hydroxy-2-deoxyguanosine predicts microvascular obstruction after primary percutaneous coronary intervention in patients with anterior ST-segment elevation myocardial infarction. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx493.p5539] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
33
|
Konishi M, Akiyama E, Matsuzawa Y, Kawashima C, Sato R, Nakahashi H, Minamimoto Y, Kimura Y, Maejima N, Iwahashi N, Hibi K, Kosuge M, Ebina T, Kimura K, Tamura K. P163Characteristics and prognostic impact of muscle wasting and fat mass in heart failure with preserved ejection fraction. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx501.p163] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
34
|
Maejima Y, Ito Y, Tamura N, Konishi M, Hirao K, Isobe M. Abstract 358: Factor Xa Deteriorates Atherosclerosis by Facilitating Inflammasome Formation via PAR-2-mediated Autophagy Suppression. Circ Res 2017. [DOI: 10.1161/res.121.suppl_1.358] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Background:
It is known that an endogenous blood coagulation factor Xa (FXa) plays a critical role in facilitating atherosclerosis by activating protease-activated receptor-2 (PAR-2). However, the precise mechanism how FXa-mediated PAR-2 activation promotes atherogenesis remains to be elucidated.
Purpose:
The aim of this study is to explore how FXa promotes atherosclerosis through PAR-2-associated signaling pathway.
Methods & Results:
Administration of direct FXa inhibitor rivaroxaban (Riv; 120 mg/kg/day) to the mice significantly suppressed the plasma FXa activity compared with untreated mice. Administration of Riv to ApoE knockout mice fed with high fat diet (ApoE-KO-HFD) significantly reduced atherosclerotic area in the aorta compared with those in the untreated ApoE-KO-HFD. The plaque size of ApoE-KO mice crossed with PAR-2 knockout mice fed with HFD was similar to those of Riv-treated ApoE-KO-HFD. Ultrastructural examinations of atherosclerotic lesions revealed that the number of autophagosomes in the plaque-resident macrophages of Riv-treated ApoE-KO-HFD was significantly smaller than those of the untreated ApoE-KO-HFD. Immunostaining of NLRP3 revealed that Riv attenuated the inflammasome formation in the atherosclerotic lesion in ApoE-KO-HFD.
In vitro
experiments demonstrated that treatment of 7-ketocholesterol (7KC) markedly enhanced autophagy activity in the murine macrophages. The addition of FXa significantly promoted mTOR (Ser
2448
) phosphorylation and blocked autophagy activity induced by 7KC, which was reversed in the presence of Riv (1 μM). Furthermore, immunoblot analyses demonstrated that FXa administration significantly accelerated inflammasome formation induced by 7KC, which was blocked in the presence of Riv. On the other hand, treatment with FXa failed to inhibit 7KC-induced autophagy and inflammasome activation in PAR-2-KO mice-derived macrophages.
Conclusion:
These results suggest that FXa worsens atherogenesis through PAR-2-mediated pathway by inhibiting macrophage autophagy which, in turn, promoting inflammasome activation.
Collapse
|
35
|
Sugihara T, Hasegawa H, Uchida H, Yoshifuji H, Nakaoka Y, Watanabe Y, Tanemoto K, Amiya E, Konishi M, Arimura Y, Isobe M. P1_27 Characteristics of patients with giant cell arteritis and Takayasu arteritis in a nationwide, retrospective cohort study in Japan. Rheumatology (Oxford) 2017. [DOI: 10.1093/rheumatology/kex108] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
36
|
Ishikawa T, Akazawa K, Hasegawa Y, Tanino H, Horiguchi J, Miura D, Hayashi M, Takao S, Kim SJ, Yamagami K, Miyashita M, Konishi M, Shigeoka Y, Suzuki M, Taguchi T, Kubota T, Kohno N. Abstract P5-16-10: Zoledronic acid combined with neoadjuvant chemotherapy for HER2-negative early breast cancer (JONIE 1 trial): Survival outcomes of a randomized multicenter phase 2 trial. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-p5-16-10] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
BACKGROUND and AIM:
Findings from a randomized phase 2 JONIE1 trial in women with HER2-negative early breast cancer have shown that the addition of zoledronic acid (ZOL) to neoadjuvant chemotherapy (CT) has potential anticancer benefits in postmenopausal and triple-negative breast cancer patients. We report the data for the prespecified secondary endpoint of disease-free survival (DFS).
METHODS:
We enrolled women with HER2-negative early breast cancer and randomly assigned them to receive CT or CT+ZOL (CTZ). All patients received 4 cycles of FEC100 (fluorouracil 500 mg/m2, epirubicin 100 mg/m2, and cyclophosphamide 500 mg/m2), followed by 12 cycles of paclitaxel at 80 mg/m2 weekly. ZOL (4 mg) was administered 3-4 times weekly for 7 weeks to the CTZ group patients. Definitive surgery was performed 3-4 weeks after the last paclitaxel dose. The primary endpoint was pathological complete response (pCR). The secondary endpoints were the clinical response rates, rate of breast-conserving surgery, safety, and DFS (defined as the time from randomization to disease occurrence or death). The trial is registered as UMIN000003261 (www.umin.ac.jp/english/) with ongoing follow-up.
FINDINGS:
Of the 188 patients enrolled, 95 were assigned to the CT group and 93 to the CTZ group. The mean (95% CI) DFS time of the CT group was 5.15 years (4.83-5.47) and that of the CTZ group was 5.38 years (5.11-5.66). The 3-year DFS rate was 84.6% (95% CI 77.2-92.0) in the CT group and 90.7% (84.6-96.8) in the CTZ group with no significant difference (p = 0.120). The particular benefit from ZOL for the neoadjuvant CT seen as improvement of the pCR rate was indicated in the 3-year DFS period for triple-negative cancer cases (CT vs CTZ: 70.6% vs 94.1%), but not for postmenopausal cases.
CONCLUSIONS:
ZOL slightly improved DFS when combined with CT. Although a significant difference was not found in this study, plans are underway for conducting a combined analysis of 3 neoadjuvant CT trials together with ZOL. The improvement of the pCR rate may be associated with DFS in triple-negative cases. Previous studies have shown that ZOL was more efficacious in an estrogen-suppressed condition. However, the short-term application of ZOL in this study may not be sufficient to improve the outcome in postmenopausal patients.
Citation Format: Ishikawa T, Akazawa K, Hasegawa Y, Tanino H, Horiguchi J, Miura D, Hayashi M, Takao S, Kim SJ, Yamagami K, Miyashita M, Konishi M, Shigeoka Y, Suzuki M, Taguchi T, Kubota T, Kohno N. Zoledronic acid combined with neoadjuvant chemotherapy for HER2-negative early breast cancer (JONIE 1 trial): Survival outcomes of a randomized multicenter phase 2 trial [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P5-16-10.
Collapse
Affiliation(s)
- T Ishikawa
- Tokyo Medical Univeristy, Tokyo, Japan; Niigata University Medical and Dental Hospital, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Japan; Kitasato University Hospital, Sagamihara; Gunma University Hospital, Maebashi, Japan; Toranomon Hospital, Tokyo, Japan; Tokyo Medical University Hachioji Medical Center, Tokyo, Japan; Hyogo Cancer Center, Kobe, Japan; Osaka University, Osaka, Japan; Shinko Hospital, Kobe, Japan; Konan Hospital, Kobe, Japan; Hyogo Prefectural Nishinomiya Hospital, Kobe, Japan; Yodogawa Christian Hospital, Osaka, Japan; National Hospital Organization, Chiba Medical Center, Chiba, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kamiiida Daiichi General Hospital, Nagoya, Japan; Kobe Kaisei Hospital, Kobe, Japan
| | - K Akazawa
- Tokyo Medical Univeristy, Tokyo, Japan; Niigata University Medical and Dental Hospital, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Japan; Kitasato University Hospital, Sagamihara; Gunma University Hospital, Maebashi, Japan; Toranomon Hospital, Tokyo, Japan; Tokyo Medical University Hachioji Medical Center, Tokyo, Japan; Hyogo Cancer Center, Kobe, Japan; Osaka University, Osaka, Japan; Shinko Hospital, Kobe, Japan; Konan Hospital, Kobe, Japan; Hyogo Prefectural Nishinomiya Hospital, Kobe, Japan; Yodogawa Christian Hospital, Osaka, Japan; National Hospital Organization, Chiba Medical Center, Chiba, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kamiiida Daiichi General Hospital, Nagoya, Japan; Kobe Kaisei Hospital, Kobe, Japan
| | - Y Hasegawa
- Tokyo Medical Univeristy, Tokyo, Japan; Niigata University Medical and Dental Hospital, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Japan; Kitasato University Hospital, Sagamihara; Gunma University Hospital, Maebashi, Japan; Toranomon Hospital, Tokyo, Japan; Tokyo Medical University Hachioji Medical Center, Tokyo, Japan; Hyogo Cancer Center, Kobe, Japan; Osaka University, Osaka, Japan; Shinko Hospital, Kobe, Japan; Konan Hospital, Kobe, Japan; Hyogo Prefectural Nishinomiya Hospital, Kobe, Japan; Yodogawa Christian Hospital, Osaka, Japan; National Hospital Organization, Chiba Medical Center, Chiba, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kamiiida Daiichi General Hospital, Nagoya, Japan; Kobe Kaisei Hospital, Kobe, Japan
| | - H Tanino
- Tokyo Medical Univeristy, Tokyo, Japan; Niigata University Medical and Dental Hospital, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Japan; Kitasato University Hospital, Sagamihara; Gunma University Hospital, Maebashi, Japan; Toranomon Hospital, Tokyo, Japan; Tokyo Medical University Hachioji Medical Center, Tokyo, Japan; Hyogo Cancer Center, Kobe, Japan; Osaka University, Osaka, Japan; Shinko Hospital, Kobe, Japan; Konan Hospital, Kobe, Japan; Hyogo Prefectural Nishinomiya Hospital, Kobe, Japan; Yodogawa Christian Hospital, Osaka, Japan; National Hospital Organization, Chiba Medical Center, Chiba, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kamiiida Daiichi General Hospital, Nagoya, Japan; Kobe Kaisei Hospital, Kobe, Japan
| | - J Horiguchi
- Tokyo Medical Univeristy, Tokyo, Japan; Niigata University Medical and Dental Hospital, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Japan; Kitasato University Hospital, Sagamihara; Gunma University Hospital, Maebashi, Japan; Toranomon Hospital, Tokyo, Japan; Tokyo Medical University Hachioji Medical Center, Tokyo, Japan; Hyogo Cancer Center, Kobe, Japan; Osaka University, Osaka, Japan; Shinko Hospital, Kobe, Japan; Konan Hospital, Kobe, Japan; Hyogo Prefectural Nishinomiya Hospital, Kobe, Japan; Yodogawa Christian Hospital, Osaka, Japan; National Hospital Organization, Chiba Medical Center, Chiba, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kamiiida Daiichi General Hospital, Nagoya, Japan; Kobe Kaisei Hospital, Kobe, Japan
| | - D Miura
- Tokyo Medical Univeristy, Tokyo, Japan; Niigata University Medical and Dental Hospital, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Japan; Kitasato University Hospital, Sagamihara; Gunma University Hospital, Maebashi, Japan; Toranomon Hospital, Tokyo, Japan; Tokyo Medical University Hachioji Medical Center, Tokyo, Japan; Hyogo Cancer Center, Kobe, Japan; Osaka University, Osaka, Japan; Shinko Hospital, Kobe, Japan; Konan Hospital, Kobe, Japan; Hyogo Prefectural Nishinomiya Hospital, Kobe, Japan; Yodogawa Christian Hospital, Osaka, Japan; National Hospital Organization, Chiba Medical Center, Chiba, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kamiiida Daiichi General Hospital, Nagoya, Japan; Kobe Kaisei Hospital, Kobe, Japan
| | - M Hayashi
- Tokyo Medical Univeristy, Tokyo, Japan; Niigata University Medical and Dental Hospital, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Japan; Kitasato University Hospital, Sagamihara; Gunma University Hospital, Maebashi, Japan; Toranomon Hospital, Tokyo, Japan; Tokyo Medical University Hachioji Medical Center, Tokyo, Japan; Hyogo Cancer Center, Kobe, Japan; Osaka University, Osaka, Japan; Shinko Hospital, Kobe, Japan; Konan Hospital, Kobe, Japan; Hyogo Prefectural Nishinomiya Hospital, Kobe, Japan; Yodogawa Christian Hospital, Osaka, Japan; National Hospital Organization, Chiba Medical Center, Chiba, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kamiiida Daiichi General Hospital, Nagoya, Japan; Kobe Kaisei Hospital, Kobe, Japan
| | - S Takao
- Tokyo Medical Univeristy, Tokyo, Japan; Niigata University Medical and Dental Hospital, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Japan; Kitasato University Hospital, Sagamihara; Gunma University Hospital, Maebashi, Japan; Toranomon Hospital, Tokyo, Japan; Tokyo Medical University Hachioji Medical Center, Tokyo, Japan; Hyogo Cancer Center, Kobe, Japan; Osaka University, Osaka, Japan; Shinko Hospital, Kobe, Japan; Konan Hospital, Kobe, Japan; Hyogo Prefectural Nishinomiya Hospital, Kobe, Japan; Yodogawa Christian Hospital, Osaka, Japan; National Hospital Organization, Chiba Medical Center, Chiba, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kamiiida Daiichi General Hospital, Nagoya, Japan; Kobe Kaisei Hospital, Kobe, Japan
| | - SJ Kim
- Tokyo Medical Univeristy, Tokyo, Japan; Niigata University Medical and Dental Hospital, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Japan; Kitasato University Hospital, Sagamihara; Gunma University Hospital, Maebashi, Japan; Toranomon Hospital, Tokyo, Japan; Tokyo Medical University Hachioji Medical Center, Tokyo, Japan; Hyogo Cancer Center, Kobe, Japan; Osaka University, Osaka, Japan; Shinko Hospital, Kobe, Japan; Konan Hospital, Kobe, Japan; Hyogo Prefectural Nishinomiya Hospital, Kobe, Japan; Yodogawa Christian Hospital, Osaka, Japan; National Hospital Organization, Chiba Medical Center, Chiba, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kamiiida Daiichi General Hospital, Nagoya, Japan; Kobe Kaisei Hospital, Kobe, Japan
| | - K Yamagami
- Tokyo Medical Univeristy, Tokyo, Japan; Niigata University Medical and Dental Hospital, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Japan; Kitasato University Hospital, Sagamihara; Gunma University Hospital, Maebashi, Japan; Toranomon Hospital, Tokyo, Japan; Tokyo Medical University Hachioji Medical Center, Tokyo, Japan; Hyogo Cancer Center, Kobe, Japan; Osaka University, Osaka, Japan; Shinko Hospital, Kobe, Japan; Konan Hospital, Kobe, Japan; Hyogo Prefectural Nishinomiya Hospital, Kobe, Japan; Yodogawa Christian Hospital, Osaka, Japan; National Hospital Organization, Chiba Medical Center, Chiba, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kamiiida Daiichi General Hospital, Nagoya, Japan; Kobe Kaisei Hospital, Kobe, Japan
| | - M Miyashita
- Tokyo Medical Univeristy, Tokyo, Japan; Niigata University Medical and Dental Hospital, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Japan; Kitasato University Hospital, Sagamihara; Gunma University Hospital, Maebashi, Japan; Toranomon Hospital, Tokyo, Japan; Tokyo Medical University Hachioji Medical Center, Tokyo, Japan; Hyogo Cancer Center, Kobe, Japan; Osaka University, Osaka, Japan; Shinko Hospital, Kobe, Japan; Konan Hospital, Kobe, Japan; Hyogo Prefectural Nishinomiya Hospital, Kobe, Japan; Yodogawa Christian Hospital, Osaka, Japan; National Hospital Organization, Chiba Medical Center, Chiba, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kamiiida Daiichi General Hospital, Nagoya, Japan; Kobe Kaisei Hospital, Kobe, Japan
| | - M Konishi
- Tokyo Medical Univeristy, Tokyo, Japan; Niigata University Medical and Dental Hospital, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Japan; Kitasato University Hospital, Sagamihara; Gunma University Hospital, Maebashi, Japan; Toranomon Hospital, Tokyo, Japan; Tokyo Medical University Hachioji Medical Center, Tokyo, Japan; Hyogo Cancer Center, Kobe, Japan; Osaka University, Osaka, Japan; Shinko Hospital, Kobe, Japan; Konan Hospital, Kobe, Japan; Hyogo Prefectural Nishinomiya Hospital, Kobe, Japan; Yodogawa Christian Hospital, Osaka, Japan; National Hospital Organization, Chiba Medical Center, Chiba, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kamiiida Daiichi General Hospital, Nagoya, Japan; Kobe Kaisei Hospital, Kobe, Japan
| | - Y Shigeoka
- Tokyo Medical Univeristy, Tokyo, Japan; Niigata University Medical and Dental Hospital, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Japan; Kitasato University Hospital, Sagamihara; Gunma University Hospital, Maebashi, Japan; Toranomon Hospital, Tokyo, Japan; Tokyo Medical University Hachioji Medical Center, Tokyo, Japan; Hyogo Cancer Center, Kobe, Japan; Osaka University, Osaka, Japan; Shinko Hospital, Kobe, Japan; Konan Hospital, Kobe, Japan; Hyogo Prefectural Nishinomiya Hospital, Kobe, Japan; Yodogawa Christian Hospital, Osaka, Japan; National Hospital Organization, Chiba Medical Center, Chiba, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kamiiida Daiichi General Hospital, Nagoya, Japan; Kobe Kaisei Hospital, Kobe, Japan
| | - M Suzuki
- Tokyo Medical Univeristy, Tokyo, Japan; Niigata University Medical and Dental Hospital, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Japan; Kitasato University Hospital, Sagamihara; Gunma University Hospital, Maebashi, Japan; Toranomon Hospital, Tokyo, Japan; Tokyo Medical University Hachioji Medical Center, Tokyo, Japan; Hyogo Cancer Center, Kobe, Japan; Osaka University, Osaka, Japan; Shinko Hospital, Kobe, Japan; Konan Hospital, Kobe, Japan; Hyogo Prefectural Nishinomiya Hospital, Kobe, Japan; Yodogawa Christian Hospital, Osaka, Japan; National Hospital Organization, Chiba Medical Center, Chiba, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kamiiida Daiichi General Hospital, Nagoya, Japan; Kobe Kaisei Hospital, Kobe, Japan
| | - T Taguchi
- Tokyo Medical Univeristy, Tokyo, Japan; Niigata University Medical and Dental Hospital, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Japan; Kitasato University Hospital, Sagamihara; Gunma University Hospital, Maebashi, Japan; Toranomon Hospital, Tokyo, Japan; Tokyo Medical University Hachioji Medical Center, Tokyo, Japan; Hyogo Cancer Center, Kobe, Japan; Osaka University, Osaka, Japan; Shinko Hospital, Kobe, Japan; Konan Hospital, Kobe, Japan; Hyogo Prefectural Nishinomiya Hospital, Kobe, Japan; Yodogawa Christian Hospital, Osaka, Japan; National Hospital Organization, Chiba Medical Center, Chiba, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kamiiida Daiichi General Hospital, Nagoya, Japan; Kobe Kaisei Hospital, Kobe, Japan
| | - T Kubota
- Tokyo Medical Univeristy, Tokyo, Japan; Niigata University Medical and Dental Hospital, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Japan; Kitasato University Hospital, Sagamihara; Gunma University Hospital, Maebashi, Japan; Toranomon Hospital, Tokyo, Japan; Tokyo Medical University Hachioji Medical Center, Tokyo, Japan; Hyogo Cancer Center, Kobe, Japan; Osaka University, Osaka, Japan; Shinko Hospital, Kobe, Japan; Konan Hospital, Kobe, Japan; Hyogo Prefectural Nishinomiya Hospital, Kobe, Japan; Yodogawa Christian Hospital, Osaka, Japan; National Hospital Organization, Chiba Medical Center, Chiba, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kamiiida Daiichi General Hospital, Nagoya, Japan; Kobe Kaisei Hospital, Kobe, Japan
| | - N Kohno
- Tokyo Medical Univeristy, Tokyo, Japan; Niigata University Medical and Dental Hospital, Niigata, Japan; Hirosaki Municipal Hospital, Hirosaki, Japan; Kitasato University Hospital, Sagamihara; Gunma University Hospital, Maebashi, Japan; Toranomon Hospital, Tokyo, Japan; Tokyo Medical University Hachioji Medical Center, Tokyo, Japan; Hyogo Cancer Center, Kobe, Japan; Osaka University, Osaka, Japan; Shinko Hospital, Kobe, Japan; Konan Hospital, Kobe, Japan; Hyogo Prefectural Nishinomiya Hospital, Kobe, Japan; Yodogawa Christian Hospital, Osaka, Japan; National Hospital Organization, Chiba Medical Center, Chiba, Japan; Kyoto Prefectural University of Medicine, Kyoto, Japan; Kamiiida Daiichi General Hospital, Nagoya, Japan; Kobe Kaisei Hospital, Kobe, Japan
| |
Collapse
|
37
|
Magata F, Tsuchiya K, Komaki H, Konishi M, Ideta A. 142 POSSIBLE BENEFIT OF INTRACYTOPLASMIC SPERM INJECTION ON THE EFFICIENCY OF EMBRYO PRODUCTION IN AGED COWS. Reprod Fertil Dev 2017. [DOI: 10.1071/rdv29n1ab142] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
Reduction in oocyte quality is a major factor responsible for declining fertility with age. The abnormal fertilization rate of oocytes from aged cows was reportedly higher than that of oocytes from young cows (Iwata et al. 2011. Reprod. Fertil. Dev. 23, 424–432). We hypothesised that assisted fertilization by intracytoplasmic sperm injection (ICSI) might improve the developmental abilities of oocytes collected from aged females. The aims of the study were (1) to determine the effect of maternal aging on the ability of bovine oocytes to undergo cytoplasmic maturation, fertilization, and further embryo development; and (2) to determine whether ICSI would improve the efficiency of embryo production in aged cows. Cows aged 30 to 50 months or >120 months were defined as young or aged, respectively. Cumulus-oocyte complexes were harvested from abattoir-derived ovaries of young (40 ± 7 months, n = 89) and aged (136 ± 12 months, n = 55) Holstein cows and matured for 23 h in TCM-199 supplemented with 5% fetal bovine serum (FBS) at 38.5°C under 5% CO2 with saturated humidity. Then, surrounding cumulus cells were removed, and cortical granules in the oocyte were stained with Lens culinaris–fluorescein isothiocyanate to evaluate the cytoplasmic maturation. Matured oocytes were inseminated by IVF or ICSI. At 15 h post-insemination, the numbers of pronuclei were determined to evaluate the fertilization rates. Presumptive IVF- or ICSI-derived zygotes were cultured for 5 days in CR1aa medium with 2% FBS and subsequently in USU6 with 5% FBS for 3 days at 38.5°C in 5% O2, 5% CO2, and 90% N2 with saturated humidity. Chromosome numbers of blastocysts were counted to evaluate the effect of maternal aging on ploidy. All experiments were performed with more than 4 independent runs, and data were analysed using chi-square tests. The distribution of matured oocytes into different cortical granule classes was affected by age, with a significantly lower (P < 0.01) proportion of class III (mature cytoplasm) oocytes from aged cows (29%) compared with those from young cows (57%). Although fertilization rates following IVF did not differ between the groups, the proportion of abnormal fertilization (more than 2 pronuclei) was 32% in the aged group: higher than in the young group (15%; P < 0.01). The rates of cleaved embryos following IVF were the same among groups, but the rate of development to the blastocyst stage of oocytes from aged cows (38%) was significantly (P < 0.05) lower than in those from young cows (52%). Moreover, the proportion of diploid blastocysts with 2 sets of chromosomes (2n = 60) was lower (47%) in the aged than in the young groups (75%; P < 0.05). However, in the ICSI embryos, the rates of development to the blastocyst stage did not differ significantly between groups (young 36%; aged 43%). Thus, maternal aging might impair the cytoplasmic maturation of bovine oocytes, which could be associated with abnormal fertilization or low developmental competence. Our results also indicate possible beneficial effects of ICSI on the efficiency of embryo production in aged cows.
Collapse
|
38
|
Konishi M, Maejima Y, Ashikaga T, Isobe M. Imaging Cell-Mediated Immunity Assesses Acute Myocarditis. J Card Fail 2016. [DOI: 10.1016/j.cardfail.2016.07.375] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
39
|
Kaise H, Ishikawa T, Miura D, Hasegawa Y, Horiguchi J, Hayashi M, Takao S, Kim SJ, Tanino H, Miyashita M, Konishi M, Shigeoka Y, Yamagami K, Suzuki M, Taguchi T, Akazawa K, Kohno N. Abstract P3-07-50: Early and accurate prediction of pathological response by magnetic resonance imaging and ultrasonography in patients undergoing neoadjuvant chemotherapy for operable breast cancer. Cancer Res 2016. [DOI: 10.1158/1538-7445.sabcs15-p3-07-50] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background: Neoadjuvant chemotherapy (NAC) reduces tumor size, and increases the frequency of breast-conserving surgery in operable breast cancers. Response predictions to NAC are made based on diagnostic imaging.
Although various studies have reported the optimal timing for diagnostic imaging, this still remains unclear.
Purpose: To identify the optimal timing of diagnostic imaging for the response prediction to NAC, and to evaluate the accuracy of response prediction.
Methods: We evaluated 146 cases enrolled in the JONIE-1 study (a randomized controlled trial comparing zoledronic acid plus chemotherapy with chemotherapy alone as a NAC in patients with HER2-negative primary breast cancer). The chemotherapy regimen was FEC100×4 courses followed by weekly paclitaxel 80×12 courses (± zoledronic acid). Statistical analysis of the association between the tumor reduction ratio and the histopathological response and the prediction of pathological complete response (pCR) was performed using JMP software. The maximum tumor diameter was evaluated using magnetic resonance imaging and ultrasound on each patient 3 times (before NAC, after FEC treatment, after NAC) and tumor reduction ratios were calculated.
Results: The average age of the patients was 49.8 years old. The menopause status was pre-menopause in 84 patients, and post-menopause in 58 patients. Regarding the subtype classification, 116 patients were of the luminal type (Lum) and 26 patients were triple negative (TN), and the Ki-67 labeling index had a median of 25% (1%-93%).
Pathological examination demonstrated that 16 patients had pCR(11.3%, Lum, 9;TN: 7), and 126 patients had non-pCR (88.7%, Lum:107; TN:19). Seven patients had clinical-CR (4.8%, Lum: 4; TN: 3) at post-FEC, and 26 patients (17.8%, Lum: 20; TN: 6) at post-NAC. The prediction of pCR at post-FEC and post-NAC was evaluated by single variable analysis, resulting in an AUC (0.75645) p=0.0017 at post-FEC, and AUC (0.76563) p=0.0001 at post-NAC. The sensitivity / specificity / positive predictive value / negative predictive value were 0.625 / 0.873 / 0.385 / 0.948 at post-FEC, 0.250 / 0.976 / 0.571 / 0.911 at post-NAC, respectively. In TN cases, the values were 0.714 / 0.947 / 0.833 / 0.900 in post-FEC, and 0.429 / 1.000 / 1.000 / 0.826 in post-NAC.
Conclusions: Diagnostic imaging evaluation performed after FEC treatment was useful for the prediction of pCR. Furthermore, the reliability was high in Triple Negative Sub type, but is affected by the existence of residual tumors in Luminal type.
Citation Format: Kaise H, Ishikawa T, Miura D, Hasegawa Y, Horiguchi J, Hayashi M, Takao S, Kim SJ, Tanino H, Miyashita M, Konishi M, Shigeoka Y, Yamagami K, Suzuki M, Taguchi T, Akazawa K, Kohno N. Early and accurate prediction of pathological response by magnetic resonance imaging and ultrasonography in patients undergoing neoadjuvant chemotherapy for operable breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P3-07-50.
Collapse
Affiliation(s)
- H Kaise
- Tokyo Medical University Hospital, Tokyo, Japan; Yokohama City University Medical Center; Toranomon Hospital; Hirosaki Municipal Hospital; Gunma University Hospital; Tokyo Medical University Hachioji Medical Center; Hyogo Cancer Center; Osaka University Hospital; Naga Municipal Hospital; Konan Hospital; Hyogo Prefectural Nishinomiya Hospital; Yodogawa Christian Hospital; Shinko Hospital; Niigata University Medical and Dental Hospital; Kobe Kaisei Hospital; National Hospital Organization Chiba Medical Center; University Hospital, Kyoto Prefectural University of Medicine
| | - T Ishikawa
- Tokyo Medical University Hospital, Tokyo, Japan; Yokohama City University Medical Center; Toranomon Hospital; Hirosaki Municipal Hospital; Gunma University Hospital; Tokyo Medical University Hachioji Medical Center; Hyogo Cancer Center; Osaka University Hospital; Naga Municipal Hospital; Konan Hospital; Hyogo Prefectural Nishinomiya Hospital; Yodogawa Christian Hospital; Shinko Hospital; Niigata University Medical and Dental Hospital; Kobe Kaisei Hospital; National Hospital Organization Chiba Medical Center; University Hospital, Kyoto Prefectural University of Medicine
| | - D Miura
- Tokyo Medical University Hospital, Tokyo, Japan; Yokohama City University Medical Center; Toranomon Hospital; Hirosaki Municipal Hospital; Gunma University Hospital; Tokyo Medical University Hachioji Medical Center; Hyogo Cancer Center; Osaka University Hospital; Naga Municipal Hospital; Konan Hospital; Hyogo Prefectural Nishinomiya Hospital; Yodogawa Christian Hospital; Shinko Hospital; Niigata University Medical and Dental Hospital; Kobe Kaisei Hospital; National Hospital Organization Chiba Medical Center; University Hospital, Kyoto Prefectural University of Medicine
| | - Y Hasegawa
- Tokyo Medical University Hospital, Tokyo, Japan; Yokohama City University Medical Center; Toranomon Hospital; Hirosaki Municipal Hospital; Gunma University Hospital; Tokyo Medical University Hachioji Medical Center; Hyogo Cancer Center; Osaka University Hospital; Naga Municipal Hospital; Konan Hospital; Hyogo Prefectural Nishinomiya Hospital; Yodogawa Christian Hospital; Shinko Hospital; Niigata University Medical and Dental Hospital; Kobe Kaisei Hospital; National Hospital Organization Chiba Medical Center; University Hospital, Kyoto Prefectural University of Medicine
| | - J Horiguchi
- Tokyo Medical University Hospital, Tokyo, Japan; Yokohama City University Medical Center; Toranomon Hospital; Hirosaki Municipal Hospital; Gunma University Hospital; Tokyo Medical University Hachioji Medical Center; Hyogo Cancer Center; Osaka University Hospital; Naga Municipal Hospital; Konan Hospital; Hyogo Prefectural Nishinomiya Hospital; Yodogawa Christian Hospital; Shinko Hospital; Niigata University Medical and Dental Hospital; Kobe Kaisei Hospital; National Hospital Organization Chiba Medical Center; University Hospital, Kyoto Prefectural University of Medicine
| | - M Hayashi
- Tokyo Medical University Hospital, Tokyo, Japan; Yokohama City University Medical Center; Toranomon Hospital; Hirosaki Municipal Hospital; Gunma University Hospital; Tokyo Medical University Hachioji Medical Center; Hyogo Cancer Center; Osaka University Hospital; Naga Municipal Hospital; Konan Hospital; Hyogo Prefectural Nishinomiya Hospital; Yodogawa Christian Hospital; Shinko Hospital; Niigata University Medical and Dental Hospital; Kobe Kaisei Hospital; National Hospital Organization Chiba Medical Center; University Hospital, Kyoto Prefectural University of Medicine
| | - S Takao
- Tokyo Medical University Hospital, Tokyo, Japan; Yokohama City University Medical Center; Toranomon Hospital; Hirosaki Municipal Hospital; Gunma University Hospital; Tokyo Medical University Hachioji Medical Center; Hyogo Cancer Center; Osaka University Hospital; Naga Municipal Hospital; Konan Hospital; Hyogo Prefectural Nishinomiya Hospital; Yodogawa Christian Hospital; Shinko Hospital; Niigata University Medical and Dental Hospital; Kobe Kaisei Hospital; National Hospital Organization Chiba Medical Center; University Hospital, Kyoto Prefectural University of Medicine
| | - SJ Kim
- Tokyo Medical University Hospital, Tokyo, Japan; Yokohama City University Medical Center; Toranomon Hospital; Hirosaki Municipal Hospital; Gunma University Hospital; Tokyo Medical University Hachioji Medical Center; Hyogo Cancer Center; Osaka University Hospital; Naga Municipal Hospital; Konan Hospital; Hyogo Prefectural Nishinomiya Hospital; Yodogawa Christian Hospital; Shinko Hospital; Niigata University Medical and Dental Hospital; Kobe Kaisei Hospital; National Hospital Organization Chiba Medical Center; University Hospital, Kyoto Prefectural University of Medicine
| | - H Tanino
- Tokyo Medical University Hospital, Tokyo, Japan; Yokohama City University Medical Center; Toranomon Hospital; Hirosaki Municipal Hospital; Gunma University Hospital; Tokyo Medical University Hachioji Medical Center; Hyogo Cancer Center; Osaka University Hospital; Naga Municipal Hospital; Konan Hospital; Hyogo Prefectural Nishinomiya Hospital; Yodogawa Christian Hospital; Shinko Hospital; Niigata University Medical and Dental Hospital; Kobe Kaisei Hospital; National Hospital Organization Chiba Medical Center; University Hospital, Kyoto Prefectural University of Medicine
| | - M Miyashita
- Tokyo Medical University Hospital, Tokyo, Japan; Yokohama City University Medical Center; Toranomon Hospital; Hirosaki Municipal Hospital; Gunma University Hospital; Tokyo Medical University Hachioji Medical Center; Hyogo Cancer Center; Osaka University Hospital; Naga Municipal Hospital; Konan Hospital; Hyogo Prefectural Nishinomiya Hospital; Yodogawa Christian Hospital; Shinko Hospital; Niigata University Medical and Dental Hospital; Kobe Kaisei Hospital; National Hospital Organization Chiba Medical Center; University Hospital, Kyoto Prefectural University of Medicine
| | - M Konishi
- Tokyo Medical University Hospital, Tokyo, Japan; Yokohama City University Medical Center; Toranomon Hospital; Hirosaki Municipal Hospital; Gunma University Hospital; Tokyo Medical University Hachioji Medical Center; Hyogo Cancer Center; Osaka University Hospital; Naga Municipal Hospital; Konan Hospital; Hyogo Prefectural Nishinomiya Hospital; Yodogawa Christian Hospital; Shinko Hospital; Niigata University Medical and Dental Hospital; Kobe Kaisei Hospital; National Hospital Organization Chiba Medical Center; University Hospital, Kyoto Prefectural University of Medicine
| | - Y Shigeoka
- Tokyo Medical University Hospital, Tokyo, Japan; Yokohama City University Medical Center; Toranomon Hospital; Hirosaki Municipal Hospital; Gunma University Hospital; Tokyo Medical University Hachioji Medical Center; Hyogo Cancer Center; Osaka University Hospital; Naga Municipal Hospital; Konan Hospital; Hyogo Prefectural Nishinomiya Hospital; Yodogawa Christian Hospital; Shinko Hospital; Niigata University Medical and Dental Hospital; Kobe Kaisei Hospital; National Hospital Organization Chiba Medical Center; University Hospital, Kyoto Prefectural University of Medicine
| | - K Yamagami
- Tokyo Medical University Hospital, Tokyo, Japan; Yokohama City University Medical Center; Toranomon Hospital; Hirosaki Municipal Hospital; Gunma University Hospital; Tokyo Medical University Hachioji Medical Center; Hyogo Cancer Center; Osaka University Hospital; Naga Municipal Hospital; Konan Hospital; Hyogo Prefectural Nishinomiya Hospital; Yodogawa Christian Hospital; Shinko Hospital; Niigata University Medical and Dental Hospital; Kobe Kaisei Hospital; National Hospital Organization Chiba Medical Center; University Hospital, Kyoto Prefectural University of Medicine
| | - M Suzuki
- Tokyo Medical University Hospital, Tokyo, Japan; Yokohama City University Medical Center; Toranomon Hospital; Hirosaki Municipal Hospital; Gunma University Hospital; Tokyo Medical University Hachioji Medical Center; Hyogo Cancer Center; Osaka University Hospital; Naga Municipal Hospital; Konan Hospital; Hyogo Prefectural Nishinomiya Hospital; Yodogawa Christian Hospital; Shinko Hospital; Niigata University Medical and Dental Hospital; Kobe Kaisei Hospital; National Hospital Organization Chiba Medical Center; University Hospital, Kyoto Prefectural University of Medicine
| | - T Taguchi
- Tokyo Medical University Hospital, Tokyo, Japan; Yokohama City University Medical Center; Toranomon Hospital; Hirosaki Municipal Hospital; Gunma University Hospital; Tokyo Medical University Hachioji Medical Center; Hyogo Cancer Center; Osaka University Hospital; Naga Municipal Hospital; Konan Hospital; Hyogo Prefectural Nishinomiya Hospital; Yodogawa Christian Hospital; Shinko Hospital; Niigata University Medical and Dental Hospital; Kobe Kaisei Hospital; National Hospital Organization Chiba Medical Center; University Hospital, Kyoto Prefectural University of Medicine
| | - K Akazawa
- Tokyo Medical University Hospital, Tokyo, Japan; Yokohama City University Medical Center; Toranomon Hospital; Hirosaki Municipal Hospital; Gunma University Hospital; Tokyo Medical University Hachioji Medical Center; Hyogo Cancer Center; Osaka University Hospital; Naga Municipal Hospital; Konan Hospital; Hyogo Prefectural Nishinomiya Hospital; Yodogawa Christian Hospital; Shinko Hospital; Niigata University Medical and Dental Hospital; Kobe Kaisei Hospital; National Hospital Organization Chiba Medical Center; University Hospital, Kyoto Prefectural University of Medicine
| | - N Kohno
- Tokyo Medical University Hospital, Tokyo, Japan; Yokohama City University Medical Center; Toranomon Hospital; Hirosaki Municipal Hospital; Gunma University Hospital; Tokyo Medical University Hachioji Medical Center; Hyogo Cancer Center; Osaka University Hospital; Naga Municipal Hospital; Konan Hospital; Hyogo Prefectural Nishinomiya Hospital; Yodogawa Christian Hospital; Shinko Hospital; Niigata University Medical and Dental Hospital; Kobe Kaisei Hospital; National Hospital Organization Chiba Medical Center; University Hospital, Kyoto Prefectural University of Medicine
| |
Collapse
|
40
|
Tominaga N, Tomomatsu M, Nakamura M, Ideta A, Konishi M, Aoyagi Y. 235 ADMINISTRATION OF LEVOTHYROXINE IMPROVES THE PROPORTION OF TRANSFERABLE EMBRYOS FOLLOWING SUPEROVULATION IN JAPANESE BLACK CATTLE. Reprod Fertil Dev 2016. [DOI: 10.1071/rdv28n2ab235] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
The thyroid gland has a major impact on the human female reproductive system. However, its influence on reproductive competence in livestock is unclear. In cattle, superovulatory treatments often lead to high numbers of ova/embryos but low numbers of transferable embryos. Levothyroxine is a synthetic thyroid hormone that is chemically identical to thyroxine (T4), and binds to T4 receptors found in follicle cells. We aimed to determine whether levothyroxine treatment (LT) could improve the proportion of transferable embryos after superovulation in Japanese black cattle (Wagyu). First, we observed associations between the concentrations of T4, free triiodothyronine and thyroxine, and superovulatory responses (n = 95). Blood was collected before superovulatory treatment by jugular venipuncture, and serum was separated and stored at –20°C until being assayed for thyroid hormones. Second, Wagyu cattle showing a low proportion of transferable embryos (<30%) were assigned randomly to an LT group (n = 10) or a control group (no LT, n = 15); the LT was administered by 3 i.m. injections of 2000 mg of levothyroxine given 3 days apart; Controls received no injection. On the last day of LT, hormonal stimulation for superovulation was started as described (Ideta et al. 2007 Cloning Stem Cells 9, 571–580). The proportion of transferable embryos was compared with the same individual before/after LT. Data were analysed using Student’s t-tests. There were no significant associations between the concentrations of thyroid hormones and the superovulatory responses (no. collected oocytes/embryos, or the proportions of transferable embryos or unfertilized oocytes). However, LT dramatically increased the proportion of transferable embryos in these low-responding Wagyu cattle (Table 1). In conclusion, administration of levothyroxine improved the proportion of transferable embryos following superovulatory treatment. Further studies will be needed to investigate how LT improves the quality of bovine embryos.
Table 1.Effect of levothyroxine treatment on the proportion of transferable embryos after superovulation in Wagyu cattle (means ± SE)
Collapse
|
41
|
Takeuchi Y, Murakami Y, Kubo K, Sakaguchi H, Imano N, Kawabata H, Doi Y, Okabe T, Kenjo M, Kimura T, Nagata Y, Fujita M, Konishi M. Interstitial Brachytherapy for Early-Stage Tongue Cancer: Analysis of the Long-term Treatment Results for Survival and Complications. Int J Radiat Oncol Biol Phys 2015. [DOI: 10.1016/j.ijrobp.2015.07.1303] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
42
|
Abstract
RATIONALE The development of molecular imaging approaches that assess specific immunopathologic mechanisms can advance the study of myocarditis. OBJECTIVE This study validates a novel molecular imaging tool that enables the in vivo visualization of granzyme B activity, a major effector of cytotoxic CD8+ T lymphocytes. METHODS AND RESULTS We synthesized and optimized a fluorogenic substrate capable of reporting on granzyme B activity and examined its specificity ex vivo in mice hearts with experimental cytotoxic CD8+ T lymphocyte-mediated myocarditis using fluorescence reflectance imaging, validated by histological examination. In vivo experiments localized granzyme B activity in hearts with acute myocarditis monitored by fluorescent molecular tomography in conjunction with coregistered computed tomography imaging. A model anti-inflammatory intervention (dexamethasone administration) in vivo reduced granzyme B activity (vehicle versus dexamethasone: 504±263 versus 194±77 fluorescence intensities in hearts; P=0.002). CONCLUSIONS Molecular imaging of granzyme B activity can visualize T cell-mediated myocardial injury and monitor the response to an anti-inflammatory intervention.
Collapse
Affiliation(s)
- Masanori Konishi
- Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School
| | - S Sibel Erdem
- Center for Systems Biology, Massachusetts General Hospital, Harvard Medical School
| | - Ralph Weissleder
- Center for Systems Biology, Massachusetts General Hospital, Harvard Medical School
| | - Andrew H Lichtman
- Division of Pathology, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School
| | - Jason R McCarthy
- Center for Systems Biology, Massachusetts General Hospital, Harvard Medical School
| | - Peter Libby
- Division of Cardiovascular Medicine, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School
| |
Collapse
|
43
|
Igawa K, Konishi M, Moriyama Y, Fukuyama K, Yokozeki H. Erythroderma as drug eruption induced by intravesical mitomycin C therapy. J Eur Acad Dermatol Venereol 2015; 29:613-4. [DOI: 10.1111/jdv.12415] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- K. Igawa
- Department of Dermatology; Tokyo Medical and Dental University; Graduate School of Medicine; Tokyo Japan
| | - M. Konishi
- Department of Dermatology; Tokyo Medical and Dental University; Graduate School of Medicine; Tokyo Japan
| | - Y. Moriyama
- Department of Dermatology; Tokyo Medical and Dental University; Graduate School of Medicine; Tokyo Japan
| | - K. Fukuyama
- Department of Dermatology; Tokyo Medical and Dental University; Graduate School of Medicine; Tokyo Japan
| | - H. Yokozeki
- Department of Dermatology; Tokyo Medical and Dental University; Graduate School of Medicine; Tokyo Japan
| |
Collapse
|
44
|
Kobayashi S, Hidano A, Tsutsui T, Yamamoto T, Hayama Y, Nishida T, Muroga N, Konishi M, Kameyama K, Murakami K. Analysis of risk factors associated with bovine leukemia virus seropositivity within dairy and beef breeding farms in Japan: A nationwide survey. Res Vet Sci 2014; 96:47-53. [DOI: 10.1016/j.rvsc.2013.11.014] [Citation(s) in RCA: 26] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/08/2012] [Revised: 11/15/2013] [Accepted: 11/26/2013] [Indexed: 10/25/2022]
|
45
|
Asakuma Y, Murakami Y, Konishi M. Anti-solvent effect of crystallization by feeding ethanol under microwave radiation. Crystal Research and Technology 2014. [DOI: 10.1002/crat.201300327] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- Y. Asakuma
- Department of Mechanical and System Engineering; Univeristy of Hyogo; Shosha 2167 Himeji 671-2280 Japan
| | - Y. Murakami
- Department of Mechanical and System Engineering; Univeristy of Hyogo; Shosha 2167 Himeji 671-2280 Japan
| | - M. Konishi
- Department of Mechanical and System Engineering; Univeristy of Hyogo; Shosha 2167 Himeji 671-2280 Japan
| |
Collapse
|
46
|
Yamagishi K, Iso H, Kokubo Y, Saito I, Yatsuya H, Ishihara J, Inoue M, Tsugane S, Sobue T, Hanaoka T, Ogata J, Baba S, Mannami T, Okayama A, K. Y, Miyakawa K, Saito F, Koizumi A, Sano Y, Hashimoto I, Ikuta T, Tanaba Y, Miyajima Y, Suzuki N, Nagasawa S, Furusugi Y, Nagai N, Sanada H, Hatayama Y, Kobayashi F, Uchino H, Shirai Y, Kondo T, Sasaki R, Watanabe Y, Miyagawa Y, Kobayashi Y, Machida M, Kishimoto Y, Takara E, Fukuyama T, Kinjo M, Irei M, Sakiyama H, Imoto K, Yazawa H, Seo T, Seiko A, Ito F, Shoji F, Saito R, Murata A, Minato K, Motegi K, Fujieda T, Abe T, Katagiri M, Suzuki M, Matsui K, Doi M, Terao A, Ishikawa Y, Tagami T, Doi H, Urata M, Okamoto N, Ide F, Sueta H, Sakiyama H, Onga N, Takaesu H, Uehara M, Horii F, Asano I, Yamaguchi H, Aoki K, Maruyama S, Ichii M, Takano M, Matsushima S, Natsukawa S, Akabane M, Konishi M, Okada K, Honda Y, Sakurai KYS, Tsuchiya N, Sugimura H, Tsubono Y, Kabuto M, Tominaga S, Iida M, Ajiki W, Ioka A, Sato S, Yasuda N, Nakamura K, Kono S, Suzuki K, Takashima Y, Yoshida M, Maruyama E, Yamaguchi M, Matsumura Y, Sasaki S, Watanabe S, Kadowaki T, Noda M, Mizoue T, Kawaguchi Y, Shimizu H. Dietary intake of saturated fatty acids and incident stroke and coronary heart disease in Japanese communities: the JPHC Study. Eur Heart J 2013; 34:1225-32. [DOI: 10.1093/eurheartj/eht043] [Citation(s) in RCA: 48] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
47
|
Affiliation(s)
- K Murakami
- Food Animal Medicine and Food Safety Research Center, 3-18-8 Ueda, Morioka, Iwate 020-8550, Japan.
| | | | | | | |
Collapse
|
48
|
Numao S, Kawano H, Endo N, Yamada Y, Konishi M, Takahashi M, Sakamoto S. Short-term low carbohydrate/high-fat diet intake increases postprandial plasma glucose and glucagon-like peptide-1 levels during an oral glucose tolerance test in healthy men. Eur J Clin Nutr 2012; 66:926-31. [PMID: 22669333 DOI: 10.1038/ejcn.2012.58] [Citation(s) in RCA: 53] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Abstract
BACKGROUND/OBJECTIVES Postprandial hyperglycemia increases the risks of development of type 2 diabetes and cardiovascular diseases. The purpose of this study was to determine whether a 3-day low-carbohydrate/high-fat diet (LC/HFD) alters postprandial plasma glucose and incretin levels during oral glucose tolerance test (OGTT) in healthy men. SUBJECTS/METHODS Nine healthy young men (age (mean ± s.e.), 27 ± 1 years; body mass index, 22 ± 1 kg/m(2)) consumed either a normal diet (ND: energy from ∼22% fat) or a LC/HFD (energy from ∼69% fat) for 3 days each. The total energy intake from each diet was similar. An OGTT was performed after each 3-day dietary intervention. Postprandial plasma glucose, insulin, free fatty acid and glucagon-like peptide-1 (GLP-1) levels were determined at rest and during the OGTT. RESULTS Plasma glucose levels and incremental area under the curve during the OGTT were significantly higher in the LC/HFD trial than in the ND trial (P=0.024). In addition, increase in GLP-1 levels was significantly higher in the LC/HFD trial than in the ND trial (P=0.025). The first-phase insulin secretion indexes were significantly lower in the LC/HFD trial than in the ND trial (P<0.041). CONCLUSIONS These results demonstrate that even short-term LC/HFD increased postprandial plasma glucose and GLP-1 levels in healthy young men. A decrease in first-phase insulin secretion may partially contribute to the short-term LC/HFD-induced increase in postprandial plasma glucose levels.
Collapse
Affiliation(s)
- S Numao
- Department of Health and Sports Sciences, Kyoto Pharmaceutical University, Kyoto, Japan.
| | | | | | | | | | | | | |
Collapse
|
49
|
Kofuji K, Aoki A, Tsubaki K, Konishi M, Isobe T, Murata Y. Antioxidant Activity of β-Glucan. ISRN Pharm 2012; 2012:125864. [PMID: 22500243 PMCID: PMC3302110 DOI: 10.5402/2012/125864] [Citation(s) in RCA: 70] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/13/2011] [Accepted: 10/31/2011] [Indexed: 11/30/2022]
Abstract
β-Glucans extracted from barley, which mainly contains β-(1,3-1,4)-D-glucan, are used extensively as supplements and food additives due to their wide biologic activities, including a reduction in blood lipid level. In this study, the antioxidant activity of β-glucan was examined to assess potential new benefits associated with β-glucan, because oxidative stress is considered one of the primary causal factors for various diseases and aging. β-Glucan extracted from barley was found to possess significant antioxidant activity. The amount of antioxidant activity was influenced by different physiologic properties (e.g., structure and molecular size) of β-glucan, which varied depending on the source and extraction method used. The antioxidant activity of β-glucan was significantly higher than that of various polymers that are used as food additives. These results indicate that β-glucan has promise as a polymeric excipient for supplement and food additive with antioxidant and other benefits, which may contribute to enhancing health and beauty.
Collapse
Affiliation(s)
- Kyoko Kofuji
- Faculty of Pharmaceutical Sciences, Hokuriku University, Ho 3, Kanagawa-Machi, Kanazawa 920-1181, Japan
| | | | | | | | | | | |
Collapse
|
50
|
Ohta Y, Nishi S, Haga T, Tsubouchi T, Hasegawa R, Konishi M, Nagano Y, Tsuruwaka Y, Shimane Y, Mori K, Usui K, Suda E, Tsutsui K, Nishimoto A, Fujiwara Y, Maruyama T, Hatada Y. Screening and Phylogenetic Analysis of Deep-Sea Bacteria Capable of Metabolizing Lignin-Derived Aromatic Compounds. ACTA ACUST UNITED AC 2012. [DOI: 10.4236/ojms.2012.24021] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|